

Review

Synthetic Calcium–Phosphate Materials for Bone Grafting

Oleg Mishchenko ¹, Anna Yanovska ^{2,*}, Oleksii Kosinov ¹, Denys Maksymov ¹, Roman Moskalenko ³,
Arunas Ramanavicius ^{4,*} and Maksym Pogorielov ^{5,6}

¹ Department of Surgical and Propaedeutic Dentistry, Zaporizhzhia State Medical and Pharmaceutical University, 26, Prosp. Mayakovskogo, 69035 Zaporizhzhia, Ukraine; dr.mishchenko@icloud.com (O.M.); alexeykosinov10@gmail.com (O.K.); maximov.d@zsmu.edu.ua (D.M.)

² Theoretical and Applied Chemistry Department, Sumy State University, R-Korsakova Street, 40007 Sumy, Ukraine

³ Department of Pathology, Sumy State University, R-Korsakova Street, 40007 Sumy, Ukraine; r.moskalenko@med.sumdu.edu.ua

⁴ NanoTechnas-Center of Nanotechnology and Materials Science, Institute of Chemistry, Faculty of Chemistry and Geosciences, Vilnius University, Naugarduko Str. 24, LT-03225 Vilnius, Lithuania

⁵ Biomedical Research Centre, Sumy State University, R-Korsakova Street, 40007 Sumy, Ukraine; m.pogorielov@gmail.com or maksym.pogorielov@lu.lv

⁶ Institute of Atomic Physics and Spectroscopy, University of Latvia, Jelgavas Iela 3, LV-1004 Riga, Latvia

* Correspondence: a.yanovska@teset.sumdu.edu.ua (A.Y.); arunas.ramanavicius@chf.vu.lt (A.R.)

Abstract: Synthetic bone grafting materials play a significant role in various medical applications involving bone regeneration and repair. Their ability to mimic the properties of natural bone and promote the healing process has contributed to their growing relevance. While calcium–phosphates and their composites with various polymers and biopolymers are widely used in clinical and experimental research, the diverse range of available polymer-based materials poses challenges in selecting the most suitable grafts for successful bone repair. This review aims to address the fundamental issues of bone biology and regeneration while providing a clear perspective on the principles guiding the development of synthetic materials. In this study, we delve into the basic principles underlying the creation of synthetic bone composites and explore the mechanisms of formation for biologically important complexes and structures associated with the various constituent parts of these materials. Additionally, we offer comprehensive information on the application of biologically active substances to enhance the properties and bioactivity of synthetic bone grafting materials. By presenting these insights, our review enables a deeper understanding of the regeneration processes facilitated by the application of synthetic bone composites.

Keywords: regenerative dentistry; synthetic bone materials; composites; hydroxyapatite; biopolymers



check for updates

Citation: Mishchenko, O.; Yanovska, A.; Kosinov, O.; Maksymov, D.; Moskalenko, R.; Ramanavicius, A.; Pogorielov, M. Synthetic Calcium–Phosphate Materials for Bone Grafting. *Polymers* **2023**, *15*, 3822. <https://doi.org/10.3390/polym15183822>

Academic Editor: Andrea Zille

Received: 25 August 2023

Revised: 8 September 2023

Accepted: 11 September 2023

Published: 19 September 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Regenerative dentistry, a significant branch of regenerative medicine, focuses on various dental pathologies, including bone defects such as periodontitis, alveolar bone resorption, caries, and pulpal necrosis. These localized skeletal diseases have a direct impact on patients' quality of life and healthcare resources. To comprehensively address these diseases, therapy should concentrate on both bone regeneration and tooth regeneration [1].

From a regenerative standpoint, the bone structure is a vascularized connective tissue that possesses an inherent ability to remodel in response to external and internal factors during skeletal growth and development, as well as regenerate after injuries and pathological conditions. These processes involve a series of complex intercellular and intracellular biological interactions among various cell types and molecular signaling pathways [2]. Bone fracture healing represents one of the most common forms of bone regeneration in clinical settings [3,4]. Significant bone loss often occurs in the craniofacial region due to factors such as tumors, traumatic injuries, periodontal disease, congenital anomalies, or

resorption resulting from tooth loss. In the fields of oral and maxillofacial surgery and orthopedics, there are cases where bone regeneration is required in larger quantities, exceeding the normal self-repair capacity. For example, in the reconstruction of large skeletal defects, such as dental implants, or when the innate regenerative ability is impaired, as seen in osteoporosis, optimizing the regenerative process is crucial to enhancing the likelihood of treatment success [5]. Bone grafting for improving the healing of bone defects involves autografts or allografts [6,7]. However, it is important to consider that autograft treatment has limitations, including relatively high morbidity rates at the donor site and a shortage of available grafts. Allografts also face challenges related to vascularization and integration with the host bone [8]. On the other hand, bioengineered bone tissue has the potential to overcome these problems and disadvantages [9].

Bone formation occurs through the differentiation of osteogenesis precursor cells into either mesenchymal osteoblasts, which synthesize randomly intertwined bone, or superficial osteoblasts, which produce highly ordered lamellar bone [10]. Recent studies suggest that endochondral and intramembranous ossifications, traditionally associated with fetal bone development, occur postnatally—particularly during skeletal regeneration following injury [11]. During the healing process, the bone recapitulates fetal bone development to achieve complete tissue regeneration without the formation of a fibrous scar [12]. Several transitional tissue types are involved in this process, including fibrous callus, low-mineralized cartilage, and tissue bone, depending on the degree of mechanical action [13,14]. These intermediate tissue types provide initial mechanical stability and are eventually replaced by ordered lamellar bone [14]. While bone has an intrinsic ability to regenerate and heal [4] and undergoes constant remodeling [15], incomplete or irregular postnatal osteogenesis can still occur in the case of large bone defects. Impaired regeneration can be caused by significant trauma, tumor resections, skeletal abnormalities, infections, or systemic disorders such as osteoporosis [16].

Achieving controlled, managed, and complete bone formation is the long-desired goal of bone tissue engineering. Autologous bone grafts are commonly used in orthopedic and maxillofacial surgery due to their superior histocompatibility, structural support, and minimal risk of immunogenic response [17]. To gain a better understanding of biomaterials' functionality, it is important to briefly consider the processes involved in the reparative phase of bone tissue regeneration. Hematoma formation occurs when blood cells accumulate at the site of a bone injury, preventing further bleeding. The constriction of blood vessels also helps suppress bleeding. Within a few hours after the fracture, a hematoma forms as a result of the accumulation of blood cells and plasma fibrinogen. The hematoma supplies the fracture site with various growth factors, initiating the subsequent regenerative processes. Although this hematoma-mediated stimulation is beneficial in the case of a fracture, under conditions of granulation tissue formation, the hematoma occupies the available space and hampers blood circulation, leading to a slowdown in the regeneration process. Eventually, the clot shrinks and undergoes proteolysis before the epithelium infiltrates it [18].

Treating large bone defects remains a significant medical challenge. Biomaterial implantation is considered an important approach to promoting bone repair, although its effectiveness still presents challenges [19–22]. Bone healing includes early inflammatory immune regulation, angiogenesis, osteogenic differentiation, and physicochemical and mechanical properties associated with bone formation [4,16,23–28]. However, the regulatory role of the immune system in the biomaterial-mediated microenvironment of bone is often overlooked, which can lead to undesirable bone repair effects [29]. Once implanted in the body, biomaterials interact with immune cells and can trigger an inflammatory response, with the types of cells involved and the duration of the response significantly impacting therapeutic outcomes, ranging from fibrosis formation to regeneration (osteogenesis and angiogenesis) [30]. An uncontrolled inflammatory response can disrupt bone homeostasis, resulting in delayed wound healing and bone regeneration. Conversely, a beneficial anti-inflammatory immune microenvironment modulated by biomaterials may enhance

bone cell differentiation, improve blood vessel formation, and enable successful long-term implantation [31,32]. Skeletal tissue regeneration achieved through the combination of pre-grown cells and growth factors with an appropriate scaffold is a promising approach, but synthetic bone graft substitutes with inherent osteoinductive properties may offer a more comprehensive solution [33]. Currently, a wide range of biomaterials are used as matrices. Major concerns, such as increased operative time, limited accessibility, and the risk of donor site morbidity [34], have led to the development of synthetic bone graft substitutes [16].

Bone is composed of hydroxyapatite (HA) (69–80%), collagen (17–20 wt.%), and other substances (water, proteins, etc.) [35]. Composite materials based on biopolymers and calcium phosphates are widely used for bone replacement [36]. Natural polymers are a good substitute for synthetic polymers. Their composition mimics extracellular matrix (ECM); they are bioabsorbable, biocompatible, biodegradable, and able to adsorb bioactive molecules. Biopolymer composites for medical applications should have similarities to the complex architecture of the human body and polymer composites. Furthermore, biopolymer-based drug and bioactive agent release systems should be developed as multi-functional release systems for maintaining the functionality of biological molecules [37,38]. There are around 28 types of collagen, but the most prevalent type found in the ECM of tendon and bone tissues is type I collagen [39]. Hydroxyapatite is deposited into the holes of type I collagen in the process of bone biomineralization [40]. Therefore, due to their compositional and structural analogies to natural bones, the composites of collagen and HA are of special interest among all kinds of bone substitutes [38,41].

Natural bones are a complex assembly of parallel type I collagen nanofibrils and HA crystals precipitated on their surface [42]. Thus, composite materials for bone replacement should be included in the process of bone formation promoted by osteoblasts (mineralization) to create an environment for the crystallization of calcium phosphates [41]. Two types of cells are involved in the bone formation process: osteoblasts (bone-forming) and osteoclasts (bone-resorbing). During the process of ossification, osteoblasts secrete type I collagen with noncollagenous proteins such as osteocalcin, bone sialoprotein, and osteopontin. Osteoblast-secreted ECM may initially be amorphous and noncrystalline but gradually transform into more crystalline forms [43]. One of the main challenges to bone tissue engineering is to develop scaffolds with optimal mechanical properties, biodegradability, and appropriate architecture for cell colonization and organization, which can ensure the integration of a scaffold with host tissue [38,41]. It should be clarified that natural bone is a kind of nanocomposite material that is heterogeneous and anisotropic. Its main components have several structural levels, from macro to nanoscale. The structure from the outer dense/cortical bone to the inner spongi/trabeculae represents the levels of macro- and microstructure, respectively [44].

Nanocomposites, primarily composed of mineralized collagens and minerals, exhibit structural characteristics similar to those of bone at the nanolevel. Consequently, to translate these novel discoveries into practical clinical applications, it is highly recommended to replicate the natural functionality of bone using advanced technologies such as 3D bioprinting and electrospinning [45].

As a result, the definition of biomaterial has evolved from being a “non-viable material used in a medical device designed to interact with biological systems” [46] to a “material intended to assume a form that can actively guide, through interactions with living systems, the progression of any medical or diagnostic procedure” [47]. This expanded definition signifies the growth and advancement of biomaterial science and technology, emphasizing its multidisciplinary, interfunctional, and translational nature.

2. General Principles of Bone Substitute Synthesis

2.1. Inorganic Phases of Bone Substitute Materials: Calcium Phosphate Materials

Materials based on calcium phosphates are widely utilized for bone regeneration due to their similar chemical composition to the mineral component of bones. Clinical studies

have confirmed that highly crystalline hydroxyapatite undergoes a slower transformation in bone tissue during the resorption process compared to highly dispersed materials, such as nanocrystalline calcium phosphates. A fundamental distinction between HA in bone tissues and chemically obtained HA is its ultra-dispersed (nano) structure, with nearly 25% of the atoms located on the surface of the crystallite.

These surface atoms play a direct role in the chemical and metabolic processes occurring on the surface, as well as the activation of osteosynthesis mechanisms. Consequently, a crucial factor in achieving an HA structure that closely resembles human bone tissue is the formation of nanostructured surface relief and nanoporosity on the substrate. This facilitates the deposition of nanosized crystals of HA, imparting unique physicochemical properties that significantly contribute to bioactivation mechanisms [48].

Calcium phosphate ceramics are naturally formed in the solid tissues of the human body through biomineralization. From a biocompatibility standpoint, artificial materials made from calcium phosphates should possess optimal chemical and physiological properties. However, biological calcium phosphates exhibit important characteristics such as poor crystallinity, a high degree of element substitution within the composition, and very small crystallites that are often in close contact with the emerging protein matrix [49].

These distinctive features are closely related to the exceptional functional properties of mineralized tissues. Exploring new synthesis routes and processes to obtain biomimetic ceramics and composites based on calcium phosphates seems promising for advancing the synthesis and performance of bioceramics. Furthermore, the discovery of excellent biocompatibility and bioactivity properties in materials composed of the $\text{SiO}_2\text{-CaO-P}_2\text{O}_5$ system has expanded the design possibilities and functionality of bioceramic materials [50].

Calcium phosphate composites enhance bioactivity, mechanical strength, elasticity, hierarchical structure, and porosity [51–53]. However, achieving materials that closely resemble the composition, structure, crystallinity, morphology, and biological properties of natural tissues is a challenging task for researchers. Nanosized low-crystalline hydroxyapatite, produced through wet chemical precipitation, shares chemical composition and particle size similarities with biological apatite but lacks essential substitution ions such as Na^+ , K^+ , Mg^{2+} , and Cl^- and exhibits high reactivity [54].

It is important to note that not all calcium phosphate compounds have biomedical applications, as indicated in Table 1. Many synthetic calcium phosphates do not naturally occur in biological systems. In skeletal structures, they are predominantly found in the form of poorly crystallized, calcium-deficient apatite.

Table 1. Existing calcium phosphates and their main properties [55–57].

Ca/P Atomic Ratio	Compound	Formula	Solubility at 25 °C, $-\log(\text{Ks})$	Solubility at 25 °C, g/L	Stability pH in Water Solutions at 25 °C
0.5	Calcium dihydrophosphate monohydrate (MCPM)	$\text{Ca}(\text{H}_2\text{PO}_4)_2 \cdot \text{H}_2\text{O}$	1.14	~18	0.0–2.0
0.5	Calcium dihydrophosphate anhydrous (MCPA)	$\text{Ca}(\text{H}_2\text{PO}_4)_2$	1.14	~17	Stable at >100 °C
1.0	Calcium hydrophosphate anhydrous (DCPA), mineral monetite	CaHPO_4	6.90	~0.048	Stable at >100 °C
1.0	Calcium hydrophosphate dihydrate (DCPD), mineral brushite	$\text{CaHPO}_4 \cdot 2\text{H}_2\text{O}$	6.59	~0.088	2.0–6.0
1.33	Octacalcium phosphate (OCP)	$\text{Ca}_8(\text{HPO}_4)_2(\text{PO}_4)_4 \cdot 5\text{H}_2\text{O}$	96.6	~0.0081	5.5–7.0
1.5	α -tricalcium phosphate (α -TCP)	$\alpha\text{-Ca}_3(\text{PO}_4)_2$	25.5	~0.0025	Obtained at solid state
1.5	β -tricalcium phosphate (β -TCP)	$\beta\text{-Ca}_3(\text{PO}_4)_2$	28.9	~0.0005	Obtained at solid state

Table 1. Cont.

Ca/P Atomic Ratio	Compound	Formula	Solubility at 25 °C, $-\log(K_s)$	Solubility at 25 °C, g/L	Stability pH in Water Solutions at 25 °C
1.0–2.2	Amorphous calcium phosphate (ACP)	$Ca_xH_y(PO_4)_z \cdot nH_2O$ $n = 3\text{--}4.5; 15\text{--}20\% H_2O$	*	*	~5–12 (always metastable)
1.5–1.67	Calcium deficient hydroxyapatite (CDHA) (as prepared HA)	$Ca_{10-x}(HPO_4)_x(PO_4)_{6-x}(OH)_{2-x}$ At $x = 1 (0 < x < 1)$ $Ca_9(HPO_4)(PO_4)_5(OH)$	~85.1	~0.0094	6.5–9.5
1.67	Hydroxyapatite (HA, HAp or OHAp)	$Ca_{10}(PO_4)_6(OH)_2$	116.8	~0.0003	9.5–12
1.67	Fluorapatite (FA or FAp)	$Ca_{10}(PO_4)_6F_2$	120.0	~0.0002	7–12
1.67	Oxyapatite (OA or OAp)	$Ca_{10}(PO_4)_6O$	~69	~0.087	Obtained at solid state
2.0	Tetracalcium phosphate (TTCP), mineral hilgenstokite	$Ca_4(PO_4)_2O$	38–44	~0.0007	Obtained at solid state

* The exact measurement is not possible, but the following data were found: 25.7 ± 0.1 (pH = 7.40), 29.9 ± 0.1 (pH = 6.00), and 32.7 ± 0.1 (pH = 5.28). Comparison of solubility in acetate buffer ACP >> α -TCP >> β -TCP > CDHA >> HA > FA.

Compounds with an ionic ratio of Ca/P < 1 are unsuitable for implantation due to their high solubility and acidity. Similarly, TTCP (tetracalcium phosphate) is not suitable for medical use because of its basic nature. However, with proper combination and incorporation of other phosphates and chemicals, even these compounds can be successfully utilized in medical applications.

The solubility of calcium phosphate (CaP) phases is primarily influenced by their chemical composition, crystal properties, and the presence of cationic or anionic substitutions within the apatite lattice [58–60]. When comparing their dissolution in an acetate buffer, the solubility order is as follows: bone > enamel > β -TCP > HA. β -TCP demonstrates faster dissolution than HA in physiological solutions. The solubility of CaP ceramics is also influenced by factors, such as porosity and particle size. Higher porosity increases the surface area in contact with fluid, leading to an accelerated dissolution rate [61]. Hydroxyapatite, or calcium-deficient hydroxyapatite, is the most commonly used calcium phosphate for bone tissue regeneration. Brushite and octacalcium phosphate are also present in the human body. They are found in dental calculus and contribute to pathological calcification, as well as serving as intermediate compounds during the deposition of more thermodynamically stable HA during bone tissue mineralization [60].

Calcium phosphate materials with brushite ($CaHPO_4 \cdot 2H_2O$) as their main component are utilized for their in vivo resorbability [62–64]. Brushite, or calcium dihydrogen phosphate, can exist as an intermediate phase during HA precipitation and bone tissue mineralization. It remains stable in an acidic environment (pH < 6). The general reaction sequence is as follows: ACP \rightarrow brushite \rightarrow OCP \rightarrow HA at pH = 6.5 and room temperature. Under physiological conditions, brushite can transform into HA in aqueous solutions [65–67].

2.1.1. Brushite (Dicalcium Phosphate Dihydrate, DCPD)

Brushite has a monoclinic crystal lattice (Figure 1a), and hydroxyapatite has a hexagonal lattice (Figure 1b).

Dicalcium phosphate dihydrate is obtained by adjusting pH in the range of 3–4 at room temperature. DCPD can be produced from calcium-containing phosphates in a slightly acidic environment. It is often used as a component of bone cement and toothpaste to promote bone and tooth mineralization due to its biocompatibility, biodegradability, and osteoconductivity. DCPD could be converted to calcium-deficient hydroxyapatite in vivo. Brushite-based biomaterials are rapidly resorbed in vivo, realizing good biocompatibility in the absence of inflammatory cells.




Figure 1. Crystal structure of (a) brushite and (b) hydroxyapatite [48,68,69].


Hexagonal modification, $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$, is idealized ($P6_3/m$). At this structure, OH^- crystal lattice nodes are placed on the screw axes of node 6_3 (hexagonal axis c). In the HA structure, OH^- crystal lattice nodes are placed above and below the mirror plane. This shift ($\sim 0.35 \text{ \AA}$) alternates layer by layer according to the vertical axis in the above and below directions, transforming the 6_3 axis into 2_1 , and the mirror plane into the b -axial plane [70].

Natural HA is usually calcium-deficient apatite with an atomic ratio $\text{Ca}/\text{P} < 1.67$ [48,71]. The general formula of naturally occurring HA is the following:

$(\text{Ca}, \text{M})_{10}(\text{PO}_4, \text{Y})_6(\text{OH}, \text{X})_2$ —where M —metal cations that include Mg^{2+} , Na^+ , K^+ , Sr^{2+} , Ba^{2+} , etc., Y —anions CO_3^{2-} , H_2PO_4^- , HPO_4^{2-} , SO_4^{2-} , etc., X — F , Cl , CO_3^{2-} , etc. [59]. It is therefore impossible to give a precise chemical formula for the mineral bone [61].

Substitutions of Ca^{2+} , PO_4^{3-} , and OH^- ions in HA with elements M , Y , and X have a significant impact on various properties of the material, including lattice parameters, crystallinity, crystal symmetry, thermal stability, morphology, solubility, and both chemical and biological behavior [71]. For instance, the substitution of OH^- groups in HA with F^- ions enhances the structural stability and corrosion resistance of the material in biological environments. This substitution also promotes the growth of larger crystals and improves crystallinity [72]. Additionally, the substitution of cations can influence the properties of apatite. For example, the substitution of Ca^{2+} with Mg^{2+} ions results in a decrease in crystallinity and an increase in the solubility of HA [71].

The most mobile elements of the HA crystal lattice ($\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2 = 2\text{Ca}_5(\text{PO}_4)_3\text{OH}$) are the Ca^{2+} cation and OH^- anion. They can easily move into an internodal position and create Frenkel point defects: cation $\text{V}^{2-}_{\text{Ca}^{2+}}$ and anion $\text{V}^+_{\text{OH}^-}$ vacancies.




and internodal position of cations Ca^{2+} and anions OH^- .

Then, cations Ca^{2+}_i and anions OH^-_i move into physiological solution:




where s is the position of the ion on the surface, and aq is the hydrated state of ions.

Activated by vacancies, HA interacts with diffusing the lattice hydrogen proton H_i^+ ; as a result, the HPO_4^{2-} anion moved into the internodal position:




Anion HPO_4^{2-} diffuses to the crystal surface and then moves into the physiological solution:



If the solution has a $\text{pH} < 6$, a primary orthophosphate ion is obtained:



To complete the dissolution of HA, the overall reaction equation is used:



The driving force of chemical dissolution (HA resorption) is the neutralization reaction of two hydroxyl groups of HA by two protons with a heat release of nearly 40 kJ/mol [48].

2.1.2. Calcium-Deficient Apatite (CDA)

Calcium-deficient apatite (CDA) can be easily prepared by dropwise titration of a saturated solution of $\text{Ca}(\text{OH})_2$ with H_3PO_4 [73]. Another synthesis method consisted of adding calcium salt to a phosphate salt in basic media pH 11 buffered with ammonia (NH_4OH) [74]. CDA crystals are poorly crystallized and are of submicron dimensions. The precipitated powders have large surface areas, typically 25 to 100 m^2/g . Upon heating at 800 °C to 1000 °C, a particular composition of CDA leads to a pure b-tricalcium phosphate [$\beta\text{-Ca}_3(\text{PO}_4)_2$] phase.

CDAs of various compositions can be precipitated in aqueous solutions. Depending on its composition, the calcium-deficient apatite decomposes at around 800 °C to 1000 °C, forming $\beta\text{-TCP}$ and HA. At high temperatures, CDA with a Ca/P ratio of 1.58 leads to a mixture of HA and b-TCP in a weight ratio of 60:40, a so-called biphasic calcium phosphate [61].

Substitution of OH groups by CO_3^{2-} leads to the formation of carbonate apatites, which are widespread in bone tissue. The CO_3^{2-} group can substitute OH groups (an A-type substitution), as well as the substitution of PO_4^{3-} -3a (B-type). In general, substitution in carbonate apatite is mainly B-type [75].

HA is widely used clinically in bone regeneration as implants or coatings for other implants due to its good biocompatibility, bioactivity, and osteoconductive properties. Therefore, it is widely used for dental surgery, the repair of bone defects, vertebral fusion operations, and maxillofacial repairs. Mg-substituted HA in different forms displayed advanced bioactivity and promoted osteogenesis.

2.1.3. Octacalcium Phosphate (OCP)

Octacalcium phosphate (OCP) is considered a mineral precursor to carbonate-containing calcium-deficient HA, which is a prototype for apatite crystals in bones and teeth. OCP has good osteoinductivity and is widely used in bone repair, including the coating of metal grafts, CaP bone cement, and scaffolds. In composite materials, OCP/collagen composite scaffolds have osteoconductivity that is positively correlated with the dose of OCP, and OCP acts as an initial deposition site for bone; its conversion to HA plays a significant role in bone formation. Moreover, osteoblasts that can initiate bone formation were found on the surface of OCP particles, and osteoblasts were directly attached to OCP to form bone matrix. The structure of OCP is closely associated with HA because OCP is composed of apatite layers stacked alternately with hydrated layers and can be converted into Ca-deficient HA in neutral aqueous conditions [38,76].

2.1.4. Amorphous Calcium Phosphate (ACP)

Amorphous calcium phosphate (ACP) is often encountered as a transient phase during the precipitation of calcium phosphates (CaPs) in aqueous solutions. ACP formation is favored by rapidly mixing highly concentrated calcium and phosphate solutions at a high pH and low temperature. ACP forms at the beginning of precipitation due to its lower surface energy compared to octacalcium phosphate or hydroxyapatite. Over time, ACP can crystallize into calcium-deficient apatite through processes of internal hydrolysis and dissolution-reprecipitation.

The conversion of ACP into calcium-deficient apatite can be delayed by the presence of inhibitors of crystal growth, such as magnesium, pyrophosphate, or carbonate [77]. The exact chemical arrangement of atoms in ACP preparations is still uncertain, as many analytical methods do not provide precise crystallographic information. X-ray patterns

typically exhibit a broad halo; infrared spectra show featureless phosphate absorption bands; and electron microscopy reveals spherical particles with diameters ranging from 20 to 200 nm and diffraction rings [59,60,77].

ACP plays an important role in the biomineralization process as a precursor of HA formation. ACPs express osteoconductivity and biodegradability, leading to a variety of applications, including CaP bone cement, scaffolds, bone repair biomaterials, and dental implants [48]. Nano-sized clusters in the ACPs have large specific surface areas and pH-responsive degradation, which makes them ideal drug delivery carriers.

2.1.5. Tricalcium Phosphate (TCP)

Tricalcium phosphate (TCP) cannot be directly precipitated from aqueous solutions. β -TCP can only be prepared by heating calcium-deficient apatite above 800 °C or through solid-state reactions. At temperatures above 1125 °C, β -TCP transforms into the high-temperature phase known as α -TCP. Although both compounds have the same chemical composition, they differ in their crystal structures [61].

In recent years, ceramics based on α and β -TCP have gained widespread use, primarily due to the higher solubility of TCP in contact with body fluids [78]. β -TCP exhibits lower solubility in water compared to α -TCP, which is more reactive in aqueous systems. When α -TCP comes into contact with water or body fluids, it undergoes rapid hydrolysis and reprecipitation as CDA, making it a valuable component in many calcium phosphate cements [61].

Compared to HA, β -TCP has better biodegradability and resorption rates, which can increase the biocompatibility of the implants. β -TCP has a relatively lower resorption rate than α -TCP, and the nanoporous structure of β -TCP provides excellent biomineralization, cell adhesion, and osteoblast proliferation.

2.1.6. Stoichiometric HA

Stoichiometric HA is the second-most stable and least soluble CaP after fluoroapatite. The preparation of pure HA from aqueous solutions is difficult owing to numerous ionic substitutions and possible lacunae in the crystal lattice. Some authors have reported its precipitation by slowly adding phosphate solution to the calcium solution and refluxing at 100 °C for 1 h [60,79]. After filtration, the precipitate is washed, dried at 80 °C, and heated at 800 °C to 1000 °C to form pure HA $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$. HA powder or slurry can be mixed with polymer spacers and heated in the range of 1000 °C to 1300 °C to form macro-porous ceramics [58,80].

In medical practice, hydroxyapatite bioceramics are used in the forms of powder, granules, solid material, porous material, part of composite materials, or a coating on various types of substrates [48,71]. HA is considered to have good biocompatibility, bioactivity, and osteoconductivity but expresses low osteoinductivity [58]. Therefore, it is better to combine HA with other materials for improved osteoinductivity. It has been applied in orthopedics, laryngology, dentistry, traumatology, maxillofacial surgery, and ophthalmology.

2.1.7. Fluorapatite (FA)

Fluorapatite (FA) is the least soluble phase among calcium phosphates. It crystallizes in the same crystallographic system as hydroxyapatite, with fluoride ions substituting hydroxyl ions in the apatite tunnels [59,60]. FA readily forms a solid phase, but obtaining pure FA through precipitation in aqueous solutions is relatively challenging. Even at high concentrations of fluoride ions, the formation of solid-state solutions stabilized by hydrogen bonds between fluoride and hydroxyl ions in the apatite tunnels leads to the formation of fluoridated hydroxyapatite (FHA).

FHA is mainly found in bone tissue, and FA is found in tooth enamel. The presence of fluoride in saliva and plasma is necessary for dental and skeletal development. The physiological importance of fluorine ions in stimulating the mineralization and crystallization of calcium phosphates in bone formation has been proven. The osteoblastic response in

terms of adhesion, differentiation, proliferation, and mineralization processes is enhanced by importing fluorine into hydroxyapatite compared to pure HA [60]. The amount of fluoride ions released directly affects the cell attachment, proliferation, morphology, and differentiation of osteoblast cells. FA has better protein absorption and cell attachment than HA [48].

HA is the most stable phase under physiological conditions and exhibits the slowest solubility and resorption kinetics in the human body. Implants made of sintered, pure HA ceramics can remain in bone defects for many years after implantation, indicating their non-resorbable nature. On the other hand, β -tricalcium phosphate (β -TCP) is resorbable, and the amount of remaining implant decreases over time. Biphasic calcium phosphate ceramics, which consist of a mixture of HA and β -TCP, are often preferred as bone substitutes. The solubility of BCP ceramics depends on the weight ratio of HA and β -TCP, making it closer to either β -TCP or HA [78,81].

Solid-state synthesis is a method used to obtain highly crystalline HA (up to 30 μm) with the required stoichiometry. However, it requires long-term annealing at temperatures up to 1300 $^{\circ}\text{C}$ under pressures of 20–31 kPa [78,81]. Among the methods for obtaining HA from aqueous solutions (Table 2), the most commonly used are the “wet methods”, which can be categorized into precipitation from solutions with constant or variable compositions, hydrothermal synthesis, and hydrolysis of calcium phosphates [78,81,82].

Table 2. The ways of hydroxyapatite synthesis from aqueous solutions [48,81].

Initial Reactants	Parameters of Synthesis	Morphology
Precipitation		
Ca(NO ₃) ₂ (NH ₄) ₂ HPO ₄ (0.5 M, 1 L)	pH = 9.5 (NH ₄ OH), 25 $^{\circ}\text{C}$, 24 g, Ca/P = 1.5	Agglomerate (10–80 μm), from granules (0.06 μm)
Ca(NO ₃) ₂ (1 M) (NH ₄) ₂ HPO ₄ (1 M)	pH = 7–11 (NH ₃ , NH ₄ NO ₃), Ca/P = 1.5–1.67	Surface area 116–119 m ² /g
Ca(NO ₃) ₂ (0.13 M, 2.5 L) (NH ₄) ₂ HPO ₄ (0.07 M, 2.5 L) CH ₃ COONH ₄ (1 N)	pH = 8.5–9.5 (NH ₃), 100 $^{\circ}\text{C}$, >5 g, Ca/P = 1.68	Granules (5 μm)
Ca(NO ₃) ₂ (0.13 M, 2.5 L) (NH ₄) ₂ HPO ₄ (0.07 M, 2.5 L) CH ₃ COONH ₄ (1 N)	pH = 3.5–9.5 (NH ₃), 100 $^{\circ}\text{C}$, >5 g, Ca/P = 1.73	Whiskers (1.9 \times 0.14 μm)
Na ₂ HPO ₄ (0.3 M) CaCl ₂ (0.5 M)	pH = 8.5–9.5 (NH ₄ OH), 70 $^{\circ}\text{C}$, 24 g, Ca/P = 1.65	Surface area 39.7 m ² /g
H ₃ PO ₄ (0.5 M, 4 L) CaCl ₂ (0.5 M, 7 L)	100 $^{\circ}\text{C}$, 18 g, Ca/P = 1.67	Surface area 16.7 m ² /g
NaH ₂ PO ₄ (0.1 M, 2 L) Ca(NO ₃) ₂ (0.167 M, 2 L)	pH = 8.5 (NaOH), 95 $^{\circ}\text{C}$, 24 h, Ca/P = 1.67	Granules (0.025 μm)
Ca(OH) ₂ H ₃ PO ₄ (0.5 M)	pH = 7.95 $^{\circ}\text{C}$, 2–6 days, Ca/P = 1.67	40–60 \times 60–90 nm
Ca(NO ₃) ₂ (0.01–1 M) (NH ₄) ₂ HPO ₄ (0.01–1 M)	pH = 7–10 (NH ₃), Ca/P = 1.5–1.67	Flat needles 15–30 \times 25–70 nm
CaHPO ₄ ·2H ₂ O (120 g) H ₂ O (4 L)	pH = 8.5 (NH ₃), 100 $^{\circ}\text{C}$, >0.5 g, Ca/P = 1.67	Granules (75 μm)
CaHPO ₄ ·2H ₂ O (80 g) H ₂ O (0.4 L)	pH = 8.5 (NH ₄ OH), 40 $^{\circ}\text{C}$, 3 r, Ca/P = 1.51	Plates with whiskers (0,1 μm)
α -Ca ₃ (PO ₄) ₂ (40 g) H ₂ O (1 L)	pH = 5.5–10 (NH ₄ OH), (HNO ₃) 80 $^{\circ}\text{C}$, 2–3 g, Ca/P = 1.5–1.68	Agglomerates (10–30 μm) flakes (2 \times 2 μm) and needles (5 \times 0.2 μm)
α -Ca ₃ (PO ₄) ₂ + Ca(OH) ₂ , HNO ₃	pH = 4–10, 95 $^{\circ}\text{C}$, 2–3 g, Ca/P = 1.67	Plates, needles (3–5 μm)


Fine crystalline precipitates of hydroxyapatite can be obtained during precipitation from alkaline aqueous solutions [78,81]. Studies have shown that prior to the formation of HA, the precipitation of amorphous calcium phosphate is observed [83,84]. In the initial stage, the sediment obtained often does not correspond to the exact composition of HA. However, when the primary precipitate of calcium phosphate is kept under appropriate conditions, the calcium-to-phosphate (Ca/P) ratio increases, and crystallization of HA takes place.

The crystallization rate of the primary HA precipitate is influenced by various factors, including the concentration of initial salts, the order and speed of reactant addition, mixing conditions, pH, reaction temperature, precipitation time, ionic strength of the solution, and the presence of impurities [85–87]. These factors play a crucial role in controlling the crystallization process of HA and achieving the desired crystalline structure and composition.

There are certain difficulties in the preparation of synthetic HA crystals, which are related to the chemical similarity of the material to some ions, the complex nature of calcium phosphate systems, and the role of kinetic parameters that depend on the experimental conditions [88].

The substitution of cations and anions in HA with appropriate groups present in bone tissue (Mg^{2+} , Na^+ , K^+ , F^- , Cl^- , CO_3^{2-} , SO_3^{2-}) is used to regulate the chemical behavior of HA.

To obtain carbonate apatite ceramics, the following synthesis could be used [89].



In the final stage of the synthesis, a mixed solution containing $(NH_4)_2HPO_4$ and $(NH_4)_2CO_3$ is added to create equal conditions for the interaction of phosphate and carbonate ions with calcium and hydroxyl ions under constant stirring [90]. The degree of crystallinity of HA obtained through precipitation from aqueous solutions increases with higher temperatures and longer sediment aging times [81,91]. However, decreasing the preparation temperature, synthesis time, and initial solution pH can lead to deviations from the stoichiometric ratio of Ca/P = 1.67 in HA [92]. Controlling multiple parameters simultaneously can be challenging, which may result in poor reproducibility of morphology, particle size, and Ca/P ratio [92].

Synthetic HA ($Ca_{10}(PO_4)_6(OH)_2$) exhibits good stability in the body, while tricalcium phosphates (α -TCP, β -TCP, $Ca_3(PO_4)_2$) are more soluble. Biphasic calcium phosphate, a mixture of HA and β -TCP, demonstrates intermediate properties depending on the weight ratio of stable and degradable phases. The dissolution rate follows the order: α -TCP > β -TCP > BCP > HA [93]. Recent advancements in the preparation of calcium phosphates have enabled the production of substituted CaP ceramics, which not only exhibit different solubility and bioactivity but also elicit modified biological responses through the release of biologically active ions during dissolution [94]. CaP ceramics can elicit various biological effects in vivo, and while most are osteoconductive, only certain types are osteoinductive. According to Samavedi et al., the osteoinductive potential of CaPs decreases in the order of BCP > TCP > HA [38,93].

High-temperature phases commonly used in medical applications, such as HA and α - and β -TCP in mono- or multi-phase forms [95], are obtained through a two-stage process: (1) synthesis of precursors and (2) high-temperature processing of these precursors. The biomimetic approach, which involves the use of simulated body fluids (SBFs) as a medium for ongoing processes, enables the production of bone-like nanosized materials with composition and ionic inclusions similar to solid tissues. Various simulated body fluids (EBSS, HBSS, SBFc, and SBFr) have been developed to mimic the composition of human extracellular plasma [96]. These fluids are complex, multicomponent systems containing Na^+ , K^+ , Ca^{2+} , Mg^{2+} , Cl^- , HCO_3^- , HPO_4^{2-} , and SO_4^{2-} ions and are supersaturated with phosphate and carbonate salts. As a result, they exhibit instability and create conditions for the simultaneous occurrence of stable and metastable crystallization processes, accompanied by dissolution, ion exchange, and other related phenomena. To explore these processes,

thermodynamic calculations are applied to predict possible crystallization events in these systems, which then guide experimental investigations.

Initially, the amorphous calcium phosphate obtained in these systems transforms into a low-crystalline bone-like carbonate apatite when present in SBFc, SBFr, and SBFcg, with the rate of transformation being dependent on the composition of the specific simulated body fluid [97,98]. The fastest transformation is observed in SBFcg, followed by SBFr. The phase transformations of amorphous products result in changes in the composition of both the solid and liquid phases during maturation, highlighting the strong influence of the simulated body fluid's composition on the dissolution/crystallization processes. The presence of glycine in SBFcg or higher concentrations of HCO_3^- ions in SBFr leads to increased complexation in solution, thereby enhancing the dissolution rate and creating supersaturation conditions relative to the thermodynamically more stable phase.

The research results confirm the hypothesis that HA can crystallize in two stages:

(1) The initial precipitation of a metastable product and (2) the recrystallization of the latter over time into a thermodynamically more stable salt.

The evidence presented suggests that the process of hydroxyapatite precipitation is primarily governed by kinetic factors rather than thermodynamic considerations. In the precipitation of Mg- or Zn-modified precursors, it was observed that all Zn^{2+} ions and approximately half of the Mg^{2+} ions from the reaction solutions were incorporated into the precipitated amorphous calcium phosphate. The different chemical behaviors of Zn^{2+} and Mg^{2+} ions can be explained by the “softness-hardness” factor and the crystal field stabilization energy (CFSE) [99].

The processing of these precursors, including filtration, washing, and calcination, can induce changes in crystal structure and agglomeration. To address this, new processing technologies need to be developed to preserve the initially obtained nanocrystals. Various biocompatible organic additives, such as natural polysaccharides (guar gum and xanthan gum), amino acids (glycine, alanine, and valine), and polyols (glycerin), have been proven to influence the composition and morphology of the obtained precursors, as well as the granulometric composition of their high-temperature phases [100]. The choice of modifiers aims to inhibit the growth of primary nuclei and improve the morphological characteristics of the particles. A biomimetic approach and continuous precipitation method were employed, wherein organic modifiers were added to the mother liquor and glycine buffer. The type, concentration, and maturation time of the organic additives play a role in shaping the initially deposited particles and their specific surface area. Low concentrations (<7 g/L) or the absence of additives, along with short maturation times, result in spherical particles with specific surface areas ranging from 28 to 48 m^2/g . On the other hand, high concentrations of additives (>142 g/L) or longer maturation times lead to a loss of the spherical shape and elongation of particles, resulting in significantly increased specific surface areas (106–242 m^2/g). While the specific surface area of the powders decreases sharply to 2–4 m^2/g with an increased temperature in all cases, the powders obtained in modified media exhibit fine, unagglomerated particles with well-formed grains. The particle size distribution of samples heated at 1000 °C reveals that the narrowest range of particle sizes (0.25–0.55 μm) was achieved in a medium modified with xanthan gum.

2.2. Guiding Principles

2.2.1. Heat Treatment of Precursors and Preparation of Final Fine Ceramic CaP Powders

To obtain ion-modified amorphous calcium phosphates, precipitation is followed by a stepwise calcination process. The amorphous precursors are subjected to calcination at temperatures of 200, 400, 600, 800, and 1000 °C, each temperature being maintained for 3 h. During calcination, the amorphous precursors transform into two-phase mixtures of HA and β -TCP, or monophasic magnesium (Mg)- or zinc (Zn)-modified β -TCP, depending on the concentration of Mg^{2+} and Zn^{2+} ions introduced into the structure. Both Mg and Zn substitutions contribute to the conversion of amorphous calcium phosphate to β -TCP, with the effect being more significant in the case of Zn substitution.

Monophasic Mg- β -TCP and Zn- β -TCP are observed at 600 °C for samples with Me/(Me + Ca) ratios above 0.05, while biphasic (HA and β -TCP) calcium phosphates are observed at ratios lower than 0.05. Rietveld refinement analysis confirms that Mg²⁺ and Zn²⁺ ions replace Ca²⁺ ions in the Ca(5) Mg/Zn- β -TCP octahedral positions, leading to a decrease in the average Ca(5)-O distances and the a and c cell parameters. The narrowing of the crystal lattice is more pronounced in Zn-substituted samples due to differences in the preferred coordination polyhedral for Zn and Mg ions [101].

The particle morphology of the calcined samples is influenced by both the deposition process and the post-treatment process. The standard approach, which includes filtration, washing, drying, and calcination, results in a dense, pore-free mass. However, to prevent particle agglomeration and obtain fine-grained unsintered ceramic powders with a composition close to that of hard tissues, a method involving several steps has been developed. These steps include biomimetic precipitation of ion-modified calcium phosphate precursors in various electrolyte systems, gelation of the suspension using xanthan gum, lyophilization at 56 °C, low-temperature (300 °C) calcination of the modified suspension for 1 h, washing the calcined sample with water, secondary gelation of the washed sample, lyophilization at 56 °C, and step sintering up to 1000 °C [102].

Selected ceramic powders with Zn/(Ca + Mg + Zn) ratios of 0, 0.01, 0.03, and 0.13, as well as Mg/(Ca + Mg + Zn) ratios of 0, 0.02, 0.05, and 0.10, were subjected to *in vitro* and *in vivo* testing to evaluate their cytotoxicity and response in bone tissue [102,103]. The results demonstrated the biocompatibility, osseointegration, and non-toxicity of the tested materials. They did not induce inflammation and only elicited a mild foreign-body reaction. The ceramic powders were found to be biodegradable within physiological limits, as evidenced by the presence of biochemical bone markers. These findings confirm the materials' potential for bone regeneration and reconstruction.

To manufacture calcium phosphate materials with micro-, meso-, and macroporosity suitable for bone implants, samples were developed using natural polymers of different compositions and origins. Plant polysaccharides such as xanthan gum and carrageenan, along with animal gelatin, were utilized due to their water absorption and gradual decomposition properties within the body. These polymers provide sustained porosity in bone implants, supporting the growth of organic cells. A technology was developed to produce properly molded composite materials, involving the following steps: preparation of hydrogels with specific compositions; homogenization of gel-powder composite mixtures; appropriate shaping techniques; lyophilization; and modification of gelatin using a 1% glutaraldehyde solution. The optimal composite material consisted of Zn-modified β -tricalcium phosphate (Zn/(Ca + Mg + Zn) = 0.13) powder/gelatin/xanthan gum/carrageenan/water with weight proportions of 73.89/0.12/0.12/2.46/1.23/22.17 (wt.%). Subsequent storage of the composite material in simulated body fluid (SBF) for one month resulted in the formation of a new phase and partial dissolution of the polymers [104,105].

2.2.2. Ordered Mesoporous Silicon–Calcium–Phosphate Composites

Ordered mesoporous ceramics belong to a class of porous materials characterized by uniform mesopores ranging from 2 to 50 nm and containing ordered mesostructures. The definition of these materials is primarily based on their physical sorption characteristics. According to the classification provided by the International Union of Pure and Applied Chemistry, porous solid materials are categorized as microporous if their pore diameter is up to 2 nm; macroporous if the pore size exceeds 50 nm; and mesoporous, indicated by the prefix “meso”, when the pore size falls between 2 and 50 nm [106]. While mesopores can be found in aerogels and columnar clays, which exhibit disordered pore systems with a wide pore size distribution, our focus lies on ordered mesoporous ceramics, specifically amorphous silicate materials synthesized in the laboratory, such as SBA-15 (Santa Barbara Amorphous No. 15) [107]. This material, first reported by Stucky et al. in 1998, consists of amorphous silica that forms cylindrical mesopores arranged in a hexagonal structure.

An analysis of its low-angle X-ray powder diffraction confirms the presence of three peaks, with d-spacing values of 9.8, 5.6, and 4.8 nm, which correspond to the (100), (110), and (200) reflections of a two-dimensional hexagonal mesostructure with a lattice constant “a” of 11.2 nm in the space group P6 mm [108]. The synthesis of SBA-15 involves the use of a nonionic surfactant, specifically a block copolymer of polyethylene oxide and propylene oxide. This method leads to the formation of materials with mesopore sizes ranging from 5 to 30 nm and thicker wall structures compared to its homologous counterpart, MCM-41, which is synthesized using a cationic surfactant known as alkylammonium.

In addition, the combination of amorphous silica composition and textural properties makes this material a very good candidate for medical applications as a biomaterial. According to the US Food and Drug Administration (FDA), silica has been “generally recognized as safe” and is particularly suitable as a biomaterial due to its high biocompatibility, non-toxicity of degradation products, and controlled hydrolytic degradation in biological environments [109]. In particular, amorphous silica particles decompose over time into the non-toxic orthosilicic acid $\text{Si}(\text{OH})_4$ and are excreted in the urine [109].

It is noteworthy that the SBA-15 type is obtained in the form of microparticles with a wide size distribution in the range from 1 to 100 microns. Some studies have evaluated the cytotoxicity of SBA-15 particles depending on their concentration in the medium. In our group, we observed that SBA-15 microparticles did not affect the viability of mouse macrophages up to concentrations of 100 $\mu\text{g}/\text{mL}$ in cell culture medium [110]. However, higher concentrations compromised the viability of cells activated by Toll-like receptors [110]. Toll-like receptors (TLRs) are involved in host defense and autoimmune and inflammatory diseases.

The local effect of SBA-15 silica material has also been studied close to brain tissue. A cylinder of compressed material was surgically implanted in the temporal lobe of adult male rats and did not cause necrosis or inflammation, and the surrounding biological material self-adapted to the contour of the inorganic material [108].

2.2.3. Growth of Hydroxyapatite Nanoparticles in Ordered Mesoporous Silica

Professor Hench’s discovery of bioglass in the 1970’s opened doors to a new category of biocompatible silica-based ceramics. He demonstrated that certain glasses with a predominant composition of silica in the ternary system $\text{SiO}_2\text{-CaO-P}_2\text{O}_5$ can bond with bone tissue. These glasses were termed bioactive glasses, and Professor Hench defined a bioactive material as one that can spontaneously bind to living tissue without forming a fibrous interface or foreign body reaction capsule. The data obtained on bioactive glasses suggest that the ionic dissolution products of these glasses influence the cell cycle of osteogenesis precursor cells and possess osteogenic and angiogenic properties [111]. In this context, a material with a large surface area and an interconnected network of pores enhances the rate of ion exchange and dissolution, resulting in the release of constituent ions into the solution. Sol-gel synthesized glasses in the ternary system $\text{SiO}_2\text{-CaO-P}_2\text{O}_5$ have demonstrated significant bioactivity [112]. Additionally, inspired by the bioinspired morphogenesis of bone-like hydroxyapatite nanoparticles using organic templates, researchers propose utilizing mesoporous silica to grow calcium phosphate apatite nanoparticles. They aim to achieve a high surface area in $\text{SiO}_2\text{-CaO-P}_2\text{O}_5$ bioceramics. The concept involves initially incorporating calcium ions into the silica matrix as nucleation sites for the anchoring and growth of calcium phosphate crystals.

The synthesis procedure involved two steps: The low pH step entailed preparing a calcium-doped silica matrix, achieved by modifying the methodology of the standard SBA-15 material. The growth of hydroxyapatite within mesoporous silica was accomplished by the alkaline pH of the 9th stage, including phosphate ions [108]. The increase in pH induces condensation of neighboring silanol groups, leading to the formation of new oxo bridges and consequently a significant reduction in silanol groups. We hypothesized that these siloxane cavities could retain metallic calcium ions, stabilizing them in a coordination

favorable for a macrocyclic effect. Such coordination can provide sites for the nucleation of hydroxyapatite crystals, ultimately filling the pores of the silica template.

NanoBone, a widely used commercial product in clinical practice [113,114], is a proprietary bone graft substitute composed of bioidentical nanocrystalline hydroxyapatite embedded in an amorphous silica gel matrix. The material is produced through a sol-gel process at temperatures up to 700 °C without undergoing sintering, resulting in a porous structure ranging in size from nanometers to micrometers. During surgical procedures, when in contact with the patient's blood, approximately 80% of the volume becomes filled with the patient's own proteins and biological material, effectively coating the entire inner surface area (approximately 84 m²/g). As a result, the biomaterial is perceived by the body as almost indistinguishable from the endogenous tissue [115].

In this context, the SBA-15-Nano HA material developed by our team consists of 20 nm HA nanoparticles incorporated into a mesostructured silica framework with a surface area of 275 m²/g. This material exhibits excellent adsorption properties, which make it highly suitable not only for adsorbing autologous proteins but also for potential applications in localized drug delivery following surgical interventions.

2.2.4. Requirements for Calcium Phosphate Cements (CPCs)

Osteoinductance refers to the active induction of de novo bone formation [116]. Osteoconductivity, on the other hand, is the property that facilitates the colonization and ingrowth of new bone cells on the material's surface. The osteoconductive nature of a material is primarily influenced by its chemical and physical properties, which promote cell adhesion and growth [117,118]. Osteogenicity, meanwhile, is associated with the presence of bone-forming cells within the bone graft. However, autologous bone grafting presents a significant drawback—the need for an additional surgical procedure to harvest a donor bone. Typically, an autologous donor bone is obtained from the iliac crest, which is easily accessible and contains a relatively high amount of cortical and cancellous bone [119]. Harvesting an autologous donor bone from the iliac crest can result in complications, with minor complications occurring in approximately 10% of cases and major complications in 5.8% of cases. Minor complications may include superficial infections, superficial seromas, and small hematomas. Major complications can involve vascular damage, deep hematomas requiring surgical intervention, deep infections at the donor site, fractures of the iliac bones, and neurological injuries [120], which may cause gait disturbances, shape deviations, paresthetic meralgia (neuropraxia of the lateral femoral cutaneous nerve), and protrusion of the intestine through an abdominal wall defect. An alternative treatment approach involves the use of allogeneic bone, where processed human cadaveric bone is transplanted into the patient. However, the allogeneic bone may not always be accepted as a bone substitute due to concerns such as adverse graft-versus-host reactions, graft necrosis, delayed engraftment, and relatively high costs [119,120]. Furthermore, both autologous and allogeneic bone grafts have limited availability [121].

Synthetic bone graft materials are actively being explored as an alternative to autologous and allogeneic bone grafts. They eliminate the need for a second surgical procedure and minimize the potential complications at the donor site. However, synthetic bone grafts do not possess all the characteristics of natural autologous bone, making continuous research efforts crucial for improving and developing an ideal material for bone replacement.

The Diamond concept [122,123] proposes that four essential parameters are necessary for unhindered fracture healing: osteogenic cells, an osteoconductive scaffold, growth factors, and a stable mechanical environment. Subsequently, vascularization at the site of the defect was recognized as an important factor in the fracture healing process [124].

The ideal bone graft material should fulfill these criteria. In this regard, various synthetic graft materials have been evaluated as scaffolds for bone restoration, with bioceramics being particularly appealing. Bioceramics can be classified into bioinert types (e.g., aluminum oxide or zirconia) and bioactive/bioresorbable types. Calcium phosphate-

based bioceramics, calcium sulfate-based bioceramics, and silica-based bioactive glasses are among the extensively studied bioactive/bioresorbable bioceramics. Khabraken et al. [125] outlined the characteristics of an ideal bioceramic material for bone tissue engineering as follows:

1. Biodegradable to support bone remodeling;
2. Macroporous structure to facilitate tissue ingrowth;
3. Mechanically stable and easy to handle;
4. Osteoconductive, guiding bone growth around and within the material;
5. Suitable for use as a carrier of growth factors or cells.

Synthetic biomaterials for bone regenerative treatments are employed due to their biological effectiveness, which is characterized by biocompatibility, bioactivity, and osteoconductive properties [126]. CaP-based bone substitutes promote attachment, proliferation, migration, and phenotypic expression of bone cells, leading to the formation of new bone in direct contact with the biomaterial [116]. CaP-based bone graft materials are commonly available as granules, blocks, and, more recently, cement. Among them, calcium phosphate cements (CPCs) are particularly attractive for clinical use due to their injectability and moldability, enabling minimally invasive application and optimal filling of irregularly shaped bone defects [127,128].

Contrarily, when using granules or blocks for implantation, they are typically mixed with a liquid (e.g., blood), resulting in suboptimal contact between the bone and the implant. Furthermore, blocks cannot be placed using minimally invasive surgery, and their size needs to be adjusted to match the defect through cutting, shaping, or drilling.

In bone regenerative procedures involving calcium phosphate cements (CPCs), the complete degradation and replacement of the CPC with a new living bone is preferred. However, as mentioned earlier, the biodegradability of CPCs is relatively low. Ideally, the rate of CPC biodegradation should closely match the rate of new bone formation to ensure the gradual restoration of mechanical properties in the newly formed bone tissue.

In vivo degradation of CPCs can occur through two different mechanisms: (1) Passive degradation due to the dissolution of the ceramic matrix in the extracellular fluid, and (2) active degradation mediated by cellular activity, including osteoclasts, giant cells, and macrophages. The rate of passive degradation, which involves the dissolution of the matrix in the extracellular fluid, depends on the CPC properties, such as surface area, calcium-to-phosphate (Ca/P) ratio, crystallinity, solubility, pH, and bodily fluid perfusion [118,129]. Previous studies [130,131] have shown that the physical destruction of CPCs can lead to ion dissolution and particle fragmentation due to the loss of mechanical integrity. On the other hand, the active degradation of CPCs is primarily mediated by giant cells and osteoclasts, with macrophages also playing a role in phagocytosing fragmented particles [132–134]. Macrophages have been observed to colonize the surface of CPCs shortly after implantation and are suggested to have a critical role in biodegradation [135]. Additionally, biomaterial particles released from CPCs can interact with immune cells, triggering the release of inflammatory mediators [136]. When macrophages encounter calcium phosphate particles, they attach to them and become activated for phagocytosis [129]. While macrophages are crucial for phagocytosing small fragments and particles, osteoclasts are primarily responsible for the active biodegradation of CPCs. These cells locally reduce the pH near the biomaterial, leading to the in vivo degradation of CPCs [137].

The presence of pores in calcium phosphate cements contributes to their degradation and various beneficial effects. Pores facilitate fluid flow, including perfusion in the case of interconnected porosity, as well as migration and proliferation of osteoblasts into the CPCs. Pores also promote vascularization and improve the stability of the tissue-implant interface by providing more surface area for cell proliferation and tissue regeneration. Pores in CPCs can be categorized based on their size as micropores (internal pore width <1 μm), mesopores (internal pore width 1–100 μm), and macropores (internal pore width >100 μm) [35,138]. The formation of microporosity in CPCs is attributed to the solidification mechanism, where crystals grow into needle-like or lamellar structures, creating a microporous structure [139].

The microporosity in CPCs can reach up to 60%, which increases the surface area, facilitates fluid penetration, and promotes protein adsorption [140].

The size of micropores can be controlled by adjusting processing parameters such as the particle size of the powder phase and the calcium-to-phosphate (Ca/P) ratio. Studies have shown that decreasing particle size leads to smaller pore sizes, and at a low Ca/P ratio, the pore size decreases due to reduced space between particles in the mixture [141]. The sintering temperature of the powder phase also affects microporosity, with higher temperatures resulting in less microporosity and changes in crystal size [142,143]. On the other hand, mesopores and macropores refer to pore sizes exceeding 1 μm and 100 μm , respectively. However, introducing meso- and macroporosity in CPCs requires specific methods. These larger pores are essential for cell migration, proliferation of osteoblasts, and mesenchymal cells, as well as promoting bone ingrowth.

High porosity and large pore sizes are known to enhance bone ingrowth into CPCs. Studies comparing porous and non-porous hydroxyapatite have shown that osteogenesis occurs in porous CPCs but not in solid particles [144]. A pore size of around 100 μm is generally considered sufficient for bone regeneration, as smaller pores may lead to ingrowth of unmineralized bone or fibrous tissue while hindering blood vessel ingrowth [145]. However, there is evidence suggesting that pores larger than 300 μm can also promote osteogenesis in certain cases, while pores smaller than 100 μm have been shown to facilitate bone formation or ingrowth into synthetic materials [146–150].

Another important aspect of CPC porosity is the connectivity of pores. Connectivity refers to the extent to which the introduced pores in CPCs are interconnected. Highly interconnected pores offer advantages over “dead-end” pores as they provide efficient pathways for fluid flow, cell migration, and distribution within the CPCs. Interconnectivity also promotes the formation of blood vessels, which are crucial for the development and remodeling of new bone tissue [151–153].

In summary, the presence of pores in CPCs, particularly micropores and interconnected porosity, plays a vital role in fluid flow, cell migration, vascularization, and promoting bone ingrowth and regeneration. Researchers continue to explore the optimal pore sizes, porosity levels, and interconnectivity to develop CPCs that effectively support bone healing and restoration.

The porosity and interconnectivity of calcium phosphate cements can be assessed using various approaches, including image-based methods and physical methods. Image analysis techniques utilizing scanning electron microscopy (SEM) or microcomputed tomography (micro-CT) are commonly employed for porosity and pore size measurements. SEM images are analyzed using software applications to quantify porosity and determine pore size [154,155]. Micro-CT imaging allows for the transformation of 2D X-ray images into 3D models, enabling the extraction of quantitative morphological data [156,157]. Physical methods for porosity assessment include gravimetry and mercury porosimetry. Gravimetry involves calculating the total porosity by comparing the density of the material comprising the CPC with the apparent density of the CPC itself [158,159]. Mercury intrusion porosimetry is a technique where mercury is injected into CPC constructs under increasing pressure. This method provides information about open and closed porosity (volume of mercury penetration into the CPC) as well as pore size (based on the decreasing radius of pores that can be filled as pressure increases) [159–161].

To enhance bone regeneration and address the limited degradation of CPCs, it becomes necessary to introduce macroporosity into the material. Macroporosity can be achieved through various methods such as the use of blowing agents, rapid prototyping techniques, or injection of blowing agents. However, it is important to consider that while increasing macroporosity is crucial for bone regeneration, it can simultaneously lead to a decrease in mechanical properties and changes in the manipulation properties of the CPC. Therefore, a compromise must be reached in the design of macroporous CPCs to balance macroporosity for bone regeneration with other important material properties. This ensures that the

resulting CPCs exhibit the desired degradation behavior, mechanical stability, and handling characteristics.

2.2.5. Foam Concentrates for Increasing Porosity of Calcium Phosphate Cement

Foaming is a viable method to introduce macroporosity into calcium phosphate cement and can be achieved through the generation of gas during a chemical reaction. Researchers have developed various techniques to create macropores in CPCs using different chemical reactions. Almirall et al. developed a technique using hydrogen peroxide decomposition to introduce oxygen macropores into α -TCP cement paste. By controlling parameters such as the Ca/P ratio and hydrogen peroxide concentration, they achieved high porosity levels of up to 66% [162].

Real et al. utilized an acid reaction between NaH_2PO_4 and NaHCO_3 to generate CO_2 bubbles within the CPC. This method resulted in porosity of up to 50% [161]. Studies in goats demonstrated that macroporous CPCs exhibited significantly greater bone formation compared to control CPCs without macroporosity. After 10 weeks, the macroporous CPCs were nearly completely degraded, and new bone formation was observed, while the control CPCs remained intact [163]. Similar positive results have been observed in animal models such as rats [164] and rabbits [165,166].

Another method involves the introduction of CO_2 bubbles into CPCs through an acid-base reaction between NaHCO_3 and citric acid monohydrate ($\text{C}_6\text{H}_8\text{O}_7 \cdot \text{H}_2\text{O}$). This approach yielded macropores with a size of 100 μm and macroporosity of up to 21% [167]. This method has been successfully employed in several studies, including the creation of pre-vascularized CPCs through the co-culture of endothelial cells and osteoblasts, which have potential applications in bone regeneration [168,169]. These studies demonstrate the effectiveness of foaming techniques in creating macroporous CPCs, and the resulting macroporosity has shown promising outcomes in promoting bone formation and tissue regeneration in various animal models.

The introduction of surfactants is another approach to creating foamed calcium phosphate cements. Surfactants can be either natural, such as albumin or gelatin, or synthetic, such as polysorbates. Synthetic surfactants, in particular, have been extensively studied and have been shown to produce highly porous CPCs with porosity levels of around 70%. These foamed CPCs exhibit osteoconductive and osteoinductive properties [170–174].

Biocompatible materials can be categorized into metals, bioglass, ceramics, and composites, which serve as stable replacements for various clinical applications such as maxillofacial surgery, implantology, neurosurgical skull reconstruction, and orthopedic surgery [12,175–177]. They are commonly used in the form of scaffolds (e.g., cementless prosthetic fixation, screws, fixation plates), intraosseous augmentation (e.g., cementoplasty, allograft), guided bone regeneration membranes, and other materials [178]. Optimizing the porous structure of bone substitutes is crucial for effectively regulating cellular responses in tissue engineering. Small pores are beneficial for cell attachment, but they may limit cell viability, proliferation, and differentiation [179,180]. On the other hand, highly porous biomaterials with larger pore sizes allow for better oxygen diffusion, which can enhance cell viability [181]. Graded pore bioceramics, particularly in the 500–800 μm size range, have shown significant improvements in cell adhesion, increased cell viability, and up-regulation of angiogenesis-related gene expression, aligning with findings reported in the literature [182].

Angiogenesis, the formation of new blood vessels from existing ones, is a crucial process for successful implant integration and tissue regeneration [183]. The architecture of the pores within a porous implant plays a significant role in vascularization by providing space for tissue ingrowth and blood vessel formation. Studies have shown that macropores larger than 400 μm can promote the development of larger diameter blood vessels and reduce fibrous tissue ingrowth [184]. Larger pores are advantageous for delivering oxygen and nutrients to cells within the implant, thereby facilitating blood vessel formation. During the early stages, pore size influences the number of blood vessels formed. However, in later

stages, pore size does not significantly affect the number of blood vessels, but it does impact their diameter. Small peripheral pores prevent the infiltration of large vessels into the central large pores, as reported in previous studies [185]. Additionally, the interconnection of pore windows within the scaffold can act as a bottleneck for vascular invasion, which affects scaffold vascularization [186,187].

The presence of small pore windows allows for the invasion of small blood vessels, but this pore architecture can restrict the penetration of blood vessels into the central region of the scaffold, regardless of the size of the pores in that region. Therefore, a graduated radial pore structure with a gradual increase in pore size from the center to the periphery is desirable for promoting vascularization of the implant. Rapid vascularization of an implant is a critical factor for successful clinical outcomes. It improves the integration of the implant with host soft tissues and reduces the risk of complications. As fibrovascular tissue grows into the macropores of a porous implant, soft tissues can be mechanically secured to the implant, reducing migration and exposure of the implant [188]. Abundant blood vessels also provide immune support, promoting wound healing and reducing the risk of postoperative infections [189]. Long-term clinical results have shown that coralline hydroxyapatite implants with 80% porosity achieve very fast vascularization rates, followed by synthetic hydroxyapatite implants (50–65% porosity), and finally Medpor implants (~41% porosity) [190,191].

Bone defects caused by various factors can have a significant impact on a patient's quality of life [192,193]. Synthetic bone materials possess important characteristics such as protein adhesion, *in vivo* degradation, and osteoconductivity [194]. The induction of osteoinductivity can be achieved by creating a macroporous three-dimensional environment [195]. Several bioceramics are commonly employed in bone defect healing and bone tissue regeneration due to their excellent biocompatibility, osteoconductivity, and osteoinductivity. These include hydroxyapatite, β -tricalcium phosphate, akermanite, and 45S5 bioglass [196–200].

Three-dimensional (3D) porous scaffolds play a crucial role in bone defect repair and bone tissue engineering. They provide mechanical support, maintain tissue shape and integrity, promote bonding with surrounding tissues, and guide tissue growth [201–203]. The porous structure facilitates cell migration, growth, nutrient and metabolite transport, and stimulates bone integration and revascularization [202,204–206]. Additionally, some scaffolds can release biologically active ions that contribute to physiological stimulation of cells [201,204–206]. Therefore, 3D porous scaffolds are key elements in bone tissue engineering. Various technologies have been employed to manufacture bioceramic-based scaffolds based on specific characteristics and technical requirements. These include the template method, freeze-drying, foaming method, electroforming, and 3D printing [201,204,206,207].

2.2.6. Calcium Phosphate (CaP) Ceramic Based Bone Grafts

Calcium phosphate ceramic-based bone grafts are gaining popularity in the field of bone grafting due to their chemical and biological similarities to the mineral phase of bone. Traditional CaP bioceramic therapy involves implanting bone grafts in the form of blocks or granules, which requires prior knowledge of the defect size and shape, followed by surgical implantation of appropriate bone substitutes [208,209].

To address the drawbacks of bone augmentation procedures, injectable bone cements have been developed and are receiving increasing attention due to their minimally invasive administration. Calcium phosphate composites are particularly known for their ability to self-align *in vivo*, making them advantageous for minimally invasive surgery [209–211]. In 1983, research by Brown and Chow led to the development of a new injectable form of CaP, which included tetracalcium phosphate, dicalcium phosphate dihydrate, $\text{CaHPO}_4 \cdot 2\text{H}_2\text{O}$, and anhydrous dicalcium phosphate (CaHPO_4) [212]. These developed materials exhibited properties such as self-hardening ability, good injectability, formability, increased reactivity, and high suitability for the development of new drug delivery systems [211,213].

To improve the cohesiveness and injectability of calcium phosphate ceramics, researchers have investigated the combination of CPC with polymer solutions and various additives [214–216]. Both natural and synthetic polymers have been incorporated as a liquid phase into injectable CPC to enhance adhesion, injectability, set time, and mechanical properties [215,217–220].

Chitosan, a natural amino-polysaccharide, has been used as a liquid phase additive to modify the physical properties of CPC, such as injectability, set time, and rheology while enhancing *in vivo* bioactivity [221]. Sodium alginate, collagen, gelatin, hyaluronic acid, and cellulose derivatives such as hydroxypropylmethylcellulose, methylcellulose, and carboxymethylcellulose have also been utilized as liquid phases for the formation of CPC [213,222–230]. The combination with biopolymers allows for the regulation of cohesiveness, injectability, mechanical properties, and bioactivity of the resulting cement.

Incorporating poly(lactic glycolic acid) microparticles into CPC has shown *in situ* macropore formation and increased cement strength, which is beneficial for bone reconstruction [231]. The addition of citric acid as a thinner has been shown to improve the injectability of CPC [232]. Studies have reported that citric acid can also enhance CPC set time and compressive strength, depending on the concentration of the additive [217,218].

Other attempts to regulate the physicochemical and biological properties of CPC include the addition of glycerol, strontium carbonate, polyethylene glycol, foaming agents, and β -dicalcium silicate [233–237]. These combinations and additives contribute to improving the performance and functionality of CPC for bone tissue engineering and regeneration applications.

In recent years, there has been growing interest in combining calcium phosphate cements with bioactive glasses (BGs) to enhance their properties. Bioactive glasses, such as 45S5 Bioglass[®], have been known since 1969 and are composed of silicon oxide (SiO₂), calcium oxide (CaO), phosphorus oxide (P₂O₅), and sodium oxide (Na₂O) [238,239]. BGs can bond chemically to bone, promoting bone growth. The composition of BGs can be varied to create different variants by adjusting the basic SiO₂-CaO-P₂O₅-Na₂O ratio [238].

When BGs come into contact with bone tissue, they release silica ions from their surface. These ions form a layer of silica gel, followed by the precipitation of amorphous calcium phosphate and the subsequent formation of a layer of hydroxyapatite. This HA layer activates cell migration and promotes new bone formation, facilitating the integration of the BG with the surrounding bone tissue [240]. The high density of silanol groups (Si-OH) on the silica layer creates a negatively charged surface that plays a crucial role in inducing HA nucleation [239].

The dissolution products of BGs have been found to stimulate gene expression in osteoblastic cells, further promoting bone formation [241,242]. Additionally, recent studies have demonstrated that BGs have angiogenic properties, promoting the formation of new blood vessels [243]. BGs have also shown antibacterial and anti-inflammatory effects, both *in vitro* and *in vivo*, making them valuable for various applications in hard tissue engineering [244,245]. BGs can be used alone or as an inorganic phase in composites or hybrid materials, contributing to their widespread use in the field of bone tissue engineering [246]. The combination of CPCs with BGs provides a promising approach to developing bioactive and functional materials for bone regeneration and repair.

The biological activity of bioactive glasses has been extensively studied, with a focus on the influence of porosity and specific surface area on their performance. When BGs come into contact with physiological fluids, initial ion release occurs, which can lead to a significant increase in pH. This elevated pH level may be detrimental to surrounding cells and tissues [247]. However, the final pH can be controlled by incorporating other ions into the BGs, thereby altering the release rate and concentration of ions in the solution. Trace elements such as strontium (Sr), zinc (Zn), copper (Cu), or cobalt (Co), which are naturally present in the human body, are known for their beneficial effects on bone regeneration [248]. Incorporating these ions into CPCs and BGs can modulate their dissolution behavior and improve the biological performance of the materials [249,250].

To address the limitations of both calcium phosphate cements and BGs and to enhance their *in vitro* and *in vivo* properties, there have been attempts to synergistically combine them. The combination of CPCs and BG has been explored in the form of composites, with studies focusing on their physicochemical and osteogenic properties. Bellucci et al. and Karadjian et al. have conducted comprehensive reviews of the literature on CPC and BG composites, highlighting their characteristics and potential applications [251,252]. However, to the best of our knowledge, there has not been a previous systematic review specifically discussing BGs incorporated into injectable CPC bone cement. Further research in this area would be valuable for understanding the synergistic effects and potential applications of these composite materials.

Radiopacity is an important characteristic to consider when developing biomaterials for bone regeneration, as it allows for the visualization of the material during and after surgery. It ensures proper positioning of the biomaterial at the defect site and enables easy detection and monitoring of any potential issues or failures during follow-up. While calcium phosphate cements possess some level of intrinsic radiopacity, they may not be sufficient for precise fluoroscopic control or distinguishing the biomaterial from surrounding bone during surgery [253]. Several systematic studies have been conducted to evaluate the radiopacity of injectable CPCs. These studies have emphasized the importance of investigating the radiopacity of injectable bone cement [254–257]. In addition to radiopacity, other properties such as mechanical properties, degradation profile, and porosity are important parameters to study in CPC composites [258]. The mechanical properties of CPCs, typically assessed in compression, can be comparable to trabecular bone (4–12 MPa). Some specific CPC formulations have reported compressive strengths of up to 80 MPa for apatite-forming CPC and up to 52 MPa for brushite-forming CPC [259]. However, the inherent fragility of CPCs still limits their clinical use to non-load-bearing applications.

To improve the mechanical properties of CPCs, various approaches have been explored, and one such attempt is modifying the porosity of the cement. It is important to carefully consider the reduction in porosity, as it can influence the biological properties of CPC, including the rate of degradation *in vitro* and *in vivo*. The degradation rate should align with the requirements for proper bone regeneration speed. Therefore, it is crucial to achieve a balance among desired material properties, mechanical properties, porosity, and degradation to meet the clinical needs effectively [260–268].

The influence of calcium phosphate cements on bone tissue regeneration and growth has been extensively studied, highlighting certain challenges related to the rate of resorption [269,270]. Both slow and rapid rates of resorption can be problematic. A slow resorption rate may hinder osseointegration, while a fast resorption rate can lead to the washing out of CPC fractions from the defect site.

To address the rapid resorption issue, combinations of different calcium phosphates have been proposed [268–273]. For instance, the rate of resorption of tricalcium phosphate can be controlled by using two-phase calcium phosphate cements, which help slow down the resorption process. Different compositions of CPCs can elicit different biological reactions based on factors such as CPC chemistry, crystallinity, stoichiometry, dissolution/precipitation behavior, surface chemistry, and porosity. While CPCs demonstrate good osteoconductivity, their effect on osteogenic differentiation is limited due to their relatively low surface reactivity. *In vitro* studies have used the formation of a surface layer of hydroxyapatite in artificial body fluid (SBF) as an indicator of “biological activity” for materials in contact with bone. However, *in vivo* studies with DCPD and β -TCP have shown conflicting results regarding their ability to directly bind to bone, despite the formation of an HA layer in SBF.

On the other hand, bioactive glasses have been recognized for their direct binding capability to bone and surrounding tissues. They can serve as an alternative to CPCs. The combination of BGs with calcium phosphate cements has recently emerged, leveraging the binding ability of BGs to bone and tissues. Overall, research in this field continues to explore

the optimization of CPC compositions, resorption rates, and the incorporation of bioactive glasses to enhance the biological activity and performance of bone graft substitutes.

The direct connection between calcium phosphate cement and bone occurs through the formation of an HA-like layer on the material's surface. The initial steps of this process involve a rapid ion exchange, where sodium ions (Na^+) are exchanged with hydrogen ions (H^+) and hydronium ions (H_3O^+). This is followed by a polycondensation reaction of surface silanols, resulting in the formation of a silica gel layer with a large surface area. Subsequently, nucleation and crystallization of a layer of hydroxycarbonate apatite take place on the surface. This HCA layer closely resembles the mineral phase of bone, enabling the proliferation and differentiation of osteoblasts within this layer to form their extracellular matrix. Thus, incorporating bioactive glasses (BGs) into CPKs is a promising approach to maintaining bioactivity both *in vitro* and *in vivo*.

A comparative study by Campion et al [269] demonstrated that silicate-substituted HA materials exhibited higher biological activity compared to commercially available β -TCP bone graft substitutes. The study showed that β -TCP exhibited characteristics of octacalcium phosphate with fewer crystals formed on its surface. In contrast, silicate-substituted HA materials had a thick, continuous layer of apatite hydroxycarbonate crystals deposited on their surface. Additionally, one of the main reasons for combining calcium phosphate cements with bioactive glasses is the release of ions from the BGs, which can promote angiogenesis (formation of new blood vessels) and osteogenic differentiation (differentiation of cells into bone-forming cells). This further enhances the biological properties and performance of the composite material [270].

2.3. Organic Components of Bone Grafting Materials

In the field of bone engineering and regenerative dentistry, extracellular scaffolds play a crucial role in providing structural support for stem cell attachment and promoting tissue development. These scaffolds are typically made from polymeric materials and serve as matrices that hold regenerative undifferentiated cells while recreating their biological microenvironment. The goal is to facilitate the differentiation, deposition, and mineralization of an extracellular matrix by undifferentiated preosteoblastic and odontoblast cells, eventually replacing the polymeric scaffold structure [273].

An ideal tissue scaffold should possess several key characteristics. First and foremost, it should be biocompatible, ensuring that it does not cause adverse reactions or toxicity when in contact with living tissues. Additionally, the scaffold should be biodegradable, meaning it can gradually break down over time and be replaced by newly formed tissue. This controlled degradation is important to match the rate of tissue regeneration. Moreover, the scaffold should be manipulable, allowing for easy shaping and customization to fit specific defect sites or anatomical structures. Tissue scaffolds can be constructed using both synthetic and natural polymers. Synthetic polymers offer advantages such as tunable mechanical properties and controlled degradation rates. However, they often exhibit fewer cellular adhesion sites, lower biological activity, and reduced biocompatibility compared to natural polymers. Natural polymers have gained popularity in tissue engineering due to their availability and similarity to the components of the native extracellular matrix found in connective tissues. Natural polymer-based scaffolds can be derived from proteins such as silk, gelatin, collagen, fibrin, and soy, or polysaccharides such as cellulose, chitosan, and alginate. These natural polymers provide a favorable environment for cell attachment, proliferation, and differentiation, promoting tissue regeneration processes.

Overall, the choice of polymer type for tissue scaffolds depends on specific application requirements, desired properties, and compatibility with the target tissue or organ. Researchers continue to explore and optimize scaffold materials and fabrication techniques to enhance their effectiveness in promoting tissue regeneration and repair [274,275].

2.3.1. Chitosan

Chitin is a widely recognized natural biomaterial with numerous biomedical applications that can be derived from both animal and plant sources. Currently, industrial extraction of chitin primarily involves obtaining it from seashells. Despite its widespread availability and significant functional properties such as biodegradability, bioactivity, and biocompatibility, the poor solubility of chitin limits its utility in tissue engineering. However, the focus can be shifted to chitosan, which is the primary derivative of chitin. Chitosan is a copolymer obtained through the alkaline deacetylation of chitin, composed of d-glucosamine and N-acetyl-d-glucosamine units [276,277]. This natural multifunctional polysaccharide has been extensively researched in the fields of biomedical, pharmaceutical, and tissue engineering. It possesses desirable properties including biodegradability, bioactivity, biocompatibility, and antimicrobial activity [278].

The biomechanical properties of chitosan can be enhanced through copolymerization with synthetic and natural biomaterials (e.g., hydroxyapatite), bioactive osteogenic molecules (e.g., bone morphogenetic protein-2 (BMP2)), or polymers (e.g., silk fibrin, collagen, and polycaprolactone). These modifications enable the production of 3D freeze-dried scaffolds, films, and hydrogels, thereby enhancing their practicality for tissue engineering applications [276,279–283]. Furthermore, the addition of bioactive molecules that influence cellular functions and tissue regeneration can further improve the process of bone regeneration [276]. Chitosan microspheres exhibit a spherical structure with diameters ranging from several micrometers to 1000 microns. These microspheres can encapsulate biologically active molecules uniformly within the polymer matrix, enabling a stable and controlled release of these molecules at targeted sites of regeneration. Additionally, novel chitosan-based scaffolds modified with mineral content, BMP, and osteoinductive drugs have been reported to promote stem cell proliferation, adhesion, and differentiation [278,284,285].

In support of this, an animal experiment demonstrated the positive impact of chitosan nanofiber scaffolds on bone regeneration. The implantation of these scaffolds exhibited a beneficial effect by enhancing regenerative bone volume and improving trabecular quality, all without causing any adverse effects. Notably, chitosan nanofibers were found to increase alkaline phosphatase (ALP) activity [282], which is an indicator of osteoblast function, as well as the expression of osteocalcin (OCN) [282]. OCN and ALP are among the biomarkers associated with osteoblasts, playing crucial roles in regulating osteoblast function and facilitating extracellular matrix mineralization during bone remodeling [286,287]. These findings highlight the potential of chitosan nanofibers to promote bone repair by influencing osteoblast activity and facilitating the mineralization process.

2.3.2. Collagen

Collagen, as the primary component responsible for maintaining the structural integrity of tissues, plays a crucial role in bone structure. Type I and V collagen are the main constituents of bone, possessing the ability to bind hydroxyapatite crystals. When properly optimized, types I and II collagen can form collagen fibers that closely mimic the properties of natural extracellular matrix (ECM) collagen [288,289]. Bovine type I collagen sponges have been found to positively affect the proliferation, attachment, and functional activity (such as osteocalcin production) of human osteoblastic cell lines [290].

Hydrogels, which are three-dimensional polymer networks capable of absorbing and retaining water, are highly biocompatible and flexible. Due to their biocompatibility and high water content, hydrogels can serve as effective vehicles for targeted drug delivery in tissue engineering [291]. In a comparative animal study, the implantation of a collagen hydrogel scaffold was shown to promote the regeneration of the periodontal ligament and bone in cases of defects [292]. Collagen scaffolds have demonstrated favorable performance and serve as suitable scaffolds for alveolar bone regeneration, minimizing bone resorption in the alveolar ridge following tooth extraction or sinus augmentation [293,294]. In human trials, collagen scaffolds have been successfully utilized as natural biodegradable carriers for osteoinductive biomaterials and factors, such as human bone morphogenetic

protein-2 (BMP2) [295], hydroxyapatite [296], or in combination with bone allografts to preserve alveolar bone and optimize bone regeneration post-tooth extraction [297–299]. The incorporation of hydroxyapatite-starch into collagen sponges in a 1:4:10 ratio has been shown to enhance mechanical properties, cell viability, and hematopoiesis.

2.3.3. Hyaluronic Acid

Hyaluronic acid, another natural polymer present in the human body, is predominantly found in connective tissue and serves as a natural glycosaminoglycan within the extracellular matrix, providing a conducive environment for regenerative processes [300]. Numerous studies have demonstrated that hyaluronic acid, when used as a carrier for growth factors, can enhance bone formation [301–303]. Sulfated hyaluronic acid, in particular, has been found to suppress osteoclasts and support osteoblasts in diabetic conditions by binding to sclerostin, a potent signaling inhibitor involved in the integration and activity of osteoblasts [304]. These glycoproteins play a pivotal role in stem cell activities such as proliferation and differentiation [305].

Cross-linked hyaluronic acid hydrogels exhibit desirable consistency and mechanical properties for calvarial bone regeneration techniques. The incorporation of tissue particles into hydrogels improves mechanical characteristics, including yield strength and compressive modulus of the graft material. Among these particles, cartilage particles contribute to the highest yield strength, while tendon particles are beneficial for enhancing bone regeneration. *In vitro* studies have shown that the addition of tendon particles to hyaluronic acid hydrogels promotes superior calcium deposition by osteoblasts [306]. Furthermore, the application of 1% hyaluronic acid gels following tooth extraction accelerates bone repair and regeneration in both healthy and infected sockets [307,308]. A hyaluronic acid-gelatin hydrogel has been successfully utilized as a composite framework plug for one-stage bone grafting into tooth extraction sockets [309]. The combination of chitosan and hyaluronic acid as polyelectrolytes can improve the properties of each polymer, enhance stability, and promote cell adhesion [310]. Chitosan and hyaluronic acid scaffolds have demonstrated the ability to promote osteoblast differentiation by increasing the expression of genes such as collagen α 1, osteocalcin, osteopontin, and Runx 2 in preclinical models [300].

2.3.4. Cellulose

Cellulose, the most abundant biopolymer in nature, is commonly found in the cell walls of green plants, but it can also be synthesized by bacteria and fungi. Bacterial cellulose, a nanostructured biopolymer present in bacterial membranes, is composed of nucleotide-activated glucose and holds great potential for applications in tissue engineering, wound healing, and drug delivery [311]. The structure of bacterial cellulose comprises a three-dimensional network of highly oriented nanofibrils, exhibiting remarkable mechanical strength, biodegradability, and antimicrobial properties in its oxidized form [312,313]. Notably, bacterial cellulose exhibits significant similarities to collagen when used in scaffolds. Resorbable bacterial cellulose membranes, treated with electron beam irradiation, have shown comparable efficacy to conventional collagen membranes in regenerating bone defects around implants. These membranes possess similar mechanical properties to collagen membranes but exhibit greater porosity [314].

In animal studies, a 0.1 mm thick bacterial cellulose membrane has been successfully employed to induce bone regeneration in rat calvarium defects, with osteoblasts observed at the periphery and center of the defect [314].

Hydroxypropylmethylcellulose has been utilized as a crosslinking agent in chitosan-based scaffolds. Scanning electron microscopy has revealed significant adhesion of osteoblasts to scaffolds containing 10%, 20%, and 25% hydroxypropyl methylcellulose, indicating that the porous structure of the scaffold provides favorable conditions for cell attachment through cytoplasmic elongation [315].

2.3.5. Soy

Soy protein isolate is a renewable and abundant protein among natural polymers, consisting of over 90% polypeptides that closely resemble the macromolecular structure of natural proteins found in bones [316–318]. Salama et al. (2020) conducted a study where they synthesized an oxidized cellulose nanofiber-grafted soy protein hydrolyzate through amidation coupled with an EDC/NHS reaction, specifically for bone tissue engineering purposes [319]. Similarly, in an experiment conducted by Wu et al. (2020), a two-component scaffold consisting of soy protein was used for bone tissue engineering. In vitro cell culture experiments, analyzed using energy-dispersive X-ray spectroscopy, demonstrated that a scaffold composed of 70% soy protein exhibited enhanced cytocompatibility and osteoblastic properties, including improved cell attachment, proliferation, growth, and acceleration of osteogenesis-related gene expression [320].

In animal studies, soy-based biomaterials were compared to synthetic bone grafts (poly(D,L-lactide glycolide) 50:50), and it was found that they induced comparable levels of bone regeneration in the inner, middle, and outer parts of the bone defect [321].

2.3.6. Alginate

Alginate is a biopolymer derived from seaweed, particularly brown algae, and it consists of mannuronic acid and guluronic acid units. One of the notable characteristics of alginate is its ability to be easily modified into various structures such as microspheres, hydrogels, and fibers. This versatility has led to its widespread use in the production of composite scaffolds when combined with other materials like chitosan [322], cellulose [323], and gelatin [324]. Alginate, therefore, serves as an excellent candidate for scaffold materials in tissue engineering applications as well as in drug delivery systems [325].

2.3.7. Silk

Silk proteins have garnered significant attention in bone engineering research due to their excellent mechanical properties. Dignaschi et al. (2016) explored this aspect by incorporating hydroxyapatite minerals into spider silk, resulting in the synthesis of an inorganic-organic hybrid scaffold. In this biomaterial, the spider silk domain contributes to the material's stability and workability, while the hydroxyapatite binding domain regulates the osteogenic process [326]. A similar study conducted by Hardy et al [327]. in 2016 also investigated *Bombyx mori* silk modification through the freeze-drying method using decellularized pulp, collagen, and fibronectin. This modification induced significant alkaline phosphatase activity in MG-63 osteoblasts [328]. These studies highlight the potential of silk-based scaffolds in promoting osteogenic properties and bone tissue regeneration.

2.3.8. Carrageenan

Carrageenan is an anionic sulfated polygalactan similar to glycosaminoglycans found in the extracellular matrix, and it occurs naturally in the cell walls of red algae. Its three-dimensional structure promotes the proliferation and adhesion of osteoblasts [329]. When combined with hydroxyapatite, carrageenan exhibits a stimulating effect on osteoblast activity [330]. The addition of carrageenan to the scaffold structure of hydroxyapatite-collagen composite gel enhances its compressive strength [331]. A mixed carrageenan hydrogel with varying ratios of nanohydroxyapatite demonstrates promising performance with minimal cytotoxicity towards human osteoblast cells and significant antimicrobial activity against *Pseudomonas aeruginosa* [332]. Studies have shown that exposure of cells to nanocomposite carrageenan hydrogel and whitlockite nanoparticles increases the expression of Runt-associated transcription factor-2 proteins and osteopontin [333]. Incorporating carrageenan onto the surface of graphene oxide facilitates the nucleation of hydroxyapatite, while the rough and hydrophilic surface of graphene-carrageenan oxide provides a more favorable structure for cell proliferation [334]. Carrageenan has also been utilized in combination with silk [335], Arabic gum [336], collagen [337], CaCO₃ particles [338], acrylic acid-graphene [339], gelatin, and chitosan [340] as hybrid bioscaffolds in tissue engineer-

ing research focused on bone regeneration. Collagen/nanohydroxyapatite-carrageenan gel has been successfully employed for the delivery of human nerve growth factor beta, promoting inferior alveolar nerve regeneration during distraction osteogenesis at a rate of 0.75 mm/12 h after six days.

2.3.9. Tragacanth Gum

Tragacanth gum is a non-cariogenic polysaccharide derived from plants of the genus *Astragalus*. It is commonly utilized in tissue engineering to create biodegradable structures, including scaffolds and drug delivery systems [341]. Tragacanth gum scaffolds have shown promising results in bone regeneration applications [342].

While natural polymers offer significant advantages, they often exhibit low stability of mechanical properties, particularly in wet conditions, which is considered a primary drawback for their potential application. To enhance their biomechanical characteristics, natural polymers can undergo modification through cross-linking or complexation procedures with ceramics or metal ions. Green chemicals or natural agents have emerged as a solution for cross-linking natural polymers, improving the mechanical properties of bone scaffolds without compromising their biocompatibility [343,344].

Nanotechnology has also provided a strategy to develop more efficient scaffolds. By reducing the size of structures, surface characteristics can be improved to enhance biocompatibility and tissue growth. Furthermore, beneficial properties like antibacterial activity can be incorporated into these scaffolds. Examples in this field include chitosan-polycaprolactone composites, hydroxyapatite and alginate nanofiber scaffolds, antibacterial chitosan-calcium phosphate composites infused with silver ions, and highly porous chitosan-hyaluronic acid composite scaffolds.

3. Inducers of Natural Osteogenesis

A delicate equilibrium between matrix retention and resorption plays a crucial role in regulating the metabolism of the skeletal system. The interplay between osteoblastic and osteoclastic activities is vital for maintaining skeletal function. Age-related bone disorders, such as osteoporosis, typically arise from an upsurge in the resorptive function of osteoclasts [345]. Understanding and regulating the balance between osteoblastic and osteoclastic function is crucial for maintaining skeletal health and preventing age-related bone disorders like osteoporosis. Therapeutic interventions aimed at promoting bone formation and inhibiting excessive bone resorption are important strategies in the management of these conditions.

3.1. Nuclear Factor Kappa-B Ligand Activator Receptor (RANKL)

The nuclear factor kappa-B ligand activator receptor (RANKL) is a ligand produced by various cells, including osteoblasts, that plays a pivotal role in the activation of osteoclasts. Osteoclasts derived from monocytes express receptors for RANKL on their surface. Upon binding of RANKL to these receptors, bone resorption by osteoclasts is initiated. The expression of osteoprotegerin (OPG) by osteoblasts serves to modulate the activity of RANKL and bone resorption. Additionally, inflammatory cytokines, such as those belonging to the interleukin family, are known to enhance osteoclast activity by inducing the expression of RANKL [346]. There is an extensive body of evidence demonstrating the anti-inflammatory, anti-osteoporotic, osteoinductive, and regenerative properties of natural components. Numerous studies have observed that natural food components can impact these processes by inhibiting bone resorption, promoting bone formation and maturation, and consequently enhancing bone regeneration in the presence of bone defects [277,347–349].

3.2. "Plant Phenols" and "Polyphenols"

Plant phenols and polyphenols are secondary metabolic compounds that are synthesized through either the shikimate/phenylpropanoid pathway or the malonate/polyketide pathway [350]. Among these compounds, flavonoids play a significant role in bone

metabolism and bone formation. They exhibit the ability to promote osteoblastogenesis and can also interfere with osteoclastogenesis, thus potentially preventing bone resorption.

Flavonoids primarily exert their effects by influencing the proliferation and differentiation of mesenchymal stem cells (MSCs), directing them towards osteoblast lineage. They enhance the expression of osteogenic transcription factors and markers through various signaling pathways, including the Wnt and mitogen-activated protein kinase pathways. Activation of these pathways favors osteoblast differentiation from pre-osteoblast cells and MSCs [351].

The mitogen-activated protein kinase pathway is particularly involved in the osteoblast differentiation process mediated by flavonoids. These compounds activate this pathway, leading to the upregulation of osteogenic markers and the promotion of osteoblast differentiation [351]. Overall, flavonoids exhibit a positive influence on bone formation by enhancing osteoblastogenesis and regulating the balance between bone formation and resorption. Their multifaceted effects on various cellular pathways make them promising candidates for the development of therapeutic approaches targeting bone health.

3.3. Epigallocatechin-3-Gallate

Camellia sinensis is a plant native to Southeast Asia that has been widely utilized in complementary medicine alongside traditional treatment approaches in various fields of dentistry [352]. The leaf extract of *Camellia sinensis* contains catechins, making it valuable in dental applications. Among the polyphenols found in *C. sinensis*, epigallocatechin-3-gallate (EGCG) is the most abundant and has gained popularity in dentistry due to its anti-inflammatory properties [353], antibacterial effects [354], and antioxidant activity [355].

EGCG has been found to effectively stimulate the proliferation, early osteogenic differentiation, and mineralization of primary human dedifferentiated cells [356]. Moreover, it has been shown to enhance the synthesis of osteoprotegerin (OPG) in osteoblasts stimulated by BMP-4 or prostaglandin E2, through the potentiation of p38 mitogen-activated protein kinase and c-Jun stress-activated protein kinase/amino-terminal kinase pathways [357,358]. EGCG also inhibits osteoblast migration induced by insulin and growth factor I, potentially contributing to the regulation of bone remodeling, possibly by suppressing p44/p42 MAP kinase [359]. The ability of EGCG to inhibit osteoblast migration induced by EGF has been proposed as a key mechanism underlying its beneficial effects on proper bone remodeling [360]. Additionally, EGCG has demonstrated the capacity to enhance cell viability in 3D human periosteal cultures and has been used as an osteogenic graft material for periodontal regenerative therapy [360]. Treatment with EGCG at concentrations of 6–10 mM has been shown to upregulate the expression of type I collagen, osteopontin, and osterix in the human periodontal ligament (PDL) cells, suggesting a promising role for this plant polyphenol in periodontal regeneration [361]. However, higher concentrations of EGCG (greater than 10 mM) may have inhibitory effects on the osteogenic differentiation of cells derived from human alveolar bone [362].

Animal experiments have demonstrated that topical administration of EGCG reduces stress-induced premature aging (characterized by the cessation of cell division) in critical-size bone defect cells [363]. Combining human bone morphogenetic protein (BMP) and EGCG as a coating material for biphasic calcium phosphate has shown potential for remodeling and enhancing regeneration in split defects around dental implants [364]. Furthermore, the combination of tricalcium phosphate particles and 0.2 mg EGCG has been shown to stimulate optimal bone regeneration in calvarial defects in animal studies [365]. Other animal and in vitro experiments have indicated that modifying gelatinous and collagenous bone scaffolds and membranes with EGCG can be beneficial for macrophage recruitment [366,367], improving bone-forming ability [368,369], reducing bone resorption [370], and preserving the bone of dental sockets [371].

Overall, the use of EGCG derived from *Camellia sinensis* holds promise in various aspects of dental applications, including periodontal regeneration, bone remodeling, and enhancement of bone healing processes.

3.4. Acemannan

Acemannan is a polydisperse mannan with a b-(1,4)-linked structure that can be derived from the aloe plant [372]. The most cost-effective extraction process of acemannan from aloe vera involves precipitation with cetyltrimethylammonium bromide, as described by Alonso M. et al. [373]. In 2019, Silva S. et al. proposed a modified approach for acemannan using methacrylic anhydride and photocrosslinking under ultraviolet irradiation to enhance its manufacturability, enabling the production of high-value structures [374].

Acemannan has been found to promote the expression of cyclin D1 in cultured fibroblasts through the AKT/mTOR signaling pathway, leading to increased translation of cyclin D1. It also induces the expression of interleukin-6/-8 and p50/DNA binding in gingival fibroblasts via a TLR5/NF- κ B-dependent signaling pathway, which plays a crucial role in wound and periodontal healing [375–377]. Moreover, acemannan enhances the production of keratinocyte growth factor-1, vascular endothelial growth factor, and type I collagen during the wound-healing process in the oral cavity [378]. In a four-week follow-up study after treating the extraction socket with acemannan gel, significant increases were observed in bone marrow stromal cell proliferation, vascular endothelial growth factor, alkaline phosphatase activity, bone sialoprotein, osteopontin expression, and mineralization [379]. In vivo studies have demonstrated that acemannan-treated groups exhibit higher bone mineral density and faster bone and periodontal ligament regeneration in animals [379–382].

Furthermore, two randomized controlled trials with 3- and 12-month follow-ups evaluated the effects of acemannan gel treatment on bone regeneration after tooth extraction and apical surgery, respectively. X-ray studies revealed that the administration of acemannan gel significantly improved the rate of bone wound healing without any reported side effects [383–385]. These findings highlight the potential of acemannan as a beneficial agent in promoting bone healing and regeneration in dental applications.

3.5. Ikariin

Epimedium is the largest genus of herbaceous plants in the Berberidaceae family [386]. Icariin, a prenylated flavonol glycoside, is closely associated with the therapeutic effects of *Herba Epimedii*. It is known to inhibit the expression of TNF- α , IL-6, and IL-1 β in lipopolysaccharide-stimulated inflammatory responses [387,388]. Icariin has been shown to significantly enhance osteogenic differentiation of MBMS cells. This is evidenced by increased ALP activity and expression of collagen I, osteopontin, and OCN genes, which are regulated through phosphorylation of extracellular signal-regulated kinase, p38 kinase, and N-terminal c-Jun kinase. These three main families of cascades of mitogen-activated protein kinases play a crucial role in osteogenesis [389,390]. Xu X et al. (2019) demonstrated that icariin enhances OCN expression via STAT [391]. Promising results have been obtained by introducing icariin into poly-(ϵ -caprolactone)/gelatin nanofibers for the synthesis of an artificial composite periosteum. Loading this membrane with icariin at the transplantation site enhances the attachment, proliferation, and differentiation of preosteoblastic cells [392]. Icariin has been utilized in preclinical studies to enhance the osteoinductivity of various biomaterials and tissue scaffolds, such as the submucosa of the small intestine [393], bioactive glass/chitosan [394,395], hydroxyapatite/alginate [361], and poly(lactic-co-glycolic acid)/ β -calcium phosphate [396]. In general, these studies have demonstrated improvements in the activation of proteins and genes associated with osteogenesis, the osteogenic activity of preosteoblastic cells, and the regenerative properties of these bone scaffolds. Topical administration of icariin solution has been shown to significantly promote periodontal tissue and alveolar bone regeneration in periodontitis minipigs, as evidenced by computed tomography, histological, and clinical assessments after a 12-week follow-up [396]. Furthermore, the potential enhancement of alveolar bone remodeling with icariin makes it a noteworthy candidate for accelerating tooth movement during orthodontic treatment, although further research is warranted [397].

3.6. Curcumin

Curcumin is the primary curcuminoid found in the *Curcuma longa* plant, which is renowned for its antibacterial, antioxidant, and healing properties [398]. It has been suggested that curcumin may have beneficial effects on various conditions, including modulating inflammatory and oxidative pathways, metabolic syndrome, arthritis, osteoporosis, and other pathologies [399,400]. In a study by Li Y and Zhang ZZ (2018), the osteogenic properties of a collagen/hydroxyapatite scaffold were evaluated under diabetic conditions after incorporating curcumin into the scaffold structure. The results demonstrated that this enhanced scaffold significantly reduced the adverse effects of diabetic serum on the proliferation, migration, and osteogenic differentiation of mesenchymal stem cells (MSCs). Furthermore, topical injection of a curcumin-loaded scaffold into bone defects in diabetic rats resulted in increased bone formation compared to controls [401]. It should be noted that the osteogenic response to curcumin in preosteoblastic cells is concentration-dependent. At a concentration of 1%, increased expression of osteogenic genes and proteins can be observed, while higher concentrations of curcumin may lead to a decrease in cellular activity [402]. Due to its antitumor activity, curcumin can also be used in combination with nanocarriers for bone regeneration in osteosarcoma patients [403,404]. Local release of curcumin from a calcium phosphate matrix can be improved by utilizing poly-(ϵ -caprolactone) and polyethylene glycol or liposome encapsulation, which enhances its bioavailability and makes it an excellent natural component for bone regeneration around implants [405]. The incorporation of curcumin into an asymmetric collagen membrane has been shown to increase the osteogenic potential at both the transcriptional and translational levels of directed tissue regeneration, imparting antibacterial properties to the modified membrane [406].

3.7. Chlorogenic Acid

Chlorogenic acid, an ester of caffeic acid, is present in various herbs, including coffee and beans. Numerous *in vitro* and *in vivo* studies have demonstrated the effectiveness of chlorogenic acid as an antibacterial, anti-inflammatory, antitumor, and analgesic agent [407–410]. In the context of osteogenesis, chlorogenic acid has shown promising results. At a concentration of 30 mM, chlorogenic acid promotes osteogenesis in mesenchymal stem cells derived from human adipose tissue, as evidenced by increased mineralization, alkaline phosphatase activity, and expression of runt-associated transcription factor-2 [411].

Osteoporosis, a prevalent metabolic bone disease, is characterized by decreased bone mass and defects in bone microarchitecture. Imbalances between bone formation and resorption lead to cortical thinning, porosity, and overall bone loss [412]. In bone regenerative processes and biomaterial osseointegration, dysregulation of bone formation and the overexpression of inflammatory and stress response pathways have a significant negative impact [413,414]. Chlorogenic acid has been found to modulate the decline in bone mineral density, increase metabolic markers, and protect bone structure in ovariectomized rats at certain doses. At concentrations of 1 or 10 mM, chlorogenic acid enhances the production of phosphorylated protein kinase B and cyclin D1, as well as the proliferation of bone mesenchymal stem cells in a concentration-dependent manner [415]. Additionally, chlorogenic acid enhances the synthesis of interleukin-6 stimulated by TNF- α in osteoblasts, which plays a crucial role in bone restoration and regeneration following fractures [416,417].

In preclinical settings, the incorporation of 60 mM chlorogenic acid into alginate scaffolds has been shown to stimulate chondrogenesis, chondrocyte proliferation, and cartilage matrix synthesis [418]. These findings highlight the potential of chlorogenic acid as a beneficial herbal ingredient for promoting bone and cartilage regeneration.

3.8. Propolis and “Royal Jelly”

Apis mellifera honeybees collect propolis from plants, and this natural product is a complex mixture containing bioactive phenolic acids, flavonoids, and esters. While propolis is an animal product, a significant portion of its functional components originates from plants [419]. Several studies have highlighted the regenerative properties of propolis in

bone healing and periodontal treatment. In an in vivo randomized controlled trial with a 56-day follow-up, Meimandi-Parizi et al. demonstrated that transdermal administration of a dilute aqueous propolis extract significantly improved hyaline bone formation and regeneration at defect sites in rats with critical bone defects [420]. Histomorphometric evaluations in dogs have shown that propolis is more effective than nanohydroxyapatite bone graft in regenerating bone in dental furcation defects, with notable improvements in bone height and surface area [421]. Propolis has also exhibited a protective effect against osteopathy in diabetic conditions [422].

The combination of propolis and bovine bone graft has been found to increase the expression of heat shock protein and osteocalcin, as well as the number of osteoblast cells in sockets after tooth extraction compared to bovine graft alone [423]. Systemic administration of propolis in albino rats stimulated osteoblast concentration and bone formation in premaxillary sutures undergoing orthopedic expansion [424].

Royal jelly, another natural product produced by *Apis mellifera* honeybees, is rich in proteins, royalactin, lipids, and vitamins such as pantothenic acid [425]. In an in vitro study by Yanagita et al. (2011), treatment of mouse periodontal ligament cells with raw royal jelly resulted in increased expression of osteopontin, osteocalcin, and osterix mRNA, as well as enhanced mineralized nodule formation. These findings suggest that royal jelly holds promise as a suitable candidate for regenerative periodontal treatment protocols [426]. Caffeic acid phenethyl ester, an active ingredient in propolis, has also been investigated for its healing properties. Intraperitoneal injection of this bioactive compound into animal bone defects and sockets after tooth extraction has been shown to accelerate healing [427,428].

Overall, propolis, royal jelly, and caffeic acid phenethyl ester offer potential therapeutic benefits for bone regeneration and periodontal treatment, making them valuable natural products for further exploration in the field of regenerative medicine.

3.9. *Salvia miltiorrhiza*

Salvia miltiorrhiza, a perennial plant, possesses a wide range of medicinal properties. The plant contains hydrophilic phenols such as salvianolic acids, lipophilic diterpenoids, flavonoids, and triterpenoids, which are its main bioactive compounds [429]. The treatment of osteoblast-like cell clones with *S. miltiorrhiza* induces the rapid expression of alkaline phosphatase, indicating enhanced bone remodeling [430]. This plant regulates the expression of alkaline phosphatase, osteocalcin, osteoprotegerin, and receptor activator of nuclear factor-kappa B ligand (RANKL) genes, further suggesting its role in bone remodeling. Salvianolic acid, derived from *S. miltiorrhiza*, stimulates the differentiation of bone marrow stromal cells into osteoblasts and activates their functions [431]. This phenolic compound promotes the osteogenic activity of mesenchymal stem cells (MSCs) through kinase signaling pathways regulated by extracellular signals, without exhibiting cytotoxicity [432]. In human periodontal ligament cells, salvianolic acid induces osteogenic differentiation via the Wnt/ β -catenin signaling pathway [433].

The combination of *S. miltiorrhiza* extract and MSCs has been reported to promote the revascularization of avascular necrotic bone by upregulating the expression of bone morphogenetic protein 2 (BMP2) and vascular endothelial growth factor, leading to reossification and revascularization [434]. When used in combination with a collagen matrix in rat calvarial defect models, *S. miltiorrhiza* extract increases bone formation activity. However, histological analysis revealed the presence of multinucleated giant cells, indicating a foreign body reaction in the defect area [435].

Tanshinol, an aqueous polyphenol isolated from *S. miltiorrhiza* Bunge, exhibits inhibitory effects on osteoclastogenesis and counteracts glucocorticoid-induced osteoporosis and oxidative stress. It achieves this by inhibiting bone marrow adiposity through the KLF15/PPAR γ 2/FoxO3a/Wnt/NF- κ B pathways [436–440].

In summary, *Salvia miltiorrhiza* and its bioactive compounds, including salvianolic acid and tanshinol, have demonstrated positive effects on bone health and regeneration.

These findings highlight the potential of *S. miltiorrhiza* as a valuable natural resource for the development of therapies targeting bone-related disorders.

3.10. Resveratrol

Resveratrol, a derivative of polyphenol and natural stilbene found in food resources such as berries, grapes, nuts, and cocoa, has been studied for its potential benefits in bone tissue engineering and bone health [441]. The formation of mature vasculature within the scaffold is crucial in bone tissue engineering, and resveratrol has shown promising effects in this regard. In an animal study, it was reported that resveratrol can prevent steroid-induced osteonecrosis by improving the blood supply to the bone structure [442]. Resveratrol induces the expression of vascular endothelial growth factor, mannose receptor C-type 1, bone morphogenetic protein 2, and alkaline phosphatase activity in human mesenchymal stem cells, irrespective of inflammation [443–445]. It also promotes osteogenic differentiation of both embryonic and induced pluripotent stem cells, protects stem cell-derived osteocyte-like cells from glucocorticoid-induced oxidative damage, and reduces the tumorigenicity of pluripotent stem cells [445].

Pretreatment of MSCs derived from human adipose tissue with resveratrol prior to seeding into 3D tissue-engineered structures has been shown to induce the production of a mineralized matrix [446]. Resveratrol exhibits antioxidant action and is able to inhibit alveolar bone and periodontal destruction in rat models of periodontitis [447,448]. In an animal study, intraperitoneal injection of resveratrol at a concentration of 10 mmol/kg significantly improved bone regeneration after tooth extraction [449]. Preclinical studies have evaluated the regenerative capacity of various bone and cartilage tissue scaffolds, such as collagen, chitosan, poly- ϵ -caprolactone, poly-caprolactone, and hyaluronic acid, after enrichment with resveratrol [450–455]. Most of these studies have shown promising results in terms of enhancing tissue regeneration.

It is important to note that while resveratrol may reduce bone loss in older animals after oophorectomy, it does not have a protective effect and may have a negative effect on bone health at an early age [456,457]. Further research is needed to understand the age-dependent effects of resveratrol on bone health.

In summary, resveratrol exhibits potential benefits in bone tissue engineering, including promoting vasculature formation, enhancing osteogenic differentiation, and improving bone regeneration. However, its effects may vary depending on age and other factors, and more research is needed to fully understand its impact on bone health.

3.11. Rutin

Morinda citrifolia, also known as noni, is a traditionally used plant with healing properties for bone fractures and connective tissue regeneration enhancement, as well as immunomodulation [458,459]. These beneficial effects have been attributed to the presence of rutin, a bioflavonoid commonly found in this plant species [460]. In vitro studies have demonstrated that *M. citrifolia* fruit juice promotes the proliferation of bone marrow stem cells and induces marker genes associated with osteogenic differentiation [458]. Furthermore, the extract derived from the plant's leaves can stimulate osteogenic activity and mineralization in human periodontal cells and gingival stem cells through the activation of the PI3K/Akt-dependent Wnt/b-catenin signaling pathway, without causing cytotoxicity [461,462].

Rutin, the bioactive compound found in *M. citrifolia*, has been reported to retain its osteogenic properties even in inflammatory conditions by inhibiting the release of reactive oxygen species [463]. In animal studies using estrogen-deficient rats, *M. citrifolia* aqueous extract has shown concentration-dependent improvements in bone density, structure, flexibility, and strength, with the optimal effects observed at a concentration of 300 mg/kg body weight. These effects are attributed to the enhancement of osteoblast activity and the inhibition of osteoclast activity [464]. Moreover, preclinical studies have demonstrated that rutin exerts osteogenic and protective effects on periodontal ligament (PDL) cells through

the activation of the PI3K/AKT/mTOR pathway. It also counteracts TNF-alpha-induced damage to the osteogenic differentiation of these cells [465,466]. Combining rutin with vitamin C has been suggested to enhance its osteogenic properties [467], as both compounds have been independently associated with bone health and regeneration.

In summary, *Morinda citrifolia* and its bioactive compound rutin have shown promising osteogenic properties and have the potential to enhance bone regeneration and protect against bone-related conditions. Further research is needed to explore their mechanisms of action and evaluate their efficacy in clinical settings.

3.12. Osthole

Osthole, a bioactive coumarin derivative found naturally in plants like *Cnidium monnieri*, has been studied for its osteogenic properties and its potential in bone healing processes. In mouse preosteoblastic cells, Osthole has been shown to induce osteogenesis by modulating the cAMP/cAMP response element signaling pathway. It promotes the downstream expression of the transcription factor Sterix and inhibits the activity of RANKL, which is involved in osteoclast-mediated bone resorption [468,469].

Furthermore, Osthole has been found to accelerate the process of endochondral ossification and bone fracture healing. It does so by inducing the expression of cartilage marker genes and bone morphogenetic protein 2 (BMP2), a key regulator of bone formation [470,471]. In periodontal ligament-derived stem cells, Osthole has shown the ability to activate the acetylation of Histone 3 lysine 9 and Histone 3 lysine 14. These modifications play a crucial role in the osteogenic differentiation of periodontal cells, suggesting that Osthole may enhance bone regeneration in the context of periodontal tissue [472,473].

Overall, Osthole exhibits osteogenic properties by regulating signaling pathways, promoting cartilage and bone marker expression, and influencing the differentiation of stem cells involved in bone formation. These findings highlight the potential of Osthole as a natural compound for promoting bone health and regeneration. However, further research is needed to fully understand its mechanisms of action and evaluate its efficacy in clinical settings.

4. Conclusions

Bone, despite its relatively simple structure composed of three types of cell subpopulations, an organic part mainly consisting of collagen, and an inorganic phase primarily composed of hydroxyapatite, presents a challenge in the development of an “ideal” bone grafting material due to the complex regulation of bone metabolism and the composite nature of its extracellular matrix. However, the application of various calcium–phosphate materials, particularly hydroxyapatite and polymer/hydroxyapatite composites, has shown relatively successful outcomes in experimental and clinical settings. It is important to note that the properties and clinical efficacy of these materials are strongly influenced by synthesis features such as the Ca/P ratio, the presence of amorphous calcium phosphates, and structural parameters like grain size and porosity. In addition to collagen, which serves as the main component of native bone tissue, other materials such as chitosan, gelatin, and alginates, among others, have demonstrated the ability to promote bone regeneration and provide additional benefits as antibacterial and vascular growth-controlling factors. Moreover, natural compounds have been explored as additives to bone grafting materials, aiming to regulate bone healing processes. Recent advancements in bone grafting material discovery have showcased their potential to offer control over bone regeneration, reduce the risk of disease transmission, and expedite the recovery process following application. Looking ahead, future research should focus on standardizing the production of bone grafting materials, controlling parameters such as porosity and mechanical properties, and tailoring their characteristics to enable precise programming of degradation and facilitate new bone growth.

Author Contributions: Methodology, O.K.; Formal analysis, O.M., D.M. and R.M.; Data curation, O.M. and A.Y.; Writing—original draft, A.Y., O.K., D.M., R.M. and M.P.; Writing—review & editing, O.M. and A.R.; Project administration, M.P.; Funding acquisition, M.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the National Research Foundation of Ukraine (2020.02/0223), the Ministry of Education and Science of Ukraine (0121U100471), and the Horizon Europe MSCA-2021-SE-01 project (ARGO #101086441).

Institutional Review Board Statement: Not applicable.

Acknowledgments: Research was funded under a grant from the National Research Foundation of Ukraine (2020.02/0223), the Horizon Europe MSCA-2021-SE-01 project (ARGO #101086441), and the Ministry of Education and Science of Ukraine research grant (Project No. 0121U100471).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Tran, S.D.; Bakkar, M.O.; Sumita, Y.; Kishimoto, N. Regenerative dentistry in periodontics. *Saudi Dent. J.* **2019**, *31*, 301–302. [[CrossRef](#)]
2. Raggatt, L.J.; Partridge, N.C. Cellular and Molecular Mechanisms of Bone Remodeling. *J. Biol. Chem.* **2010**, *285*, 25103–25108. [[CrossRef](#)]
3. Burge, R.; Dawson-Hughes, B.; Solomon, D.H.; Wong, J.B.; King, A.; Tosteson, A. Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025. *J. Bone Miner. Res.* **2006**, *22*, 465–475. [[CrossRef](#)]
4. Einhorn, T.A.; Gerstenfeld, L.C. Fracture healing: Mechanisms and interventions. *Nat. Rev. Rheumatol.* **2014**, *11*, 45–54. [[CrossRef](#)]
5. Raja, S.; Byakod, G.; Pudakalkatti, P. Growth factors in periodontal regeneration. *Int. J. Dent. Hyg.* **2009**, *7*, 82–89. [[CrossRef](#)]
6. Sakkas, A.; Wilde, F.; Heufelder, M.; Winter, K.; Schramm, A. Autogenous bone grafts in oral implantology—Is it still a “gold standard”? A consecutive review of 279 patients with 456 clinical procedures. *Int. J. Implant. Dent.* **2017**, *3*, 23. [[CrossRef](#)]
7. Baldwin, P.; Li, D.J.; Auston, D.A.; Mir, H.S.; Yoon, R.S.; Koval, K.J. Autograft, Allograft, and Bone Graft Substitutes: Clinical Evidence and Indications for Use in the Setting of Orthopaedic Trauma Surgery. *J. Orthop. Trauma* **2019**, *33*, 203–213. [[CrossRef](#)]
8. Betz, R.R. Limitations of Autograft and Allograft: New Synthetic Solutions. *Orthopedics* **2002**, *25*, 561–570. [[CrossRef](#)]
9. Ho-Shui-Ling, A.; Bolander, J.; Rustom, L.E.; Johnson, A.W.; Luyten, F.P.; Picart, C. Bone regeneration strategies: Engineered scaffolds, bioactive molecules and stem cells current stage and future perspectives. *Biomaterials* **2018**, *180*, 143–162. [[CrossRef](#)]
10. Shapiro, F. Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts and surface osteoblasts. *Eur. Cells Mater.* **2008**, *15*, 53–76. [[CrossRef](#)]
11. Ferguson, C.; Alpern, E.; Miclau, T.; Helms, J.A. Does adult fracture repair recapitulate embryonic skeletal formation? *Mech. Dev.* **1999**, *87*, 57–66. [[CrossRef](#)] [[PubMed](#)]
12. Marsell, R.; Einhorn, T.A. The biology of fracture healing. *Injury* **2011**, *42*, 551–555. [[CrossRef](#)] [[PubMed](#)]
13. Vetter, A.; Epari, D.R.; Seidel, R.; Schell, H.; Fratzl, P.; Duda, G.N.; Weinkamer, R. Temporal tissue patterns in bone healing of sheep. *J. Orthop. Res.* **2010**, *28*, 1440–1447. [[CrossRef](#)] [[PubMed](#)]
14. Lacroix, D.; Prendergast, P. A mechano-regulation model for tissue differentiation during fracture healing: Analysis of gap size and loading. *J. Biomech.* **2002**, *35*, 1163–1171. [[CrossRef](#)]
15. Hadjidakis, D.J.; Androulakis, I.I. Bone remodeling. *Ann. N. Y. Acad. Sci.* **2006**, *1092*, 385–396. [[CrossRef](#)]
16. Dimitriou, R.; Jones, E.; McGonagle, D.; Giannoudis, P.V. Bone regeneration: Current concepts and future directions. *BMC Med.* **2011**, *31*, 66. [[CrossRef](#)]
17. Bauer, T.W.; Muschler, G.F. Bone graft materials. An overview of the basic science. *Clin. Orthop. Relat. Res.* **2000**, *371*, 10–27. [[CrossRef](#)]
18. Pountos, I.; Giannoudis, P.V. Fracture Healing: Back to Basics and Latest Advances. In *Fracture Reduction and Fixation Techniques: Upper Extremities*; Giannoudis, P.V., Ed.; Springer International Publishing: Cham, Switzerland, 2018; pp. 3–17, ISBN 978-3-319-68627-1, ISBN 978-3-319-68628-8 (eBook). [[CrossRef](#)]
19. Kozik, V.V.; Borilo, L.P.; Lyutova, E.S.; Brichkov, A.S.; Chen, Y.-W.; Izosimova, E.A. Preparation of CaO@TiO₂-SiO₂ Biomaterial with a Sol-Gel Method for Bone Implantation. *ACS Omega* **2020**, *5*, 27221–27226. [[CrossRef](#)]
20. Zhu, L.; Luo, D.; Liu, Y. Effect of the nano/microscale structure of biomaterial scaffolds on bone regeneration. *Int. J. Oral Sci.* **2020**, *12*, 6. [[CrossRef](#)]
21. Jiang, X.Q. Biomaterials for bone defect repair and bone regeneration. *Zhonghua Kou Qiang Yi Xue Za Zhi* **2017**, *52*, 600–604.
22. Gouveia, P.F.; Mesquita-Guimarães, J.; Galárraga-Vinueza, M.E.; Souza, J.C.; Silva, F.S.; Fredel, M.C.; Boccaccini, A.R.; Detsch, R.; Henriques, B. In-vitro mechanical and biological evaluation of novel zirconia reinforced bioglass scaffolds for bone repair. *J. Mech. Behav. Biomed. Mater.* **2020**, *114*, 104164. [[CrossRef](#)]
23. Yedekçi, B.; Tezcaner, A.; Alshemary, A.Z.; Yılmaz, B.; Demir, T.; Evis, Z. Synthesis and sintering of B, Sr, Mg multi-doped hydroxyapatites: Structural, mechanical and biological characterization. *J. Mech. Behav. Biomed. Mater.* **2020**, *115*, 104230. [[CrossRef](#)]

24. McNamara, S.L.; McCarthy, E.M.; Schmidt, D.F.; Johnston, S.P.; Kaplan, D.L. Rheological characterization, compression, and injection molding of hydroxyapatite-silk fibroin composites. *Biomaterials* **2021**, *269*, 120643. [CrossRef]
25. Dewey, M.J.; Nosatov, A.V.; Subedi, K.; Shah, R.; Jakus, A.; Harley, B.A. Inclusion of a 3D-printed Hyperelastic Bone mesh improves mechanical and osteogenic performance of a mineralized collagen scaffold. *Acta Biomater.* **2021**, *121*, 224–236. [CrossRef]
26. Shao, Y.-F.; Qing, X.; Peng, Y.; Wang, H.; Shao, Z.; Zhang, K.-Q. Enhancement of mechanical and biological performance on hydroxyapatite/silk fibroin scaffolds facilitated by microwave-assisted mineralization strategy. *Colloids Surfaces B Biointerfaces* **2021**, *197*, 111401. [CrossRef] [PubMed]
27. Haugen, H.J.; Lyngstadaas, S.P.; Rossi, F.; Perale, G. Bone grafts: Which is the ideal biomaterial? *J. Clin. Periodontol.* **2019**, *46* (Suppl. S21), 92–102. [CrossRef] [PubMed]
28. Safari, B.; Aghanejad, A.; Roshangar, L.; Davaran, S. Osteogenic effects of the bioactive small molecules and minerals in the scaffold-based bone tissue engineering. *Colloids Surfaces B Biointerfaces* **2021**, *198*, 111462. [CrossRef] [PubMed]
29. Wang, X.; Xu, S.; Zhou, S.; Xu, W.; Leary, M.; Choong, P.; Qian, M.; Brandt, M.; Xie, Y.M. Topological design and additive manufacturing of porous metals for bone scaffolds and orthopaedic implants: A review. *Biomaterials* **2016**, *83*, 127–141. [CrossRef] [PubMed]
30. Eming, S.A.; Wynn, T.A.; Martin, P. Inflammation and metabolism in tissue repair and regeneration. *Science* **2017**, *356*, 1026–1030. [CrossRef] [PubMed]
31. He, J.; Chen, G.; Liu, M.; Xu, Z.; Chen, H.; Yang, L.; Lv, Y. Scaffold strategies for modulating immune microenvironment during bone regeneration. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2020**, *108*, 110411. [CrossRef]
32. Wang, Q.; Tang, Y.; Ke, Q.; Yin, W.; Zhang, C.; Guo, Y.; Guan, J. Magnetic lanthanum-doped hydroxyapatite/chitosan scaffolds with endogenous stem cell-recruiting and immunomodulatory properties for bone regeneration. *J. Mater. Chem. B* **2020**, *8*, 5280–5292. [CrossRef] [PubMed]
33. Hing, K.A. Bone repair in the twenty-first century: Biology, chemistry or engineering? *Philos. Trans. R. Soc. A Math. Phys. Eng. Sci.* **2004**, *362*, 2821–2850. [CrossRef] [PubMed]
34. Finkemeier, C.G. Bone-Grafting and Bone-Graft Substitutes. *J. Bone Jt. Surg. Am.* **2002**, *84*, 454–464. [CrossRef]
35. Karageorgiou, V.; Kaplan, D. Porosity of 3D biomaterial scaffolds and osteogenesis. *Biomaterials* **2005**, *26*, 5474–5491. [CrossRef] [PubMed]
36. Haroun, A.A.; Migonney, V. Synthesis and in vitro evaluation of gelatin/hydroxyapatite graft copolymers to form bionanocomposites. *Int. J. Biol. Macromol.* **2010**, *46*, 310–316. [CrossRef]
37. Park, S.-B.; Lih, E.; Park, K.-S.; Joung, Y.K.; Han, D.K. Biopolymer-based functional composites for medical applications. *Prog. Polym. Sci.* **2017**, *68*, 77–105. [CrossRef]
38. Yanovska, A.; Bolshanina, S. Chapter 13—Composite materials based on hydroxyapatite embedded in biopolymer matrices: Ways of synthesis and application. In *Materials for Biomedical Engineering*; Alina-Maria, H., Alexandru, M.G., Eds.; Elsevier: Amsterdam, The Netherlands, 2019; pp. 403–440, ISBN 9780128169018. [CrossRef]
39. Gelse, K.; Pöschl, E.; Aigner, T. Collagens—Structure, function, and biosynthesis. *Adv. Drug Deliv. Rev.* **2003**, *55*, 1531–1546. [CrossRef]
40. Patino, M.G.; Neiders, M.E.; Andreana, S.; Noble, B.; Cohen, R.E. Collagen: An Overview. *Implant. Dent.* **2002**, *11*, 280–285. [CrossRef]
41. Ferreira, A.M.; Gentile, P.; Chiono, V.; Ciardelli, G. Collagen for bone tissue regeneration. *Acta Biomater.* **2012**, *8*, 3191–3200. [CrossRef]
42. Currey, J.D. The structure and mechanics of bone. *J. Mater. Sci.* **2011**, *47*, 41–54. [CrossRef]
43. Boskey, A. Biomineralization: An Overview. *Connect. Tissue Res.* **2003**, *44* (Suppl. S1), 5–9. [CrossRef]
44. Turnbull, G.; Clarke, J.; Picard, F.; Riches, P.; Jia, L.; Han, F.; Li, B.; Shu, W. 3D bioactive composite scaffolds for bone tissue engineering. *Bioact. Mater.* **2017**, *3*, 278–314. [CrossRef]
45. Jones, J.R.; Lin, S.; Yue, S.; Lee, P.D.; Hanna, J.V.; E Smith, M.; Newport, R.J. Bioactive glass scaffolds for bone regeneration and their hierarchical characterisation. *Proc. Inst. Mech. Eng. Part H J. Eng. Med.* **2010**, *224*, 1373–1387. [CrossRef]
46. Williams, D.F. Definitions in Biomaterials: Proceedings of a Consensus Conference of the European Society for Biomaterials, v. 4. In *1986 European Society for Biomaterials*; Elsevier: Chester, UK, 1987; ISBN 9780444423986. Available online: <https://books.google.com.ua/books?id=6zdrAAAAMAAJ> (accessed on 30 July 2008).
47. Williams, D.; Zhang, X. (Eds.) *Definitions of Biomaterials for the Twenty-First Century*, 1st ed.; Elsevier: Amsterdam, The Netherlands, 2019; pp. 15–23. ISBN 9780128182925. [CrossRef]
48. Yanovska, G.O. Physico-Chemical Features of Calcium-Phosphate Coatings Formation on Titanium and Magnesium Metal Implants. Ph.D. Thesis, Institute of Applied Physics, Sumy, Ukraine, 2014.
49. Dorozhkin, S.V. Calcium orthophosphates and human beings: A historical perspective from the 1770's until 1940. *Biomatter* **2012**, *2*, 53–70. [CrossRef]
50. Hench, L.L. Bioceramics: From Concept to Clinic. *J. Am. Ceram. Soc.* **1991**, *74*, 1487–1510. [CrossRef]
51. Vallet-Regí, M. Ceramics for medical applications. *J. Chem. Soc. Dalton Trans.* **2001**, *74*, 97–108. [CrossRef]
52. Ramiro-Gutiérrez, M.L.; Will, J.; Boccaccini, A.R.; Díaz-Cuenca, A. Reticulated bioactive scaffolds with improved textural properties for bone tissue engineering: Nanostructured surfaces and porosity. *J. Biomed. Mater. Res. Part A* **2013**, *102*, 2982–2992. [CrossRef]

53. Romero-Sánchez, L.B.; Borrego-González, S.; Díaz-Cuenca, A. High surface area biopolymeric-ceramic scaffolds for hard tissue engineering. *Biomed. Phys. Eng. Express* **2017**, *3*, 035012. [CrossRef]
54. Drouet, C. Apatite Formation: Why It May Not Work as Planned, and How to Conclusively Identify Apatite Compounds. *BioMed Res. Int.* **2013**, *2013*, 490946. [CrossRef]
55. Dorozhkin, S.V. Calcium Orthophosphates as Bioceramics: State of the Art. *J. Funct. Biomater.* **2010**, *1*, 22–107. [CrossRef]
56. Dorozhkin, S.V. Calcium orthophosphates. *J. Mater. Sci.* **2007**, *42*, 1061–1095. [CrossRef]
57. Dorozhkin, S.V. Calcium Orthophosphates in Nature, Biology and Medicine. *Materials* **2009**, *2*, 399–498. [CrossRef]
58. De Groot, K. *Bioceramics of Calcium Phosphate*; CRC Press: Boca Raton, FL, USA, 2018. [CrossRef]
59. LeGeros, R.Z. Calcium phosphates in oral biology and medicine. *Monogr. Oral Sci.* **1991**, *15*, 1–201.
60. Elliot, J.C. *Structure and Chemistry of the Apatites and Other Calcium Orthophosphates*, 1st ed.; Elsevier: Amsterdam, The Netherlands, 1994; pp. 1–62, ISBN 9781483290317.
61. León, B.; John, J. *Thin Calcium Phosphate Coatings for Medical Implants*; Springer: New York, NY, USA, 2009; pp. 1–328, ISBN 978-0-387-77718-4. [CrossRef]
62. Flautre, B.; Maynou, C.; Lemaitre, J.; Van Landuyt, P.; Hardouin, P. Bone colonization of β -TCP granules incorporated in brushite cements. *J. Biomed. Mater. Res.* **2002**, *63*, 413–417. [CrossRef]
63. Bohner, M.; Theiss, F.; Apelt, D.; Hirsiger, W.; Houriet, R.; Rizzoli, G.; Gnos, E.; Frei, C.; Auer, J.; von Rechenberg, B. Compositional changes of a dicalcium phosphate dihydrate cement after implantation in sheep. *Biomaterials* **2003**, *24*, 3463–3474. [CrossRef]
64. Bohner, M.; Gbureck, U.; Barralet, J. Technological issues for the development of more efficient calcium phosphate bone cements: A critical assessment. *Biomaterials* **2005**, *26*, 6423–6429. [CrossRef]
65. Mandel, S.; Tas, A.C. Brushite ($\text{CaHPO}_4 \cdot 2\text{H}_2\text{O}$) to octacalcium phosphate ($\text{Ca}_8(\text{HPO}_4)_2(\text{PO}_4)_4 \cdot 5\text{H}_2\text{O}$) transformation in DMEM solutions at 36.5 °C. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2010**, *30*, 245–254. [CrossRef]
66. Johnsson, M.S.-A.; Nancollas, G.H. The Role of Brushite and Octacalcium Phosphate in Apatite Formation. *Crit. Rev. Oral Biol. Med.* **1992**, *3*, 61–82. [CrossRef]
67. Madsen, H.E. Influence of magnetic field on the precipitation of some inorganic salts. *J. Cryst. Growth* **1995**, *152*, 94–100. [CrossRef]
68. Schofield, P.F.; Knight, K.S.; van der Houwen, J.A.M.; Valsami-Jones, E. The role of hydrogen bonding in the thermal expansion and dehydration of brushite, di-calcium phosphate dihydrate. *Phys. Chem. Miner.* **2004**, *31*, 606–624. [CrossRef]
69. Available online: <http://webmineral.com/data/Brushite.shtml> (accessed on 10 September 2023).
70. Hughes, J.M.; Rakovan, J. The Crystal Structure of Apatite, $\text{Ca}_5(\text{PO}_4)_3(\text{F},\text{OH},\text{Cl})$. *Rev. Miner. Geochem.* **2002**, *48*, 1–12. [CrossRef]
71. Shi, D.; Wen, X. Bioactive Ceramics: Structure, Synthesis, and Mechanical Properties. In *Introduction to Biomaterials*; Shi, D., Ed.; Tsinghua University Press: Beijing, China, 2006; p. 13. Available online: <https://books.google.com.ua/books?id=5jrAQgAACAAJ> (accessed on 3 September 2006).
72. Ong, J.L.; Chan, D.C.N. Hydroxyapatite and Their Use as Coatings in Dental Implants: A Review. *Crit. Rev. Biomed. Eng.* **2000**, *28*, 667–707. [CrossRef]
73. Osaka, A.; Miura, Y.; Takeuchi, K.; Asada, M.; Takahashi, K. Calcium apatite prepared from calcium hydroxide and orthophosphoric acid. *J. Mater. Sci. Mater. Electron.* **1991**, *2*, 51–55. [CrossRef]
74. Heughebaert, J.C.; Montel, G. Conversion of amorphous tricalcium phosphate into apatitic tricalcium phosphate. *Calcif Tissue Int.* **1982**, *34*, S103–S108.
75. Bai, X. Processing and Characterization of Functionally Graded Hydroxyapatite Coatings for Biomedical Implants—A dissertation submitted to the Graduate Faculty of North Carolina State University in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Available online: <https://repository.lib.ncsu.edu/handle/1840.16/6206?show=full#:~:text=http%3A/www.lib.ncsu.edu/resolver/1840.16/6206> (accessed on 10 September 2023).
76. Handa, T.; Anada, T.; Honda, Y.; Yamazaki, H.; Kobayashi, K.; Kanda, N.; Kamakura, S.; Echigo, S.; Suzuki, O. The effect of an octacalcium phosphate co-precipitated gelatin composite on the repair of critical-sized rat calvarial defects. *Acta Biomater.* **2012**, *8*, 1190–1200. [CrossRef]
77. Eanes, E.D.; Gillissen, I.H.; Posner, A.S. Intermediate States in the Precipitation of Hydroxyapatite. *Nature* **1965**, *208*, 365–367. [CrossRef]
78. Suchanek, W.; Yoshimura, M. Processing and properties of hydroxyapatite-based biomaterials for use as hard tissue replacement implants. *J. Mater. Res.* **1998**, *13*, 94–117. [CrossRef]
79. Yamasaki, H.; Sakai, H. Osteogenic response to porous hydroxyapatite ceramics under the skin of dogs. *Biomaterials* **1992**, *13*, 308–312. [CrossRef]
80. Li, S.H.; De Wijn, J.R.; Layrolle, P.; De Groot, K. Synthesis of macroporous hydroxyapatite scaffolds for bone tissue engineering. *J. Biomed. Mater. Res.* **2002**, *61*, 109–120. [CrossRef]
81. Kanazawa, T. *Inorganic Phosphate Materials, Materials Science Monographs*; Elsevier: Amsterdam, The Netherlands, 1989.
82. Pu'Ad, N.M.; Haq, R.A.; Noh, H.M.; Abdullah, H.; Idris, M.; Lee, T. Synthesis method of hydroxyapatite: A review. *Mater. Today Proc.* **2020**, *29*, 233–239. [CrossRef]
83. Christoffersen, J.; Christoffersen, M.R.; Kibalczyk, W.; Andersen, F.A. A contribution to the understanding of the formation of calcium phosphates. *J. Cryst. Growth* **1989**, *94*, 767–777. [CrossRef]
84. Christoffersen, M.; Christoffersen, J.; Kibalczyk, W. Apparent solubilities of two amorphous calcium phosphates and of octacalcium phosphate in the temperature range 30–42 °C. *J. Cryst. Growth* **1990**, *106*, 349–354. [CrossRef]

85. Harding, I.; Rashid, N.; Hing, K. Surface charge and the effect of excess calcium ions on the hydroxyapatite surface. *Biomaterials* **2005**, *26*, 6818–6826. [[CrossRef](#)] [[PubMed](#)]
86. Zhu, P.; Masuda, Y.; Koumoto, K. The effect of surface charge on hydroxyapatite nucleation. *Biomaterials* **2004**, *25*, 3915–3921. [[CrossRef](#)]
87. Wang, L.; Nancollas, G.H. Calcium Orthophosphates: Crystallization and Dissolution. *Chem. Rev.* **2008**, *108*, 4628–4669. [[CrossRef](#)] [[PubMed](#)]
88. Koutsopoulos, S. Synthesis and characterization of hydroxyapatite crystals: A review study on the analytical methods. *J. Biomed. Mater. Res.* **2002**, *62*, 600–612. [[CrossRef](#)] [[PubMed](#)]
89. Fleet, M.E. Infrared spectra of carbonate apatites: Evidence for a connection between bone mineral and body fluids. *Am. Miner.* **2017**, *102*, 149–157. [[CrossRef](#)]
90. Madupalli, H.; Pavan, B.; Tecklenburg, M.M. Carbonate substitution in the mineral component of bone: Discriminating the structural changes, simultaneously imposed by carbonate in A and B sites of apatite. *J. Solid State Chem.* **2017**, *255*, 27–35. [[CrossRef](#)]
91. Liu, C.; Huang, Y.; Shen, W.; Cui, J. Kinetics of hydroxyapatite precipitation at pH 10 to 11. *Biomaterials* **2000**, *22*, 301–306. [[CrossRef](#)]
92. Rodríguez-Lorenzo, L.M.; Vallet-Regí, M. Controlled Crystallization of Calcium Phosphate Apatites. *Chem. Mater.* **2000**, *12*, 2460–2465. [[CrossRef](#)]
93. Samavedi, S.; Whittington, A.R.; Goldstein, A.S. Calcium phosphate ceramics in bone tissue engineering: A review of properties and their influence on cell behavior. *Acta Biomater.* **2013**, *9*, 8037–8045. [[CrossRef](#)] [[PubMed](#)]
94. Dziadek, M.; Stodolak-Zych, E.; Cholewa-Kowalska, K. Biodegradable ceramic-polymer composites for biomedical applications: A review. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2017**, *71*, 1175–1191. [[CrossRef](#)] [[PubMed](#)]
95. Al-Sanabani, J.S.; Madfa, A.A.; Al-Sanabani, F.A. Application of Calcium Phosphate Materials in Dentistry. *Int. J. Biomater.* **2013**, *2013*, 876132. [[CrossRef](#)] [[PubMed](#)]
96. Yilmaz, B.; Pazarcivren, A.E.; Tezcaner, A.; Evis, Z. Historical development of simulated body fluids used in biomedical applications: A review. *Microchem. J.* **2020**, *155*, 104713. [[CrossRef](#)]
97. Rabadjieva, D.; Gergulova, R.; Titorenkova, R.; Tepavitcharova, S.; Dyulgerova, E.; Balarew, C.; Petrov, O. Biomimetic transformations of amorphous calcium phosphate: Kinetic and thermodynamic studies. *J. Mater. Sci. Mater. Med.* **2010**, *21*, 2501–2509. [[CrossRef](#)]
98. Rabadjieva, D.; Tepavitcharova, S.; Sezanova, K.; Gergulova, R. Chemical Equilibria Modeling of Calcium Phosphate Precipitation and Transformation in Simulated Physiological Solutions. *J. Solut. Chem.* **2016**, *45*, 1620–1633. [[CrossRef](#)]
99. Rabadjieva, D.; Tepavitcharova, S.; Gergulova, R.; Sezanova, K.; Titorenkova, R.; Petrov, O.; Dyulgerova, E. Mg- and Zn-modified calcium phosphates prepared by biomimetic precipitation and subsequent treatment at high temperature. *J. Mater. Sci. Mater. Med.* **2011**, *22*, 2187–2196. [[CrossRef](#)]
100. Sezanova, K.; Tepavitcharova, S.; Rabadjieva, D.; Gergulova, R.; Ilieva, R. Optimization of calcium phosphate fine ceramic powders preparation. *AIP Conf. Proc.* **2013**, *1569*, 433–436. [[CrossRef](#)]
101. Sezanova, K.; Kovacheva, D.; Rabadjieva, D.; Gergulova, R. Mg and Zn modified calcium phosphate fine powders examined by Rietveld refinement. *Bulg. Chem. Commun.* **2018**, *50*, 99–106.
102. Gergulova, R.; Tepavitcharova, S.; Sezanova, K.; Rabadjieva, D.; Ilieva, R. Method for preparation of ion-modified calcium orthophosphate fine powders and their use in composite materials. *J. Int. Sci. Publ. Mater. Methods Technol.* **2017**, *11*, 168–177. Available online: <https://www.scientific-publications.net/en/article/1001463/> (accessed on 29 July 2017).
103. Tepavicharova, S.; Gergulova, R.; Rabadjieva, D.; Sezanova, K.; Ilieva, R.; Gabrashanska, M.; Alexandrov, M.; Alexandrova, R. Calcium phosphate fine powders for bone defects—Synthesis, in vitro and in vivo studies. In *Monograph Series of the International Conferences on Coordination and Bioinorganic Chemistry*; Melník, M., Segl'a, P., Tatarko, M., Eds.; Press of Slovak University of Technology Bratislava: Bratislava, Slovakia, 2013; pp. 446–453.
104. Ilieva, R.; Rabadjieva, D.; Sezanova, K.; Tepavitcharova, S.; Gergulova, R.; Gabrashanska, M.; Alexandrov, M.; Nanev, V. Calcium phosphate composites and their in vivo behaviour. In *Monograph Series of the International Conferences on Coordination and Bioinorganic Chemistry*; Melník, M., Segl'a, P., Tatarko, M., Eds.; Press of Slovak University of Technology Bratislava: Bratislava, Slovakia, 2013; Volume 11, pp. 141–146.
105. Rabadjieva, D.; Tepavitcharova, S.; Gergulova, R.; Sezanova, K.; Ilieva, R.; Gabrashanska, M.; Alexandrov, M. Calcium phosphate porous composites and ceramics prospective as bone implants. *AIP Conf. Proc.* **2013**, *1569*, 466–470. [[CrossRef](#)]
106. Sing, K.S.W.; Everett, D.H.; Haul, R.A.W.; Moscou, L.; Pierotti, R.A.; Rouquérol, J.; Siemieniewska, T. Reporting physisorption data for gas/solid systems—With special reference to the determination of surface area and porosity. *Pure Appl. Chem.* **1985**, *57*, 603–619. [[CrossRef](#)]
107. Zhao, D.; Feng, J.; Huo, Q.; Melosh, N.; Fredrickson, G.H.; Chmelka, B.F.; Stucky, G.D. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. *Science* **1998**, *279*, 548–552. [[CrossRef](#)] [[PubMed](#)]
108. Díaz, A.; López, T.; Manjarrez, J.; Basaldella, E.; Martínez-Blanes, J.M.; Odriozola, J.A. Growth of hydroxyapatite in a biocompatible mesoporous ordered silica. *Acta Biomater.* **2006**, *2*, 173–179. [[CrossRef](#)]
109. Croissant, G.; Fatiev, Y.; Khashab, N.M. Degradability and clearance of silicon, organosilica, silsesquioxane, silica mixed oxide, and mesoporous silica nanoparticles. *Adv. Mater.* **2017**, *29*, 1604634. [[CrossRef](#)] [[PubMed](#)]

110. Cejudo-Guillén, M.; Ramiro-Gutiérrez, M.; Labrador-Garrido, A.; Díaz-Cuenca, A.; Pozo, D. Nanoporous silica microparticle interaction with toll-like receptor agonists in macrophages. *Acta Biomater.* **2012**, *8*, 4295–4303. [[CrossRef](#)] [[PubMed](#)]
111. Hench, L.L.; Polak, J.M.; Xynos, I.D.; Buttery, L.D.K. Bioactive materials to control cell cycle. *Mat. Res. Innovat.* **2000**, *3*, 313–323. [[CrossRef](#)]
112. Saravanapavan, P.; Jones, J.R.; Pryce, R.S.; Hench, L.L. Bioactivity of gel-glass powders in the CaO-SiO₂ system: A comparison with ternary (CaO-P₂O₅-SiO₂) and quaternary glasses (SiO₂-CaO-P₂O₅-Na₂O). *J. Biomed. Mater. Res.* **2003**, *66*, 110–119. [[CrossRef](#)]
113. Götz, W.; Gerber, T.; Michel, B.; Lossdörfer, S.; Henkel, K.-O.; Heinemann, F. Immunohistochemical characterization of nanocrystalline hydroxyapatite silica gel (NanoBone[®]) osteogenesis: A study on biopsies from human jaws. *Clin. Oral Implant. Res.* **2008**, *19*, 1016–1026. [[CrossRef](#)]
114. Adam, S.A.N.; Elarab, A.E.; Rahman, A.R.A.; Rahim, D.F.A. Evaluation of implant stability and marginal bone loss in immediate implant using “nano bone” versus “autogenous bone” for the treatment of patients with unrestorable single tooth: A randomized controlled trial. *J. Osseointegr.* **2019**, *12*, 8–17. [[CrossRef](#)]
115. Gerike, W.; Bienengraber, V.; Henkel, K.O.; Bayerlein, T.; Gedrange, P.; Proff, T.; Gerber, T.H. The manufacture of synthetic non-sintered and degradable bone grafting substitutes. *Folia Morphol.* **2006**, *65*, 54–55. [[PubMed](#)]
116. Urist Marshall, R. Bone: Formation by Autoinduction. *Science* **1965**, *150*, 893–899. Available online: <http://www.jstor.org/stable/1717499> (accessed on 25 April 2023). [[CrossRef](#)] [[PubMed](#)]
117. Burchardt, H. The biology of bone graft repair. *Clin. Orthop. Relat. Res.* **1983**, *174*, 28–42. [[CrossRef](#)]
118. LeGeros, R.Z. Properties of Osteoconductive Biomaterials: Calcium Phosphates. *Clin. Orthop. Relat. Res.* **2002**, *395*, 81–98. [[CrossRef](#)] [[PubMed](#)]
119. Giannoudis, P.V.; Dinopoulos, H.; Tsiridis, E. Bone substitutes: An update. *Injury* **2005**, *36* (Suppl. S3), S20–S27. [[CrossRef](#)]
120. Arrington, E.D.; Smith, W.J.; Chambers, H.G.; Bucknell, A.L.; Davino, N.A. Complications of Iliac Crest Bone Graft Harvesting. *Clin. Orthop. Relat. Res.* **1996**, *329*, 300–309. [[CrossRef](#)]
121. Banwart, J.C.; Asher, M.A.; Hassanein, R.S. Iliac Crest Bone Graft Harvest Donor Site Morbidity. A statistical evaluation. *Spine* **1995**, *20*, 1055–1060. [[CrossRef](#)]
122. Giannoudis, P.V.; Einhorn, T.A.; Marsh, D. Fracture healing: The diamond concept. *Injury* **2007**, *38* (Suppl. 4), S3–S6. [[CrossRef](#)]
123. Giannoudis, P.V.; Einhorn, T.A.; Schmidmaier, G.; Marsh, D. The diamond concept—Open questions. *Injury* **2008**, *39*, S5–S8. [[CrossRef](#)]
124. Calori, G.; Mazza, E.; Colombo, M.; Ripamonti, C. The use of bone-graft substitutes in large bone defects: Any specific needs? *Injury* **2011**, *42*, S56–S63. [[CrossRef](#)]
125. Habraken, W.; Wolke, J.; Jansen, J. Ceramic composites as matrices and scaffolds for drug delivery in tissue engineering. *Adv. Drug Deliv. Rev.* **2007**, *59*, 234–248. [[CrossRef](#)] [[PubMed](#)]
126. Hannink, G.; Arts, J.C. Bioresorbability, porosity and mechanical strength of bone substitutes: What is optimal for bone regeneration? *Injury* **2011**, *42*, S22–S25. [[CrossRef](#)] [[PubMed](#)]
127. Doi, Y.; Shimizu, Y.; Moriwaki, Y.; Aga, M.; Iwanaga, H.; Shibutani, T.; Yamamoto, K.; Iwayama, Y. Development of a new calcium phosphate cement that contains sodium calcium phosphate. *Biomaterials* **2001**, *22*, 847–854. [[CrossRef](#)] [[PubMed](#)]
128. Hurle, K.; Neubauer, J.; Bohner, M.; Doebelin, N.; Goetz-Neunhoffer, F. Effect of amorphous phases during the hydraulic conversion of α -TCP into calcium-deficient hydroxyapatite. *Acta Biomater.* **2014**, *10*, 3931–3941. [[CrossRef](#)]
129. Lu, J.; Descamps, M.; Dejou, J.; Koubi, G.; Hardouin, P.; Lemaitre, J.; Proust, J.-P. The biodegradation mechanism of calcium phosphate biomaterials in bone. *J. Biomed. Mater. Res.* **2002**, *63*, 408–412. [[CrossRef](#)]
130. Tamimi, F.; Sheikh, Z.; Barralet, J. Dicalcium phosphate cements: Brushite and monetite. *Acta Biomater.* **2012**, *8*, 474–487. [[CrossRef](#)]
131. Radin, S.R.; Ducheyne, P. Effect of bioactive ceramic composition and structure on in vitro behavior. III. Porous versus dense ceramics. *J. Biomed. Mater. Res.* **1994**, *28*, 1303–1309. [[CrossRef](#)]
132. Yamada, S.; Heymann, D.; Bouler, J.M.; Daculsi, G. Osteoclastic resorption of biphasic calcium phosphate ceramic in vitro. *J. Biomed. Mater. Res.* **1997**, *37*, 346–352. [[CrossRef](#)]
133. Yamada, S.; Heymann, D.; Bouler, J.-M.; Daculsi, G. Osteoclastic resorption of calcium phosphate ceramics with different hydroxyapatite/ β -tricalcium phosphate ratios. *Biomaterials* **1997**, *18*, 1037–1041. [[CrossRef](#)]
134. Gisep, A.; Wieling, R.; Bohner, M.; Matter, S.; Schneider, E.; Rahn, B. Resorption patterns of calcium-phosphate cements in bone. *J. Biomed. Mater. Res.* **2003**, *66A*, 532–540. [[CrossRef](#)]
135. Rae, T. The macrophage response to implant materials—with special reference to those used in orthopedics. *CRC Crit. Rev. Biocompat.* **1986**, *2*, 97–126.
136. Velard, F.; Braux, J.; Amedee, J.; Laquerriere, P. Inflammatory cell response to calcium phosphate biomaterial particles: An overview. *Acta Biomater.* **2013**, *9*, 4956–4963. [[CrossRef](#)] [[PubMed](#)]
137. Yuan, H.; Li, Y.; de Bruijn, J.; de Groot, K.; Zhang, X. Tissue responses of calcium phosphate cement: A study in dogs. *Biomaterials* **2000**, *21*, 1283–1290. [[CrossRef](#)] [[PubMed](#)]
138. Blokhuis, T.J.; Termaat, M.F.; Boer, F.C.D.; Patka, P.; Bakker, F.C.; Haarman, H.J.T.M. Properties of Calcium Phosphate Ceramics in Relation to Their In Vivo Behavior. *J. Trauma* **2000**, *48*, 179–186. [[CrossRef](#)]
139. Rey, C.; Combes, C.; Drouet, C.; Grossin, D.; Bertrand, G.; Soulié, J. 1.11 Bioactive Calcium Phosphate Compounds: Physical Chemistry. In *Comprehensive Biomaterials II*; Elsevier: Amsterdam, The Netherlands, 2017; pp. 244–290. [[CrossRef](#)]

140. Hing, K.A. Bioceramic Bone Graft Substitutes: Influence of Porosity and Chemistry. *Int. J. Appl. Ceram. Technol.* **2005**, *2*, 184–199. [[CrossRef](#)]
141. Espanol, M.; Perez, R.; Montufar, E.; Marichal, C.; Sacco, A.; Ginebra, M. Intrinsic porosity of calcium phosphate cements and its significance for drug delivery and tissue engineering applications. *Acta Biomater.* **2009**, *5*, 2752–2762. [[CrossRef](#)]
142. Daculsi, G.; Aguado, E.; Miramond, T. Essential Requirements for Resorbable Bioceramic Development: Research, Manufacturing, and Preclinical Studies. In *Handbook of Bioceramics and Biocomposites*; Antoniac, I., Ed.; Springer International Publishing: Cham, Switzerland, 2016. [[CrossRef](#)]
143. LeGeros, R.Z.; Lin, S.; Rohanizadeh, R.; Mijares, D.; LeGeros, J.P. Biphasic calcium phosphate bioceramics: Preparation, properties and applications. *J. Mater. Sci. Mater. Med.* **2003**, *14*, 201–209. [[CrossRef](#)]
144. Kuboki, Y.; Takita, H.; Kobayashi, D.; Tsuruga, E.; Inoue, M.; Murata, M.; Nagai, N.; Dohi, Y.; Ohgushi, H. BMP-induced osteogenesis on the surface of hydroxyapatite with geometrically feasible and nonfeasible structures: Topology of osteogenesis. *J. Biomed. Mater. Res.* **1998**, *39*, 190–199. [[CrossRef](#)]
145. Hulbert, S.F.; Young, F.A.; Mathews, R.S.; Klawitter, J.J.; Talbert, C.D.; Stelling, F.H. Potential of ceramic materials as permanently implantable skeletal prostheses. *J. Biomed. Mater. Res.* **1970**, *4*, 433–456. [[CrossRef](#)]
146. Kuboki, Y.; Jin, Q.; Kikuchi, M.; Mamood, J.; Takita, H. Geometry of Artificial ECM: Sizes of Pores Controlling Phenotype Expression in BMP-Induced Osteogenesis and Chondrogenesis. *Connect. Tissue Res.* **2002**, *43*, 529–534. [[CrossRef](#)]
147. Tsuruga, E.; Takita, H.; Itoh, H.; Wakisaka, Y.; Kuboki, Y. Pore Size of Porous Hydroxyapatite as the Cell-Substratum Controls BMP-Induced Osteogenesis. *J. Biochem.* **1997**, *121*, 317–324. [[CrossRef](#)]
148. Lanao, R.P.F.; Hoekstra, J.W.M.; Wolke, J.G.C.; Leeuwenburgh, S.C.G.; Plachokova, A.S.; Boerman, O.C.; Beucken, J.J.J.P.v.D.; Jansen, J.A. Porous calcium phosphate cement for alveolar bone regeneration. *J. Tissue Eng. Regen. Med.* **2014**, *8*, 473–482. [[CrossRef](#)] [[PubMed](#)]
149. Lanao, R.P.F.; Sariibrahimoglu, K.; Wang, H.; Wolke, J.G.; Jansen, J.A.; Leeuwenburgh, S.C.; An, J.; Klijn, R.J.; Beucken, J.J.v.D.; Veldhuis, G.; et al. Accelerated Calcium Phosphate Cement Degradation Due to Incorporation of Glucono-Delta-Lactone Microparticles. *Tissue Eng. Part A* **2014**, *20*, 378–388. [[CrossRef](#)] [[PubMed](#)]
150. Renno, A.; van de Watering, F.; Nejadnik, M.; Crovace, M.; Zanotto, E.; Wolke, J.; Jansen, J.; Beucken, J.v.D. Incorporation of bioactive glass in calcium phosphate cement: An evaluation. *Acta Biomater.* **2013**, *9*, 5728–5739. [[CrossRef](#)] [[PubMed](#)]
151. Gauthier, O.; Bouler, J.-M.; Weiss, P.; Bosco, J.; Daculsi, G.; Aguado, E. Kinetic study of bone ingrowth and ceramic resorption associated with the implantation of different injectable calcium-phosphate bone substitutes. *J. Biomed. Mater. Res.* **1999**, *47*, 28–35. [[CrossRef](#)]
152. Jones, A.C.; Arns, C.H.; Sheppard, A.P.; Hutmacher, D.W.; Milthorpe, B.K.; Knackstedt, M.A. Assessment of bone ingrowth into porous biomaterials using MICRO-CT. *Biomaterials* **2007**, *28*, 2491–2504. [[CrossRef](#)]
153. Otsuki, B.; Takemoto, M.; Fujibayashi, S.; Neo, M.; Kokubo, T.; Nakamura, T. Pore throat size and connectivity determine bone and tissue ingrowth into porous implants: Three-dimensional micro-CT based structural analyses of porous bioactive titanium implants. *Biomaterials* **2006**, *27*, 5892–5900. [[CrossRef](#)]
154. Damien, E.; Hing, K.; Saeed, S.; Revell, P.A. A preliminary study on the enhancement of the osteointegration of a novel synthetic hydroxyapatite scaffold in vivo. *J. Biomed. Mater. Res.* **2003**, *66A*, 241–246. [[CrossRef](#)]
155. Kim, H.D.; Valentini, R.F. Retention and activity of BMP-2 in hyaluronic acid-based scaffolds in vitro. *J. Biomed. Mater. Res.* **2002**, *59*, 573–584. [[CrossRef](#)]
156. Félix Lanao, R.P.; Leeuwenburgh, S.C.G.; Wolke, J.G.C.; Jansen, J.A. In vitro degradation rate of apatitic calcium phosphate cement with incorporated PLGA micro-spheres. *Acta Bio-Mater.* **2011**, *7*, 3459–3468. [[CrossRef](#)]
157. Klijn, R.J.; Beucken, J.J.v.D.; Lanao, R.P.F.; Veldhuis, G.; Leeuwenburgh, S.C.; Wolke, J.G.; Meijer, G.J.; Jansen, J.A.; Bodde, E.W.; Habraken, W.J.; et al. Three Different Strategies to Obtain Porous Calcium Phosphate Cements: Comparison of Performance in a Rat Skull Bone Augmentation Model. *Tissue Eng. Part A* **2012**, *18*, 1171–1182. [[CrossRef](#)]
158. Hu, Y.; Grainger, D.W.; Winn, S.R.; Hollinger, J.O. Fabrication of poly(α -hydroxy acid) foam scaffolds using multiple solvent systems. *J. Biomed. Mater. Res.* **2002**, *59*, 563–572. [[CrossRef](#)] [[PubMed](#)]
159. Maspero, F.A.; Ruffieux, K.; Müller, B.; Wintermantel, E. Resorbable defect analog PLGA scaffolds using CO₂ as solvent: Structural characterization. *J. Biomed. Mater. Res.* **2002**, *62*, 89–98. [[CrossRef](#)] [[PubMed](#)]
160. Botchwey, E.A.; Pollack, S.R.; Levine, E.M.; Laurencin, C.T. Bone tissue engineering in a rotating bioreactor using a microcarrier matrix system. *J. Biomed. Mater. Res.* **2001**, *55*, 242–253. [[CrossRef](#)] [[PubMed](#)]
161. Del Real, R.; Wolke, J.; Vallet-Regí, M.; Jansen, J. A new method to produce macropores in calcium phosphate cements. *Biomaterials* **2002**, *23*, 3673–3680. [[CrossRef](#)] [[PubMed](#)]
162. Almirall, A.; Larrecq, G.; Delgado, J.; Martínez, S.; Planell, J.; Ginebra, M. Fabrication of low temperature macroporous hydroxyapatite scaffolds by foaming and hydrolysis of an α -TCP paste. *Biomaterials* **2004**, *25*, 3671–3680. [[CrossRef](#)]
163. Del Real, R.P.; Ooms, E.; Wolke, J.G.C.; Vallet-Regí, M.; Jansen, J.A. *In vivo* bone response to porous calcium phosphate cement. *J. Biomed. Mater. Res. Part A* **2003**, *65A*, 30–36. [[CrossRef](#)]
164. Huse, R.O.; Ruhe, P.Q.; Wolke, J.G.C.; Jansen, J.A. The use of porous calcium phosphate scaffolds with transforming growth factor beta 1 as an onlay bone graft substitute. *Clin. Oral Implant. Res.* **2004**, *15*, 741–749. [[CrossRef](#)]
165. Jansen, J.; Vehof, J.; Ruhé, P.; Kroeze-Deutman, H.; Kuboki, Y.; Takita, H.; Hedberg, E.; Mikos, A. Growth factor-loaded scaffolds for bone engineering. *J. Control. Release* **2005**, *101*, 127–136. [[CrossRef](#)]

166. Kroese-Deutman, H.C.; Ruhé, P.; Spauwen, P.H.; Jansen, J.A. Bone inductive properties of rhBMP-2 loaded porous calcium phosphate cement implants inserted at an ectopic site in rabbits. *Biomaterials* **2005**, *26*, 1131–1138. [[CrossRef](#)]
167. Hesaraki, S.; Zamanian, A.; Moztarzadeh, F. The influence of the acidic component of the gas-foaming porogen used in preparing an injectable porous calcium phosphate cement on its properties: Acetic acid versus citric acid. *J. Biomed. Mater. Res. Part B Appl. Biomater.* **2008**, *86B*, 208–216. [[CrossRef](#)] [[PubMed](#)]
168. Chen, W.; Thein-Han, W.; Weir, M.D.; Chen, Q.; Xu, H.H. Prevascularization of biofunctional calcium phosphate cement for dental and craniofacial repairs. *Dent. Mater.* **2014**, *30*, 535–544. [[CrossRef](#)] [[PubMed](#)]
169. Thein-Han, W.; Xu, H.H. Prevascularization of a Gas-Foaming Macroporous Calcium Phosphate Cement Scaffold Via Coculture of Human Umbilical Vein Endothelial Cells and Osteoblasts. *Tissue Eng. Part A* **2013**, *19*, 1675–1685. [[CrossRef](#)] [[PubMed](#)]
170. Ginebra, M.-P.; Delgado, J.-A.; Harr, I.; Almirall, A.; Del Valle, S.; Planell, J.A. Factors affecting the structure and properties of an injectable self-setting calcium phosphate foam. *J. Biomed. Mater. Res. Part A* **2007**, *80A*, 351–361. [[CrossRef](#)]
171. Montufar, E.B.; Traykova, T.; Schacht, E.; Ambrosio, L.; Santin, M.; Planell, J.A.; Ginebra, M.-P. Self-hardening calcium deficient hydroxyapatite/gelatine foams for bone regeneration. *J. Mater. Sci. Mater. Med.* **2010**, *21*, 863–869. [[CrossRef](#)]
172. Montufar, E.; Traykova, T.; Gil, C.; Harr, I.; Almirall, A.; Aguirre, A.; Engel, E.; Planell, J.; Ginebra, M. Foamed surfactant solution as a template for self-setting injectable hydroxyapatite scaffolds for bone regeneration. *Acta Biomater.* **2010**, *6*, 876–885. [[CrossRef](#)]
173. Barba, A.; Maazouz, Y.; Diez-Escudero, A.; Rappe, K.; Espanol, M.; Montufar, E.B.; Öhman-Mägi, C.; Persson, C.; Fontecha, P.; Manzanares, M.-C.; et al. Osteogenesis by foamed and 3D-printed nanostructured calcium phosphate scaffolds: Effect of pore architecture. *Acta Biomater.* **2018**, *79*, 135–147. [[CrossRef](#)]
174. Barba, A.; Diez-Escudero, A.; Maazouz, Y.; Rappe, K.; Espanol, M.; Montufar, E.B.; Bonany, M.; Sadowska, J.M.; Guillem-Marti, J.; Öhman-Mägi, C.; et al. Osteoinduction by Foamed and 3D-Printed Calcium Phosphate Scaffolds: Effect of Nanostructure and Pore Architecture. *ACS Appl. Mater. Interfaces* **2017**, *9*, 41722–41736. [[CrossRef](#)]
175. Hutmacher, D.W. Scaffolds in tissue engineering bone and cartilage. *Biomaterials* **2000**, *21*, 2529–2543. [[CrossRef](#)]
176. Amini, A.R.; Adams, D.J.; Laurencin, C.T.; Nukavarapu, S.P.; Michael, F.M.; Khalid, M.; Walvekar, R.; Ratnam, C.T. Optimally Porous and Biomechanically Compatible Scaffolds for Large-Area Bone Regeneration. *Tissue Eng. Part A* **2012**, *18*, 1376–1388. [[CrossRef](#)]
177. Nukavarapu, S.P.; Wallace, J.; Elgendy, H.; Lieberman, J.; Laurencin, C.T. Bone and Biomaterials. In *An Introduction to Biomaterials and Their Applications*, 2nd ed.; Hollinger, J.O., Ed.; CRC Press: Boca Raton, FL, USA, 2011; pp. 571–593.
178. Albrektsson, T.; Johansson, C. Osteoinduction, osteoconduction and osseointegration. *Eur. Spine J.* **2001**, *10* (Suppl. 2), S96–S101. [[CrossRef](#)] [[PubMed](#)]
179. Bobbert, F.S.L.; Zadpoor, A.A. Effects of bone substitute architecture and surface properties on cell response, angiogenesis, and structure of new bone. *J. Mater. Chem. B* **2017**, *5*, 6175–6192. [[CrossRef](#)] [[PubMed](#)]
180. Van Bael, S.; Chai, Y.C.; Truscetto, S.; Moesen, M.; Kerckhofs, G.; Van Oosterwyck, H.; Kruth, J.-P.; Schrooten, J. The effect of pore geometry on the in vitro biological behavior of human periosteum-derived cells seeded on selective laser-melted Ti6Al4V bone scaffolds. *Acta Biomater.* **2012**, *8*, 2824–2834. [[CrossRef](#)] [[PubMed](#)]
181. Kim, K.; Dean, D.; Wallace, J.; Breithaupt, R.; Mikos, A.G.; Fisher, J.P. The influence of stereolithographic scaffold architecture and composition on osteogenic signal expression with rat bone marrow stromal cells. *Biomaterials* **2011**, *32*, 3750–3763. [[CrossRef](#)] [[PubMed](#)]
182. Marrella, A.; Lee, T.Y.; Lee, D.H.; Karuthedom, S.; Sylva, D.; Chawla, A.; Khademhosseini, A.; Jang, H.L. Engineering vascularized and innervated bone biomaterials for improved skeletal tissue regeneration. *Mater. Today* **2018**, *21*, 362–376. [[CrossRef](#)]
183. Carano, R.A.; Filvaroff, E.H. Angiogenesis and bone repair. *Drug Discov. Today* **2003**, *8*, 980–989. [[CrossRef](#)]
184. Feng, B.; Jinkang, Z.; Zhen, W.; Jianxi, L.; Jiang, C.; Jian, L.; Guolin, M.; Xin, D. The effect of pore size on tissue ingrowth and neovascularization in porous bioceramics of controlled architecture in vivo. *Biomed. Mater.* **2011**, *6*, 015007. [[CrossRef](#)]
185. Li, J.; Xu, T.; Hou, W.; Liu, F.; Qing, W.; Huang, L.; Ma, G.; Mu, Y.; Weng, J. The response of host blood vessels to graded distribution of macro-pores size in the process of ectopic osteogenesis. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2020**, *109*, 110641. [[CrossRef](#)]
186. Bai, F.; Wang, Z.; Lu, J.; Liu, J.; Chen, G.; Lv, R.; Wang, J.; Lin, K.; Zhang, J.; Huang, X. The Correlation Between the Internal Structure and Vascularization of Controllable Porous Bioceramic Materials In Vivo: A Quantitative Study. *Tissue Eng. Part A* **2010**, *16*, 3791–3803. [[CrossRef](#)]
187. Mastrogiacomo, M.; Scaglione, S.; Martinetti, R.; Dolcini, L.; Beltrame, F.; Cancedda, R.; Quarto, R. Role of scaffold internal structure on in vivo bone formation in macroporous calcium phosphate bioceramics. *Biomaterials* **2006**, *27*, 3230–3237. [[CrossRef](#)]
188. Chalasani, R.; Poole-Warren, L.; Conway, R.M.; Ben-Nissan, B. Porous Orbital Implants in Enuclation: A Systematic Review. *Surv. Ophthalmol.* **2007**, *52*, 145–155. [[CrossRef](#)]
189. Baino, F.; Potestio, I. Orbital implants: State-of-the-art review with emphasis on biomaterials and recent advances. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2016**, *69*, 1410–1428. [[CrossRef](#)]
190. Rubin, P.A.D.; Popham, J.K.; Bilyk, J.R.; Shore, J.W. Comparison of Fibrovascular Ingrowth into Hydroxyapatite and Porous Polyethylene Orbital Implants. *Ophthalmic Plast. Reconstr. Surg.* **1994**, *10*, 96–103. [[CrossRef](#)]
191. Celik, T.; Yuksel, D.; Kosker, M.; Kasim, R.; Simsek, S. Vascularization of Coralline versus Synthetic Hydroxyapatite Orbital Implants Assessed by Gadolinium Enhanced Magnetic Resonance Imaging. *Curr. Eye Res.* **2015**, *40*, 346–353. [[CrossRef](#)] [[PubMed](#)]

192. Mebarki, M.; Coquelin, L.; Layrolle, P.; Battaglia, S.; Tossou, M.; Hernigou, P.; Rouard, H.; Chevallier, N. Enhanced human bone marrow mesenchymal stromal cell adhesion on scaffolds promotes cell survival and bone formation. *Acta Biomater.* **2017**, *59*, 94–107. [CrossRef] [PubMed]
193. Habraken, W.; Habibovic, P.; Epple, M.; Bohner, M. Calcium phosphates in biomedical applications: Materials for the future? *Mater. Today* **2016**, *19*, 69–87. [CrossRef]
194. LeGeros, R.Z. Calcium Phosphate-Based Osteoinductive Materials. *Chem. Rev.* **2008**, *108*, 4742–4753. [CrossRef]
195. Habibovic, P.; Yuan, H.; van der Valk, C.M.; Meijer, G.; van Blitterswijk, C.A.; de Groot, K. 3D microenvironment as essential element for osteoinduction by biomaterials. *Biomaterials* **2005**, *26*, 3565–3575. [CrossRef]
196. Shekhawat, D.; Singh, A.; Banerjee, M.; Singh, T.; Patnaik, A. Bioceramic composites for orthopaedic applications: A comprehensive review of mechanical, biological, and microstructural properties. *Ceram. Int.* **2021**, *47*, 3013–3030. [CrossRef]
197. Feng, C.; Zhang, K.; He, R.; Ding, G.; Xia, M.; Jin, X.; Xie, C. Additive manufacturing of hydroxyapatite bioceramic scaffolds: Dispersion, digital light processing, sintering, mechanical properties, and biocompatibility. *J. Adv. Ceram.* **2020**, *9*, 360–373. [CrossRef]
198. Jodati, H.; Yilmaz, B.; Evis, Z. Calcium zirconium silicate (baghdadite) ceramic as a biomaterial. *Ceram. Int.* **2020**, *46*, 21902–21909. [CrossRef]
199. Kargozar, S.; Bairo, F.; Hamzehlou, S.; Hill, R.G.; Mozafari, M. Bioactive Glasses: Sprouting Angiogenesis in Tissue Engineering. *Trends Biotechnol.* **2018**, *36*, 430–444. [CrossRef] [PubMed]
200. Yao, Y.; Qin, W.; Xing, B.; Sha, N.; Jiao, T.; Zhao, Z. High performance hydroxyapatite ceramics and a triply periodic minimum surface structure fabricated by digital light processing 3D printing. *J. Adv. Ceram.* **2021**, *10*, 39–48. [CrossRef]
201. Zhang, L.; Yang, G.; Johnson, B.N.; Jia, X. Three-dimensional (3D) printed scaffold and material selection for bone repair. *Acta Biomater.* **2019**, *84*, 16–33. [CrossRef]
202. Jodati, H.; Yilmaz, B.; Evis, Z. A review of bioceramic porous scaffolds for hard tissue applications: Effects of structural features. *Ceram. Int.* **2020**, *46*, 15725–15739. [CrossRef]
203. O'Brien, F.J. Biomaterials & scaffolds for tissue engineering. *Mater. Today* **2011**, *14*, 88–95. [CrossRef]
204. Nikolova, M.P.; Chavali, M.S. Recent advances in biomaterials for 3D scaffolds: A review. *Bioact. Mater.* **2019**, *4*, 271–292. [CrossRef]
205. Abbasi, N.; Hamlet, S.; Love, R.M.; Nguyen, N.-T. Porous scaffolds for bone regeneration. *J. Sci. Adv. Mater. Devices* **2020**, *5*, 1–9. [CrossRef]
206. Roseti, L.; Parisi, V.; Petretta, M.; Cavallo, C.; Desando, G.; Bartolotti, I.; Grigolo, B. Scaffolds for bone tissue engineering: State of the art and new perspectives. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2017**, *78*, 1246–1262. [CrossRef]
207. Chen, Z.W.; Li, Z.Y.; Li, J.J.; Liu, C.B.; Lao, C.S.; Fu, Y.L.; Liu, C.Y.; Li, W.; Wang, P.; He, Y. 3D printing of ceramics: A review. *J. Eur. Ceram. Soc.* **2019**, *39*, 661–687. [CrossRef]
208. Şahin, E. Calcium Phosphate Bone Cements. *Cem. Based Mater. IntechOpen* **2018**, 206–230. [CrossRef]
209. O'Neill, R.; McCarthy, H.; Montufar, E.; Ginebra, M.-P.; Wilson, D.; Lennon, A.; Dunne, N. Critical review: Injectability of calcium phosphate pastes and cements. *Acta Biomater.* **2017**, *50*, 1–19. [CrossRef] [PubMed]
210. Ginebra, M.-P.; Canal, C.; Espanol, M.; Pastorino, D.; Montufar, E.B. Calcium phosphate cements as drug delivery materials. *Adv. Drug Deliv. Rev.* **2012**, *64*, 1090–1110. [CrossRef]
211. Ginebra, M.P.; Traykova, T.; Planell, J.A. Calcium phosphate cements as bone drug delivery systems: A review. *J. Contr. Release* **2006**, *113*, 102–110. [CrossRef]
212. Brown, W.E.; Chow, L.C. A new calcium phosphate, water-setting cement. *Cem. Res. Prog.* **1986**, 351–379. Available online: <http://ci.nii.ac.jp/naid/10004554570/en/> (accessed on 10 September 2023).
213. Thai, V.V.; Lee, B.T. Fabrication of calcium phosphate—Calcium sulfate injectable bone substitute using hydroxy-propyl-methyl-cellulose and citric acid. *J. Mater. Sci. Mater. Med.* **2010**, *21*, 1867–1874. [CrossRef]
214. Liao, H.; Walboomers, X.F.; Habraken, W.J.; Zhang, Z.; Li, Y.; Grijpma, D.W.; Mikos, A.G.; Wolke, J.G.; Jansen, J.A. Injectable calcium phosphate cement with PLGA, gelatin and PTMC microspheres in a rabbit femoral defect. *Acta Biomater.* **2011**, *7*, 1752–1759. [CrossRef]
215. A Perez, R.; Kim, H.-W.; Ginebra, M.-P. Polymeric additives to enhance the functional properties of calcium phosphate cements. *J. Tissue Eng.* **2012**, *3*. [CrossRef]
216. Rajzer, I.; Castaño, O.; Engel, E.; Planell, J.A. Injectable and fast resorbable calcium phosphate cement for body-setting bone grafts. *J. Mater. Sci. Mater. Med.* **2010**, *21*, 2049–2056. [CrossRef]
217. Sarda, S.; Fernández, E.; Nilsson, M.; Balcells, M.; Planell, J.A. Kinetic study of citric acid influence on calcium phosphate bone cements as water-reducing agent. *J. Biomed. Mater. Res.* **2002**, *61*, 653–659. [CrossRef]
218. Yokoyama, A.; Yamamoto, S.; Kawasaki, T.; Kohgo, T.; Nakasu, M. Development of calcium phosphate cement using chitosan and citric acid for bone substitute materials. *Biomaterials* **2002**, *23*, 1091–1101. [CrossRef] [PubMed]
219. Lee, H.J.; Kim, B.; Padalhin, A.R.; Lee, B.T. Incorporation of chitosan-alginate complex into injectable calcium phosphate cement system as a bone graft material. *Mater. Sci. Eng. C* **2019**, *94*, 385–392. [CrossRef] [PubMed]
220. Ginebra, M.P.; Rilliard, A.; Fernández, E.; Elvira, C.; San Román, J.; Planell, J.A. Mechanical and rheological improvement of a calcium phosphate cement by the addition of a polymeric drug. *J. Biomed. Mater. Res.* **2001**, *57*, 113–118. [CrossRef] [PubMed]

221. Song, H.-Y.; Rahman, A.H.M.E.; Lee, B.-T. Fabrication of calcium phosphate-calcium sulfate injectable bone substitute using chitosan and citric acid. *J. Mater. Sci. Mater. Med.* **2009**, *20*, 935–941. [[CrossRef](#)]
222. Shi, H.; Zhang, W.; Liu, X.; Zeng, S.; Yu, T.; Zhou, C. Synergistic effects of citric acid—Sodium alginate on physicochemical properties of α -tricalcium phosphate bone cement. *Ceram. Int.* **2019**, *45*, 2146–2152. [[CrossRef](#)]
223. Zhong, W.; Sun, L.; Yu, T.; Zhou, C. Preparation and characterization of calcium phosphate cement with enhanced tissue adhesion for bone defect repair. *Ceram. Int.* **2021**, *47*, 1712–1720. [[CrossRef](#)]
224. Li, D.X.; Fan, H.S.; Zhu, X.D.; Tan, Y.F.; Xiao, W.Q.; Lu, J.; Xiao, Y.M.; Chen, J.Y.; Zhang, X.D. Controllable release of salmon-calcitonin in injectable calcium phosphate cement modified by chitosan oligosaccharide and collagen polypeptide. *J. Mater. Sci. Mater. Med.* **2007**, *18*, 2225–2231. [[CrossRef](#)]
225. Caballero, S.S.R.; Ferri-Angulo, D.; Debret, R.; Granier, F.; Marie, S.; Lefèvre, F.; Bouler, J.; Despas, C.; Sohier, J.; Bujoli, B. Combination of biocompatible hydrogel precursors to apatitic calcium phosphate cements (CPCs): Influence of the in situ hydrogel reticulation on the CPC properties. *J. Biomed. Mater. Res. Part B Appl. Biomater.* **2021**, *109*, 102–116. [[CrossRef](#)]
226. Nezafati, N.; Farokhi, M.; Heydari, M.; Hesarakhi, S.; Nasab, N.A. In vitro bioactivity and cytocompatibility of an injectable calcium phosphate cement/silanated gelatin microsphere composite bone cement. *Compos. Part B Eng.* **2019**, *175*, 107146. [[CrossRef](#)]
227. Oğuz, D.; Ege, D. Preparation of graphene oxide-reinforced calcium phosphate/calcium sulfate/methylcellulose-based injectable bone substitutes. *MRS Commun.* **2019**, *9*, 1174–1180. [[CrossRef](#)]
228. Babo, P.S.; Santo, V.E.; Gomes, M.E.; Reis, R.L. Development of an Injectable Calcium Phosphate/Hyaluronic Acid Microparticles System for Platelet Lysate Sustained Delivery Aiming Bone Regeneration. *Macromol. Biosci.* **2016**, *16*, 1662–1677. [[CrossRef](#)] [[PubMed](#)]
229. Kucko, N.W.; Li, W.; Martinez, M.A.G.; Rehman, I.U.; Ulset, A.-S.T.; Christensen, B.E.; Leeuwenburgh, S.C.G.; Herber, R.-P. Sterilization effects on the handling and degradation properties of calcium phosphate cements containing poly (D,L-lactic-co-glycolic acid) porogens and carboxymethyl cellulose. *J. Biomed. Mater. Res. Part B Appl. Biomater.* **2019**, *107*, 2216–2228. [[CrossRef](#)] [[PubMed](#)]
230. Oğuz, D.; Ege, D. Rheological and Mechanical Properties of Thermo-responsive Methylcellulose/Calcium Phosphate-Based Injectable Bone Substitutes. *Materials* **2018**, *11*, 604. [[CrossRef](#)] [[PubMed](#)]
231. Link, D.P.; Dolder, J.v.D.; Jurgens, W.J.; Wolke, J.G.; Jansen, J.A. Mechanical evaluation of implanted calcium phosphate cement incorporated with PLGA microparticles. *Biomaterials* **2006**, *27*, 4941–4947. [[CrossRef](#)] [[PubMed](#)]
232. Low, K.L.; Tan, S.H.; Zein, S.H.S.; Roether, J.A.; Mouriño, V.; Boccaccini, A.R. Calcium phosphate-based composites as injectable bone substitute materials. *J. Biomed. Mater. Res. Part B Appl. Biomater.* **2010**, *94*, 273–286. [[CrossRef](#)]
233. Leroux, L.; Hatim, Z.; Frèche, M.; Lacout, J. Effects of various adjuvants (lactic acid, glycerol, and chitosan) on the injectability of a calcium phosphate cement. *Bone* **1999**, *25*, 31S–34S. [[CrossRef](#)]
234. Wang, X.; Ye, J.; Wang, Y. Influence of a novel radiopacifier on the properties of an injectable calcium phosphate cement. *Acta Biomater.* **2007**, *3*, 757–763. [[CrossRef](#)]
235. Chen, F.; Liu, C.; Wei, J.; Chen, X.; Zhao, Z.; Gao, Y. Preparation and characterization of injectable calcium phosphate cement paste modified by polyethylene glycol-6000. *Mater. Chem. Phys.* **2011**, *125*, 818–824. [[CrossRef](#)]
236. Zhang, J.; Liu, W.; Gauthier, O.; Sourice, S.; Pilet, P.; Rethore, G.; Khairoun, K.; Bouler, J.-M.; Tancret, F.; Weiss, P. A simple and effective approach to prepare injectable macroporous calcium phosphate cement for bone repair: Syringe-foaming using a viscous hydrophilic polymeric solution. *Acta Biomater.* **2016**, *31*, 326–338. [[CrossRef](#)]
237. Wang, X.; Ye, J.; Wang, Y.; Chen, L. Self-setting properties of a β -dicalcium silicate reinforced calcium phosphate cement. *J. Biomed. Mater. Res. Part B Appl. Biomater.* **2007**, *82B*, 93–99. [[CrossRef](#)]
238. Hench, L.L. The story of Bioglass[®]. *J. Mater. Sci. Mater. Med.* **2006**, *17*, 967–978. [[CrossRef](#)] [[PubMed](#)]
239. Wu, Z.; Lin, Z.; Yao, A.; Ye, S.; Pan, H.; Cui, X.; Wang, D. Influence of particle size distribution on the rheological properties and mathematical model fitting of injectable borosilicate bioactive glass bone cement. *Ceram. Int.* **2020**, *46*, 24395–24406. [[CrossRef](#)]
240. van Vugt, T.A.; Geurts, J.A.P.; Arts, J.J.; Lindfors, N.C. Biomaterials in treatment of orthopedic infections. In *Management of Periprosthetic Joint Infections (PJIS)*, 1st ed.; Chris Arts, J.J., Jan, G., Eds.; Woodhead Publishing Series in Biomaterials; Woodhead publishing: Amsterdam, The Netherlands, 2017; pp. 41–68.
241. Xynos, I.D.; Edgar, A.J.; Buttery, L.D.; Hench, L.L.; Polak, J.M. Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass 45S5 dissolution. *J. Biomed. Mater. Res.* **2001**, *55*, 151–157. [[CrossRef](#)]
242. Ojansivu, M.; Mishra, A.; Vanhatupa, S.; Juntunen, M.; Larionova, A.; Massera, J.; Miettinen, S. The effect of S53P4-based borosilicate glasses and glass dissolution products on the osteogenic commitment of human adipose stem cells. *PLoS ONE* **2018**, *13*, e0202740. [[CrossRef](#)]
243. Gorustovich, A.A.; Roether, J.A.; Boccaccini, A.R. Effect of Bioactive Glasses on Angiogenesis: A Review of In Vitro and In Vivo Evidences. *Tissue Eng. Part B Rev.* **2010**, *16*, 199–207. [[CrossRef](#)]
244. Zhang, D.; Leppäranta, O.; Munukka, E.; Ylänen, H.; Viljanen, M.K.; Eerola, E.; Hupa, M.; Hupa, L. Antibacterial effects and dissolution behavior of six bioactive glasses. *J. Biomed. Mater. Res. Part A* **2001**, *9999A*, 475–483. [[CrossRef](#)]
245. Day, R.M.; Boccaccini, A.R. Effect of particulate bioactive glasses on human macrophages and monocytes in vitro. *J. Biomed. Mater. Res. Part A* **2005**, *73A*, 73–79. [[CrossRef](#)]
246. Thomas, M.V.; Puleo, D.A.; Al-Sabbagh, M. Bioactive Glass Three Decades On. *J. Long Term Eff. Med. Implant.* **2005**, *15*, 585–597. [[CrossRef](#)]

247. Rahaman, M.N.; Day, D.E.; Bal, B.S.; Fu, Q.; Jung, S.B.; Bonewald, L.F.; Tomsia, A.P. Bioactive glass in tissue engineering. *Acta Biomater.* **2011**, *7*, 2355–2373. [[CrossRef](#)]
248. Huang, W.; Day, D.E.; Kittiratanapiboon, K.; Rahaman, M.N. Kinetics and mechanisms of the conversion of silicate (45S5), borate, and borosilicate glasses to hydroxyapatite in dilute phosphate solutions. *J. Mater. Sci. Mater. Med.* **2006**, *17*, 583–596. [[CrossRef](#)]
249. Nielsen, F.H. New Essential Trace Elements for the Life Sciences. *Biol. Trace. Elem. Res.* **1990**, 599–611. [[CrossRef](#)]
250. Pemmer, B.; Roschger, A.; Wastl, A.; Hofstaetter, J.; Wobrauschek, P.; Simon, R.; Thaler, H.; Roschger, P.; Klaushofer, K.; Strelin, C. Spatial distribution of the trace elements zinc, strontium and lead in human bone tissue. *Bone* **2013**, *57*, 184–193. [[CrossRef](#)] [[PubMed](#)]
251. Bellucci, D.; Sola, A.; Cannillo, V. Hydroxyapatite and tricalcium phosphate composites with bioactive glass as second phase: State of the art and current applications. *J. Biomed. Mater. Res. Part A* **2016**, *104*, 1030–1056. [[CrossRef](#)] [[PubMed](#)]
252. Karadjian, M.; Essers, C.; Tsitlakidis, S.; Reible, B.; Moghaddam, A.; Boccaccini, A.R.; Westhauser, F. Biological Properties of Calcium Phosphate Bioactive Glass Composite Bone Substitutes: Current Experimental Evidence. *Int. J. Mol. Sci.* **2019**, *20*, 305. [[CrossRef](#)]
253. Liu, C.; He, H. *Developments and Applications of Calcium Phosphate Bone Cement*; Springer: Berlin, Germany, 2018. [[CrossRef](#)]
254. Wu, C.-C.; Yang, K.-C.; Yang, S.-H.; Lin, M.-H.; Kuo, T.-F.; Lin, F.-H. In Vitro Studies of Composite Bone Filler Based on Poly(Propylene Fumarate) and Biphasic α -Tricalcium Phosphate/Hydroxyapatite Ceramic Powder. *Artif. Organs* **2012**, *36*, 418–428. [[CrossRef](#)]
255. Persson, C.; Berg, S. Strategies towards injectable, load-bearing materials for the intervertebral disc: A review and outlook. *J. Mater. Sci. Mater. Med.* **2013**, *24*, 1–10. [[CrossRef](#)]
256. Liu, H.; Zhang, Z.; Gao, C.; Bai, Y.; Liu, B.; Wang, W.; Ma, Y.; Saijilafu; Yang, H.; Li, Y.; et al. Enhancing effects of radiopaque agent BaSO₄ on mechanical and biocompatibility properties of injectable calcium phosphate composite cement. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2020**, *116*, 110904. [[CrossRef](#)]
257. Di Filippo, M.F.; Dolci, L.S.; Albertini, B.; Passerini, N.; Torricelli, P.; Parrilli, A.; Fini, M.; Bonvi-cini, F.; Gentilomi, G.A.; Panzavolta, S.; et al. A radiopaque calcium phosphate bone cement with long-lasting antibacterial effect: From paste to injectable formulation. *Ceram. Int.* **2020**, *46*, 10048–10057. [[CrossRef](#)]
258. Schröter, L.; Kaiser, F.; Stein, S.; Gbureck, U.; Ignatius, A. Biological and mechanical performance and degradation characteristics of calcium phosphate cements in large animals and humans. *Acta Biomater.* **2020**, *117*, 1–20. [[CrossRef](#)]
259. Charrière, E.; Terrazzoni, S.; Pittet, C.; Mordasini, P.; Dutoit, M.; Lemaître, J.; Zysset, P. Mechanical characterization of brushite and hydroxyapatite cements. *Biomaterials* **2001**, *22*, 2937–2945. [[CrossRef](#)] [[PubMed](#)]
260. Dorozhkin, S.V.; Epple, M. Biological and Medical Significance of Calcium Phosphates. *Angew. Chem. Int. Ed.* **2002**, *41*, 3130–3146. [[CrossRef](#)]
261. Bohner, M. Calcium orthophosphates in medicine: From ceramics to calcium phosphate cements. *Injury* **2000**, *31*, D37–D47. [[CrossRef](#)] [[PubMed](#)]
262. Basu, S.; Basu, B. Doped biphasic calcium phosphate: Synthesis and structure. *J. Asian Ceram. Soc.* **2019**, *7*, 265–283. [[CrossRef](#)]
263. Hench, L.L.; Splinter, R.J.; Allen, W.C.; Greenlee, T.K. Bonding mechanisms at the interface of ceramic prosthetic materials. *J. Biomed. Mater. Res.* **1971**, *5*, 117–141. [[CrossRef](#)]
264. Giocondi, J.L.; El-Dasher, B.S.; Nancollas, G.H.; Orme, C.A. Molecular mechanisms of crystallization impacting calcium phosphate cements. *Philos. Trans. R. Soc. A Math. Phys. Eng. Sci.* **2010**, *368*, 1937–1961. [[CrossRef](#)]
265. Davies, J.E. Bone bonding at natural and biomaterial surfaces. *Biomaterials* **2007**, *28*, 5058–5067. [[CrossRef](#)] [[PubMed](#)]
266. Rahaman, M. 3-Bioactive ceramics and glasses for tissue engineering. In *Tissue Engineering Using Ceramics and Polymers*, 2nd ed.; Woodhead Publishing: Southton, UK, 2014; pp. 67–114. [[CrossRef](#)]
267. Hench, L.L. Bioceramics, a clinical success. *Am. Ceram. Soc. Bull.* **1998**, *77*, 67–74.
268. Ingole, V.; Sathe, B.; Ghule, A. *Bioactive Ceramic Composite Material Stability, Characterization, and Bonding to Bone*; Elsevier: Amsterdam, The Netherlands, 2018; pp. 273–296. [[CrossRef](#)]
269. Champion, C.R.; Ball, S.L.; Clarke, D.L.; Hing, K.A. Microstructure and chemistry affects apatite nucleation on calcium phosphate bone graft substitutes. *J. Mater. Sci. Mater. Med.* **2013**, *24*, 597–610. [[CrossRef](#)]
270. Gerhardt, L.-C.; Boccaccini, A.R. Bioactive Glass and Glass-Ceramic Scaffolds for Bone Tissue Engineering. *Materials* **2010**, *3*, 3867–3910. [[CrossRef](#)]
271. Crush, J.; Hussain, A.; Seah, K.T.M.; Khan, W.S. Bioactive Glass: Methods for Assessing Angiogenesis and Osteogenesis. *Front. Cell Dev. Biol.* **2021**, *9*, 643781. [[CrossRef](#)]
272. Hollister, S.J. Porous scaffold design for tissue engineering. *Nat. Mater.* **2005**, *4*, 518–524. [[CrossRef](#)] [[PubMed](#)]
273. Chang, B.; Ahuja, N.; Ma, C.; Liu, X. Injectable scaffolds: Preparation and application in dental and craniofacial regeneration. *Mater. Sci. Eng. R: Rep.* **2017**, *111*, 1–26. [[CrossRef](#)] [[PubMed](#)]
274. Donnalaja, F.; Jacchetti, E.; Soncini, M.; Raimondi, M.T. Natural and Synthetic Polymers for Bone Scaffolds Optimization. *Polymers* **2020**, *12*, 905. [[CrossRef](#)] [[PubMed](#)]
275. Filippi, M.; Born, G.; Chaaban, M.; Scherberich, A. Natural Polymeric Scaffolds in Bone Regeneration. *Front. Bioeng. Biotechnol.* **2020**, *8*, 474. [[CrossRef](#)]
276. Muxika, A.; Etxabide, A.; Uranga, J.; Guerrero, P.; de la Caba, K. Chitosan as a bioactive polymer: Processing, properties and applications. *Int. J. Biol. Macromol.* **2017**, *105*, 1358–1368. [[CrossRef](#)]

277. Moghadam, E.T.; Yazdani, M.; Tahmasebi, E.; Tebyanian, H.; Ranjbar, R.; Yazdani, A.; Seifalian, A.; Tafazoli, A. Current herbal medicine as an alternative treatment in dentistry: In vitro, in vivo and clinical studies. *Eur. J. Pharmacol.* **2020**, *889*, 173665. [[CrossRef](#)]
278. Fakhri, E.; Eslami, H.; Maroufi, P.; Pakdel, F.; Taghizadeh, S.; Ganbarov, K.; Yousefi, M.; Tanomand, A.; Yousefi, B.; Mahmoudi, S.; et al. Chitosan biomaterials application in dentistry. *Int. J. Biol. Macromol.* **2020**, *162*, 956–974. [[CrossRef](#)]
279. Aguilar, A.; Zein, N.; Harmouch, E.; Hafdi, B.; Bornert, F.; Offner, D.; Clauss, F.; Fioretti, F.; Huck, O.; Jessel, B.; et al. Application of Chitosan in Bone and Dental Engineering. *Molecules* **2019**, *24*, 3009. [[CrossRef](#)]
280. Zhang, L.; Dong, Y.; Zhang, N.; Shi, J.; Zhang, X.; Qi, C.; Midgley, A.C.; Wang, S. Potentials of sandwich-like chitosan/polycaprolactone/gelatin scaffolds for guided tissue regeneration membrane. *Mater. Sci. Eng. C-Mater. Biol. Appl.* **2020**, *109*, 110618. [[CrossRef](#)]
281. Ranganathan, S.; Balagangadharan, K.; Selvamurugan, N. Chitosan and gelatin-based electrospun fibers for bone tissue engineering. *Int. J. Biol. Macromol.* **2019**, *133*, 354–364. [[CrossRef](#)]
282. Georgopoulou, A.; Papadogiannis, F.; Batsali, A.; Marakis, J.; Alpantaki, K.; Eliopoulos, A.G.; Pontikoglou, C.; Chatzinikolaidou, M. Chitosan/gelatin scaffolds support bone regeneration. *J. Mater. Sci. Mater. Med.* **2018**, *29*, 59. [[CrossRef](#)]
283. Elango, J.; Saravanakumar, K.; Rahman, S.U.; Henrotin, Y.; Regenstein, J.M.; Wu, W.; Bao, B. Chitosan-Collagen 3D Matrix Mimics Trabecular Bone and Regulates RANKL-Mediated Paracrine Cues of Differentiated Osteoblast and Mesenchymal Stem Cells for Bone Marrow Macrophage-Derived Osteoclastogenesis. *Biomolecules* **2019**, *9*, 173. [[CrossRef](#)]
284. Li, H.; Ji, Q.; Chen, X.; Sun, Y.; Xu, Q.; Deng, P.; Hu, F.; Yang, J. Accelerated bony defect healing based on chitosan thermosensitive hydrogel scaffolds embedded with chitosan nanoparticles for the delivery of BMP2 plasmid DNA. *J. Biomed. Mater. Res. Part A* **2017**, *105*, 265–273. [[CrossRef](#)]
285. Lee, Y.-H.; Kim, J.-S.; Kim, J.-E.; Lee, M.-H.; Jeon, J.-G.; Park, I.-S.; Yi, H.-K. Nanoparticle mediated PPAR γ gene delivery on dental implants improves osseointegration via mitochondrial biogenesis in diabetes mellitus rat model. *Nanomedicine* **2017**, *13*, 1821–1832. [[CrossRef](#)]
286. Ho, M.-H.; Yao, C.-J.; Liao, M.-H.; Lin, P.-I.; Liu, S.-H.; Chen, R.-M. Chitosan nanofiber scaffold improves bone healing via stimulating trabecular bone production due to upregulation of the Runx2/osteocalcin/alkaline phosphatase signaling pathway. *Int. J. Nanomed.* **2015**, *10*, 5941–5954. [[CrossRef](#)]
287. Golub, E.; Boesze-Battaglia, K. The role of alkaline phosphatase in mineralization. *Curr. Opin. Orthop.* **2007**, *18*, 444–448. [[CrossRef](#)]
288. Dong, C.; Lv, Y. Application of Collagen Scaffold in Tissue Engineering: Recent Advances and New Perspectives. *Polymers* **2016**, *8*, 42. [[CrossRef](#)]
289. Cen, L.; Liu, W.; Cui, L.; Zhang, W.; Cao, Y. Collagen Tissue Engineering: Development of Novel Biomaterials and Applications. *Pediatr. Res.* **2008**, *63*, 492–496. [[CrossRef](#)]
290. Masi, L.; Franchi, A.; Santucci, M.; Danielli, D.; Arganini, L.; Giannone, V.; Formigli, L.; Benvenuti, S.; Tanini, A.; Beghe, F.; et al. Adhesion, growth, and matrix production by osteoblasts on collagen substrata. *Calcif. Tissue Int.* **1992**, *51*, 202–212. [[CrossRef](#)]
291. Chai, Q.; Jiao, Y.; Yu, X. Hydrogels for Biomedical Applications: Their Characteristics and the Mechanisms behind Them. *Gels* **2017**, *3*, 6. [[CrossRef](#)]
292. Kosen, Y.; Miyaji, H.; Kato, A.; Sugaya, T.; Kawanami, M. Application of collagen hydrogel/sponge scaffold facilitates periodontal wound healing in class II furcation defects in beagle dogs. *J. Periodontol.* **2012**, *47*, 626–634. [[CrossRef](#)] [[PubMed](#)]
293. Hojo, S.; Bamba, N.; Kojima, K.; Kodama, T. Examination of β -TCP/collagen composite in bone defects without periosteum in dogs: A histological and cast model evaluation. *Odontology* **2020**, *108*, 578–587. [[CrossRef](#)] [[PubMed](#)]
294. Kim, C.-H.; Ju, M.-H.; Kim, B.-J. Comparison of recombinant human bone morphogenetic protein-2-infused absorbable collagen sponge, recombinant human bone morphogenetic protein-2-coated tricalcium phosphate, and platelet-rich fibrin-mixed tricalcium phosphate for sinus augmentation in rabbits. *J. Dent. Sci.* **2017**, *12*, 205–212. [[CrossRef](#)]
295. Coomes, A.M.; Mealey, B.L.; Huynh-Ba, G.; Barboza-Arguello, C.; Moore, W.S.; Cochran, D.L. Buccal Bone Formation after Flapless Extraction: A Randomized, Controlled Clinical Trial Comparing Recombinant Human Bone Morphogenetic Protein 2/Absorbable Collagen Carrier and Collagen Sponge Alone. *J. Periodontol.* **2014**, *85*, 525–535. [[CrossRef](#)]
296. Ohba, S.; Sumita, Y.; Nakatani, Y.; Noda, S.; Asahina, I. Alveolar bone preservation by a hydroxyapatite/collagen composite material after tooth extraction. *Clin. Oral Investig.* **2019**, *23*, 2413–2419. [[CrossRef](#)]
297. Kim, J.-W.; Seong, T.-W.; Cho, S.; Kim, S.-J. Randomized controlled trial on the effectiveness of absorbable collagen sponge after extraction of impacted mandibular third molar: Split-mouth design. *BMC Oral Health* **2020**, *20*, 77. [[CrossRef](#)] [[PubMed](#)]
298. Parashis, A.O.; Hawley, C.E.; Stark, P.C.; Ganguly, R.; Hanley, J.B.; Steffensen, B. Prospective Clinical and Radiographic Study of Alveolar Ridge Preservation Combining Freeze-Dried Bone Allograft With Two Xenogeneic Collagen Matrices. *J. Periodontol.* **2016**, *87*, 416–425. [[CrossRef](#)] [[PubMed](#)]
299. Natto, Z.S.; Parashis, A.; Steffensen, B.; Ganguly, R.; Finkelman, M.D.; Jeong, Y.N. Efficacy of collagen matrix seal and collagen sponge on ridge preservation in combination with bone allograft: A randomized controlled clinical trial. *J. Clin. Periodontol.* **2017**, *44*, 649–659. [[CrossRef](#)]
300. Zhai, P.; Peng, X.; Li, B.; Liu, Y.; Sun, H.; Li, X. The application of hyaluronic acid in bone regeneration. *Int. J. Biol. Macromol.* **2020**, *151*, 1224–1239. [[CrossRef](#)]

301. Bhakta, G.; Lim, Z.X.; Rai, B.; Lin, T.; Hui, J.H.; Prestwich, G.D.; van Wijnen, A.J.; Nurcombe, V.; Cool, S.M. The influence of collagen and hyaluronan matrices on the delivery and bioactivity of bone morphogenetic protein-2 and ectopic bone formation. *Acta Biomater.* **2013**, *9*, 9098–9106. [[CrossRef](#)]
302. Fujioka-Kobayashi, M.; Schaller, B.; Kobayashi, E.; Hernandez, M.; Zhang, Y.; Miron, R.J. Hyaluronic Acid Gel-Based Scaffolds as Potential Carrier for Growth Factors: An In Vitro Bioassay on Its Osteogenic Potential. *J. Clin. Med.* **2016**, *5*, 112. [[CrossRef](#)] [[PubMed](#)]
303. Park, S.H.; Park, J.Y.; Ji, Y.B.; Ju, H.J.; Min, B.H.; Kim, M.S. An injectable click-crosslinked hyaluronic acid hydrogel modified with a BMP-2 mimetic peptide as a bone tissue engineering scaffold. *Acta Biomater.* **2020**, *117*, 108–120. [[CrossRef](#)] [[PubMed](#)]
304. Picke, A.-K.; Salbach-Hirsch, J.; Hintze, V.; Rother, S.; Rauner, M.; Kascholke, C.; Möller, S.; Bernhardt, R.; Rammelt, S.; Pisabarro, M.T.; et al. Sulfated hyaluronan improves bone regeneration of diabetic rats by binding sclerostin and enhancing osteoblast function. *Biomaterials* **2016**, *96*, 11–23. [[CrossRef](#)] [[PubMed](#)]
305. Maeda, K.; Kobayashi, Y.; Koide, M.; Uehara, S.; Okamoto, M.; Ishihara, A.; Kayama, T.; Saito, M.; Marumo, K. The Regulation of Bone Metabolism and Disorders by Wnt Signaling. *Int. J. Mol. Sci.* **2019**, *20*, 5525. [[CrossRef](#)]
306. Townsend, J.M.; Andrews, B.T.; Feng, Y.; Wang, J.; Nudo, R.J.; Van Kampen, E.; Gehrke, S.H.; Berkland, C.J.; Detamore, M.S. Superior calvarial bone regeneration using pentenoate-functionalized hyaluronic acid hydrogels with devitalized tendon particles. *Acta Biomater.* **2018**, *71*, 148–155. [[CrossRef](#)] [[PubMed](#)]
307. Alcântara, C.E.P.; Castro, M.A.A.; de Noronha, M.S.; Martins-Junior, P.A.; Mendes, R.d.M.; Caliari, M.V.; Mesquita, R.A.; Ferreira, A.J. Hyaluronic acid accelerates bone repair in human dental sockets: A randomized triple-blind clinical trial. *Braz. Oral Res.* **2018**, *32*, e84. [[CrossRef](#)] [[PubMed](#)]
308. Kim, J.-J.; Song, H.Y.; Ben Amara, H.; Kyung-Rim, K.; Koo, K.-T. Hyaluronic Acid Improves Bone Formation in Extraction Sockets with Chronic Pathology: A Pilot Study in Dogs. *J. Periodontol.* **2016**, *87*, 790–795. [[CrossRef](#)]
309. Kang, H.-J.; Park, S.-S.; Saleh, T.; Ahn, K.-M.; Lee, B.-T. In vitro and in vivo evaluation of Ca/P-hyaluronic acid/gelatin based novel dental plugs for one-step socket preservation. *Mater. Des.* **2020**, *194*, 108891. [[CrossRef](#)]
310. Florczyk, S.J.; Wang, K.; Jana, S.; Wood, D.L.; Sytsma, S.K.; Sham, J.G.; Kievit, F.M.; Zhang, M. Porous chitosan-hyaluronic acid scaffolds as a mimic of glioblastoma microenvironment ECM. *Biomaterials* **2013**, *34*, 10143–10150. [[CrossRef](#)]
311. Morgan, J.L.W.; Strumillo, J.; Zimmer, J. Crystallographic snapshot of cellulose synthesis and membrane translocation. *Nature* **2013**, *493*, 181–186. [[CrossRef](#)]
312. Weyell, P.; Beekmann, U.; Küpper, C.; Dederichs, M.; Thamm, J.; Fischer, D.; Kralisch, D. Tailor-made material characteristics of bacterial cellulose for drug delivery applications in dentistry. *Carbohydr. Polym.* **2019**, *207*, 1–10. [[CrossRef](#)] [[PubMed](#)]
313. Wu, H.-L.; Bremner, D.H.; Wang, H.-J.; Wu, J.-Z.; Li, H.-Y.; Wu, J.-R.; Niu, S.-W.; Zhu, L.-M. Fabrication and investigation of a biocompatible microfilament with high mechanical performance based on regenerated bacterial cellulose and bacterial cellulose. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2017**, *79*, 516–524. [[CrossRef](#)] [[PubMed](#)]
314. Lee, S.-H.; An, S.-J.; Lim, Y.-M.; Huh, J.-B. The Efficacy of Electron Beam Irradiated Bacterial Cellulose Membranes as Compared with Collagen Membranes on Guided Bone Regeneration in Peri-Implant Bone Defects. *Materials* **2017**, *10*, 1018. [[CrossRef](#)]
315. Iqbal, H.; Ali, M.; Zeeshan, R.; Mutahir, Z.; Iqbal, F.; Nawaz, M.A.H.; Shahzadi, L.; Chaudhry, A.A.; Yar, M.; Luan, S.; et al. Chitosan/hydroxyapatite (HA)/hydroxypropylmethyl cellulose (HPMC) spongy scaffolds-synthesis and evaluation as potential alveolar bone substitutes. *Colloids Surfaces B Biointerfaces* **2017**, *160*, 553–563. [[CrossRef](#)]
316. Tokudome, Y.; Nakamura, K.; Kage, M.; Todo, H.; Sugibayashi, K.; Hashimoto, F. Effects of soybean peptide and collagen peptide on collagen synthesis in normal human dermal fibroblasts. *Int. J. Food Sci. Nutr.* **2012**, *63*, 689–695. [[CrossRef](#)]
317. Ahn, S.; Chantre, C.O.; Gannon, A.R.; Lind, J.U.; Campbell, P.H.; Grevesse, T.; O'Connor, B.B.; Parker, K.K. Soy Protein/Cellulose Nanofiber Scaffolds Mimicking Skin Extracellular Matrix for Enhanced Wound Healing. *Adv. Health. Mater.* **2018**, *7*, e1701175. [[CrossRef](#)] [[PubMed](#)]
318. Tansaz, S.; Liverani, L.; Vester, L.; Boccaccini, A.R. Soy protein meets bioactive glass: Electrospun composite fibers for tissue engineering applications. *Mater. Lett.* **2017**, *199*, 143–146. [[CrossRef](#)]
319. Salama, A.; Abou-Zeid, R.E.; Cruz-Maya, I.; Guarino, V. Soy protein hydrolysate grafted cellulose nanofibrils with bioactive signals for bone repair and regeneration. *Carbohydr. Polym.* **2020**, *229*, 115472. [[CrossRef](#)]
320. Wu, M.; Wu, P.; Xiao, L.; Zhao, Y.; Yan, F.; Liu, X.; Xie, Y.; Zhang, C.; Chen, Y.; Cai, L. Biomimetic mineralization of novel hydroxyethyl cellulose/soy protein isolate scaffolds promote bone regeneration in vitro and in vivo. *Int. J. Biol. Macromol.* **2020**, *162*, 1627–1641. [[CrossRef](#)]
321. Giavaresi, G.; Fini, M.; Salvage, J.; Aldini, N.N.; Giardino, R.; Ambrosio, L.; Nicolais, L.; Santin, M. Bone regeneration potential of a soybean-based filler: Experimental study in a rabbit cancellous bone defects. *J. Mater. Sci. Mater. Med.* **2010**, *21*, 615–626. [[CrossRef](#)]
322. Kim, H.-L.; Jung, G.-Y.; Yoon, J.-H.; Han, J.-S.; Park, Y.-J.; Kim, D.-G.; Zhang, M.; Kim, D.-J. Preparation and characterization of nano-sized hydroxyapatite/alginate/chitosan composite scaffolds for bone tissue engineering. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2015**, *54*, 20–25. [[CrossRef](#)]
323. Tohamy, K.M.; Mabrouk, M.; Soliman, I.E.; Beherei, H.H.; Aboelnasr, M.A. Novel alginate/hydroxyethyl cellulose/hydroxyapatite composite scaffold for bone regeneration: In vitro cell viability and proliferation of human mesenchymal stem cells. *Int. J. Biol. Macromol.* **2018**, *112*, 448–460. [[CrossRef](#)]

324. Purohit, S.D.; Bhaskar, R.; Singh, H.; Yadav, I.; Gupta, M.K.; Mishra, N.C. Development of a nanocomposite scaffold of gelatin–alginate–graphene oxide for bone tissue engineering. *Int. J. Biol. Macromol.* **2019**, *133*, 592–602. [[CrossRef](#)]
325. Venkatesan, J.; Bhatnagar, I.; Manivasagan, P.; Kang, K.-H.; Kim, S.-K. Alginate composites for bone tissue engineering: A review. *Int. J. Biol. Macromol.* **2015**, *72*, 269–281. [[CrossRef](#)]
326. Dinjaski, N.; Plowright, R.; Zhou, S.; Belton, D.J.; Perry, C.C.; Kaplan, D.L. Osteoinductive recombinant silk fusion proteins for bone regeneration. *Acta Biomater.* **2017**, *49*, 127–139. [[CrossRef](#)]
327. Hardy, J.G.; Torres-Rendon, J.G.; Leal-Egaña, A.; Walther, A.; Schlaad, H.; Cölfen, H.; Scheibel, T.R. Biomimetic Mineralization of Engineered Spider Silk Protein-Based Composite Materials for Bone Tissue Engineering. *Materials* **2016**, *9*, 560. [[CrossRef](#)]
328. Sangkert, S.; Kamonmattayakul, S.; Chai, W.L.; Meesane, J. A biofunctional-modified silk fibroin scaffold with mimic reconstructed extracellular matrix of decellularized pulp/collagen/fibronectin for bone tissue engineering in alveolar bone resorption. *Mater. Lett.* **2016**, *166*, 30–34. [[CrossRef](#)]
329. Mihaila, S.M.; Popa, E.G.; Reis, R.L.; Marques, A.P.; Gomes, M.E. Fabrication of Endothelial Cell-Laden Carrageenan Microfibers for Microvascularized Bone Tissue Engineering Applications. *Biomacromolecules* **2014**, *15*, 2849–2860. [[CrossRef](#)]
330. Ocampo, J.I.G.; de Paula, M.M.M.; Bassous, N.J.; Lobo, A.O.; Orozco, C.P.O.; Webster, T.J. Osteoblast responses to injectable bone substitutes of kappa-carrageenan and nano hydroxyapatite. *Acta Biomater.* **2018**, *83*, 425–434. [[CrossRef](#)]
331. Feng, W.; Feng, S.; Tang, K.; He, X.; Jing, A.; Liang, G. A novel composite of collagen-hydroxyapatite/kappa-carrageenan. *J. Alloys Compd.* **2017**, *693*, 482–489. [[CrossRef](#)]
332. González Ocampo, J.I.; Bassous, N.; Ossa Orozco, C.P.; Webster, T.J. Evaluation of cytotoxicity and antimicrobial activity of an injectable bone substitute of carrageenan and nano hydroxyapatite. *J. Biomed. Mater. Res. Part A* **2018**, *106*, 2984–2993. [[CrossRef](#)]
333. Yegappan, R.; Selvaprithiviraj, V.; Amirthalingam, S.; Mohandas, A.; Hwang, N.S.; Jayakumar, R. Injectable angiogenic and osteogenic carrageenan nanocomposite hydrogel for bone tissue engineering. *Int. J. Biol. Macromol.* **2019**, *122*, 320–328. [[CrossRef](#)]
334. Liu, H.; Cheng, J.; Chen, F.; Hou, F.; Bai, D.; Xi, P.; Zeng, Z. Biomimetic and Cell-Mediated Mineralization of Hydroxyapatite by Carrageenan Functionalized Graphene Oxide. *ACS Appl. Mater. Interfaces* **2014**, *6*, 3132–3140. [[CrossRef](#)] [[PubMed](#)]
335. Nourmohammadi, J.; Roshanfar, F.; Farokhi, M.; Nazarpak, M.H. Silk fibroin/kappa-carrageenan composite scaffolds with enhanced biomimetic mineralization for bone regeneration applications. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2017**, *76*, 951–958. [[CrossRef](#)]
336. Mirza, S.; Jolly, R.; Zia, I.; Umar, M.S.; Owais, M.; Shakir, M. Bioactive Gum Arabic/ κ -Carrageenan-Incorporated Nano-Hydroxyapatite Nanocomposites and Their Relative Biological Functionalities in Bone Tissue Engineering. *ACS Omega* **2020**, *5*, 11279–11290. [[CrossRef](#)] [[PubMed](#)]
337. Nogueira, L.F.B.; Maniglia, B.C.; Blácido, D.R.T.; Ramos, A.P. Organic–inorganic collagen/iota-carrageenan/hydroxyapatite hybrid membranes are bioactive materials for bone regeneration. *J. Appl. Polym. Sci.* **2019**, *136*, 48004. [[CrossRef](#)]
338. Nogueira, L.F.; Maniglia, B.C.; Pereira, L.S.; Tapia-Blácido, D.R.; Ramos, A.P. Formation of carrageenan-CaCO₃ bioactive membranes. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2016**, *58*, 1–6. [[CrossRef](#)]
339. Khan, M.U.A.; Raza, M.A.; Mehboob, H.; Kadir, M.R.A.; Razak, S.I.A.; Shah, S.A.; Iqbal, M.Z.; Amin, R. Development and in vitro evaluation of κ -carrageenan based polymeric hybrid nanocomposite scaffolds for bone tissue engineering. *RSC Adv.* **2020**, *10*, 40529–40542. [[CrossRef](#)]
340. Li, J.; Yang, B.; Qian, Y.; Wang, Q.; Han, R.; Hao, T.; Shu, Y.; Zhang, Y.; Yao, F.; Wang, C. Iota-carrageenan/chitosan/gelatin scaffold for the osteogenic differentiation of adipose-derived MSCs in vitro. *J. Biomed. Mater. Res. Part B Appl. Biomater.* **2015**, *103*, 1498–1510. [[CrossRef](#)]
341. Yazdi, M.E.T.; Nazarnezhad, S.; Mousavi, S.H.; Amiri, M.S.; Darroudi, M.; Baines, F.; Kargozar, S. Gum Tragacanth (GT): A Versatile Biocompatible Material beyond Borders. *Molecules* **2021**, *26*, 1510. [[CrossRef](#)]
342. Lett, J.A.; Sundareswari, M.; Ravichandran, K.; Latha, B.; Sagadevan, S. Fabrication and characterization of porous scaffolds for bone replacements using gum tragacanth. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2018**, *96*, 487–495. [[CrossRef](#)] [[PubMed](#)]
343. Kaczmarek, B.; Mazur, O. Collagen-Based Materials Modified by Phenolic Acids—A Review. *Materials* **2020**, *13*, 3641. [[CrossRef](#)] [[PubMed](#)]
344. Oryan, A.; Kamali, A.; Moshiri, A.; Baharvand, H.; Daemi, H. Chemical crosslinking of biopolymeric scaffolds: Current knowledge and future directions of crosslinked engineered bone scaffolds. *Int. J. Biol. Macromol.* **2018**, *107*, 678–688. [[CrossRef](#)]
345. Chen, X.; Wang, Z.; Duan, N.; Zhu, G.; Schwarz, E.M.; Xie, C. Osteoblast–osteoclast interactions. *Connect. Tissue Res.* **2018**, *59*, 99–107. [[CrossRef](#)] [[PubMed](#)]
346. Steeve, K.T.; Marc, P.; Sandrine, T.; Dominique, H.; Yannick, F. IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology. *Cytokine Growth Factor Rev.* **2004**, *15*, 49–60. [[CrossRef](#)]
347. Číž, M.; Dvořáková, A.; Skočková, V.; Kubala, L. The Role of Dietary Phenolic Compounds in Epigenetic Modulation Involved in Inflammatory Processes. *Antioxidants* **2020**, *9*, 691. [[CrossRef](#)]
348. Shen, C.-L.; von Bergen, V.; Chyu, M.-C.; Jenkins, M.R.; Mo, H.; Chen, C.-H.; Kwun, I.-S. Fruits and dietary phytochemicals in bone protection. *Nutr. Res.* **2012**, *32*, 897–910. [[CrossRef](#)]
349. Suvarna, V.; Sarkar, M.; Chaubey, P.; Khan, T.; Sherje, A.; Patel, K.; Dravyakar, B. Bone Health and Natural Products- An Insight. *Front. Pharmacol.* **2018**, *9*, 981. [[CrossRef](#)]
350. Wang, Y.; Chen, S.; Yu, O. Metabolic engineering of flavonoids in plants and microorganisms. *Appl. Microbiol. Biotechnol.* **2011**, *91*, 949–956. [[CrossRef](#)]

351. Soundarya, S.P.; Sanjay, V.; Menon, A.H.; Dhivya, S.; Selvamurugan, N. Effects of flavonoids incorporated biological macromolecules based scaffolds in bone tissue engineering. *Int. J. Biol. Macromol.* **2018**, *110*, 74–87. [[CrossRef](#)]
352. Tafazoli, A.; Moghadam, E.T. Camellia Sinensis Mouthwashes in Oral Care: A Systematic Review. *J. Dent.* **2020**, *21*, 249–262. [[CrossRef](#)]
353. Bhattacharya, S.; Chandra, S.; Chatterjee, P.; Dey, P. Evaluation of anti-inflammatory effects of green tea and black tea: A comparative in vitro study. *J. Adv. Pharm. Technol. Res.* **2012**, *3*, 136–138. [[CrossRef](#)]
354. Hengge, R. Targeting Bacterial Biofilms by the Green Tea Polyphenol EGCG. *Molecules* **2019**, *24*, 2403. [[CrossRef](#)] [[PubMed](#)]
355. Kim, H.-S.; Quon, M.J.; Kim, J.-A. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. *Redox Biol.* **2014**, *2*, 187–195. [[CrossRef](#)] [[PubMed](#)]
356. Kaida, K.; Honda, Y.; Hashimoto, Y.; Tanaka, M.; Baba, S. Application of Green Tea Catechin for Inducing the Osteogenic Differentiation of Human Dedifferentiated Fat Cells in Vitro. *Int. J. Mol. Sci.* **2015**, *16*, 27988–28000. [[CrossRef](#)]
357. Fujita, K.; Otsuka, T.; Yamamoto, N.; Kainuma, S.; Ohguchi, R.; Kawabata, T.; Sakai, G.; Kuroyanagi, G.; Matsushima-Nishiwaki, R.; Kozawa, O.; et al. (–)Epigallocatechin gallate but not chlorogenic acid upregulates osteoprotegerin synthesis through regulation of bone morphogenetic protein-4 in osteoblasts. *Exp. Ther. Med.* **2017**, *14*, 417–423. [[CrossRef](#)]
358. Kawabata, T.; Tokuda, H.; Sakai, G.; Fujita, K.; Matsushima-Nishiwaki, R.; Otsuka, T.; Kozawa, O. Repression of IGF-I-induced osteoblast migration by (–)epigallocatechin gallate through p44/p42 MAP kinase signaling. *Biomed. Rep.* **2018**, *9*, 318–326. [[CrossRef](#)]
359. Kawabata, T.; Otsuka, T.; Fujita, K.; Sakai, G.; Matsushima-Nishiwaki, R.; Kozawa, O.; Tokuda, H. (–)Epigallocatechin gallate but not chlorogenic acid suppresses EGF-stimulated migration of osteoblasts via attenuation of p38 MAPK activity. *Int. J. Mol. Med.* **2018**, *42*, 3149–3156. [[CrossRef](#)]
360. Kamiya, M.; Kawase, T.; Kobayashi, M.; Sekine, Y.; Okuda, K.; Nagata, M.; Fuse, I.; Nakata, K.; Wolff, L.F.; Yoshie, H.; et al. A Short-Term Preservation of Human Cultured Periosteal Sheets, Osteogenic Grafting Materials, Using a Commercial Preservation Solution Containing Epigallocatechin-3-gallate (Theliokeep®) under Hypothermic Conditions. *Biopreservation Biobanking* **2012**, *10*, 245–252. [[CrossRef](#)]
361. Xie, Y.; Sun, W.; Yan, F.; Liu, H.; Deng, Z.; Cai, L. Icarin-loaded porous scaffolds for bone regeneration through the regulation of the coupling process of osteogenesis and osteoclastic activity. *Int. J. Nanomed.* **2019**, *14*, 6019–6033. [[CrossRef](#)]
362. Mah, Y.-J.; Song, J.S.; Kim, S.-O.; Lee, J.-H.; Jeon, M.; Jung, U.-W.; Moon, S.J.; Kim, J.-H.; Choi, H.-J. The effect of epigallocatechin-3-gallate (EGCG) on human alveolar bone cells both in vitro and in vivo. *Arch. Oral Biol.* **2014**, *59*, 539–549. [[CrossRef](#)] [[PubMed](#)]
363. Honda, Y.; Huang, A.; Tanaka, T.; Han, X.; Gao, B.; Liu, H.; Wang, X.; Zhao, J.; Hashimoto, Y.; Yamamoto, K.; et al. Augmentation of Bone Regeneration by Depletion of Stress-Induced Senescent Cells Using Catechin and Senolytics. *Int. J. Mol. Sci.* **2020**, *21*, 4213. [[CrossRef](#)] [[PubMed](#)]
364. Shin, Y.-S.; Seo, J.-Y.; Oh, S.-H.; Kim, J.-H.; Kim, S.-T.; Park, Y.-B.; Moon, H.-S. The effects of ErhBMP-2-/EGCG-coated BCP bone substitute on dehiscence around dental implants in dogs. *Oral Dis.* **2014**, *20*, 281–287. [[CrossRef](#)] [[PubMed](#)]
365. Rodriguez, R.; Kondo, H.; Nyan, M.; Hao, J.; Miyahara, T.; Ohya, K.; Kasugai, S. Implantation of green tea catechin α -tricalcium phosphate combination enhances bone repair in rat skull defects. *J. Biomed. Mater. Res. Part B Appl. Biomater.* **2011**, *98B*, 263–271. [[CrossRef](#)]
366. Chu, C.; Liu, L.; Wang, Y.; Yang, R.; Hu, C.; Rung, S.; Man, Y.; Qu, Y. Evaluation of epigallocatechin-3-gallate (EGCG)-modified scaffold determines macrophage recruitment. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2019**, *100*, 505–513. [[CrossRef](#)]
367. Chu, C.; Wang, Y.; Wang, Y.; Yang, R.; Liu, L.; Rung, S.; Xiang, L.; Wu, Y.; Du, S.; Man, Y.; et al. Evaluation of epigallocatechin-3-gallate (EGCG) modified collagen in guided bone regeneration (GBR) surgery and modulation of macrophage phenotype. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2019**, *99*, 73–82. [[CrossRef](#)]
368. Honda, Y.; Takeda, Y.; Li, P.; Huang, A.; Sasayama, S.; Hara, E.; Uemura, N.; Ueda, M.; Hashimoto, M.; Arita, K.; et al. Epigallocatechin Gallate-Modified Gelatin Sponges Treated by Vacuum Heating as a Novel Scaffold for Bone Tissue Engineering. *Molecules* **2018**, *23*, 876. [[CrossRef](#)]
369. Hara, E.; Honda, Y.; Suzuki, O.; Tanaka, T.; Matsumoto, N. Epigallocatechin Gallate-Modified Gelatins with Different Compositions Alter the Quality of Regenerated Bones. *Int. J. Mol. Sci.* **2018**, *19*, 3232. [[CrossRef](#)]
370. Katsumata, Y.; Kanzaki, H.; Honda, Y.; Tanaka, T.; Yamaguchi, Y.; Itohiya, K.; Fukaya, S.; Miyamoto, Y.; Narimiya, T.; Wada, S.; et al. Single Local Injection of Epigallocatechin Gallate-Modified Gelatin Attenuates Bone Resorption and Orthodontic Tooth Movement in Mice. *Polymers* **2018**, *10*, 1384. [[CrossRef](#)]
371. Hong, J.-Y.; Yon, J.; Lee, J.-S.; Lee, I.-K.; Yang, C.; Kim, M.-S.; Choi, S.-H.; Jung, U.-W. Effects of epigallocatechin-3-gallate on the healing of extraction sockets with a periapical lesion: A pilot study in dogs. *J. Biomed. Mater. Res. Part B Appl. Biomater.* **2015**, *103*, 727–734. [[CrossRef](#)]
372. Liu, C.; Cui, Y.; Pi, F.; Cheng, Y.; Guo, Y.; Qian, H. Extraction, Purification, Structural Characteristics, Biological Activities and Pharmacological Applications of Acemannan, a Polysaccharide from Aloe vera: A Review. *Molecules* **2019**, *24*, 1554. [[CrossRef](#)] [[PubMed](#)]
373. Alonso, M.; Tambara, Y.; Lopez, M.; Aguilar, J.C.; Mayo, O.; Prieto, E.; Cremata, J.; Gerwig, G.; Kamerling, H.; Hardy, E. On the isolation of immunostimulatory active acemannan from Aloe barbadensis. *Biotechnol. Appl.* **2012**, *29*, 87.
374. Silva, S.S.; da Costa, D.S.; Reis, R.L. Photocrosslinked acemannan-based 3D matrices for in vitro cell culture. *J. Mater. Chem. B* **2019**, *7*, 4184–4190. [[CrossRef](#)]

375. Xing, W.; Guo, W.; Zou, C.-H.; Fu, T.-T.; Li, X.-Y.; Zhu, M.; Qi, J.-H.; Song, J.; Dong, C.-H.; Li, Z.; et al. Acemannan accelerates cell proliferation and skin wound healing through AKT/mTOR signaling pathway. *J. Dermatol. Sci.* **2015**, *79*, 101–109. [[CrossRef](#)] [[PubMed](#)]
376. Thunyakitpisal, P.; Ruangpornvisuti, V.; Kengkwasing, P.; Chokboribal, J.; Sangvanich, P. Acemannan increases NF- κ B/DNA binding and IL-6/-8 expression by selectively binding Toll-like receptor-5 in human gingival fibroblasts. *Carbohydr. Polym.* **2017**, *161*, 149–157. [[CrossRef](#)]
377. Chokboribal, J.; Tachaboonyakiat, W.; Sangvanich, P.; Ruangpornvisuti, V.; Jettanacheawchankit, S.; Thunyakitpisal, P. Deacetylation affects the physical properties and bioactivity of acemannan, an extracted polysaccharide from Aloe vera. *Carbohydr. Polym.* **2015**, *133*, 556–566. [[CrossRef](#)]
378. Jettanacheawchankit, S.; Sasithanasate, S.; Sangvanich, P.; Banlunara, W.; Thunyakitpisal, P. Acemannan Stimulates Gingival Fibroblast Proliferation; Expressions of Keratinocyte Growth Factor-1, Vascular Endothelial Growth Factor, and Type I Collagen; and Wound Healing. *J. Pharmacol. Sci.* **2009**, *109*, 525–531. [[CrossRef](#)]
379. Boonyagul, S.; Banlunara, W.; Sangvanich, P.; Thunyakitpisal, P. Effect of acemannan, an extracted polysaccharide from Aloe vera, on BMSCs proliferation, differentiation, extracellular matrix synthesis, mineralization, and bone formation in a tooth extraction model. *Odontology* **2014**, *102*, 310–317. [[CrossRef](#)] [[PubMed](#)]
380. Godoy, D.J.D.; Chokboribal, J.; Pauwels, R.; Banlunara, W.; Sangvanich, P.; Jaroenporn, S.; Thunyakitpisal, P. Acemannan increased bone surface, bone volume, and bone density in a calvarial defect model in skeletally-mature rats. *J. Dent. Sci.* **2018**, *13*, 334–341. [[CrossRef](#)]
381. Chantarawatit, P.; Sangvanich, P.; Banlunara, W.; Soontornvipart, K.; Thunyakitpisal, P. Acemannan sponges stimulate alveolar bone, cementum and periodontal ligament regeneration in a canine class II furcation defect model. *J. Periodontal Res.* **2014**, *49*, 164–178. [[CrossRef](#)]
382. Soares, I.M.V.; Fernandes, G.V.d.O.; Cavalcante, L.C.; Leite, Y.K.P.d.C.; Bezerra, D.d.O.; de Carvalho, M.A.M.; Carvalho, C.M.R.S. The influence of Aloe vera with mesenchymal stem cells from dental pulp on bone regeneration: Characterization and treatment of non-critical defects of the tibia in rats. *J. Appl. Oral Sci.* **2019**, *27*, e20180103. [[CrossRef](#)] [[PubMed](#)]
383. Jansisyanont, P.; Tiyaopongprapan, S.; Chuenchompoonut, V.; Sangvanich, P.; Thunyakitpisal, P. The effect of acemannan sponges in post-extraction socket healing: A randomized trial. *J. Oral Maxillofac. Surgery Med. Pathol.* **2016**, *28*, 105–110. [[CrossRef](#)]
384. Vu, N.B.; Chuenchompoonut, V.; Jansisyanont, P.; Sangvanich, P.; Pham, T.H.; Thunyakitpisal, P. Acemannan-induced tooth socket healing: A 12-month randomized controlled trial. *J. Dent. Sci.* **2021**, *16*, 643–653. [[CrossRef](#)] [[PubMed](#)]
385. Le Van, C.; Thu, H.P.T.; Sangvanich, P.; Chuenchompoonut, V.; Thunyakitpisal, P. Acemannan induces rapid early osseous defect healing after apical surgery: A 12-month follow-up of a randomized controlled trial. *J. Dent. Sci.* **2020**, *15*, 302–309. [[CrossRef](#)] [[PubMed](#)]
386. Zhai, Y.-K.; Guo, X.; Pan, Y.-L.; Niu, Y.-B.; Li, C.-R.; Wu, X.-L.; Mel, Q.-B. A systematic review of the efficacy and pharmacological profile of Herba Epimedii in osteoporosis therapy. *Pharmazie* **2013**, *68*, 713–722.
387. Hsieh, T.-P.; Sheu, S.-Y.; Sun, J.-S.; Chen, M.-H. Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF- κ B regulated HIF-1 α and PGE2 synthesis. *Phytomedicine* **2011**, *18*, 176–185. [[CrossRef](#)]
388. Xu, C.-Q.; Liu, B.-J.; Wu, J.-F.; Xu, Y.-C.; Duan, X.-H.; Cao, Y.-X.; Dong, J.-C. Icariin attenuates LPS-induced acute inflammatory responses: Involvement of PI3K/Akt and NF- κ B signaling pathway. *Eur. J. Pharmacol.* **2010**, *642*, 146–153. [[CrossRef](#)]
389. Wu, Y.; Xia, L.; Zhou, Y.; Xu, Y.; Jiang, X. Icariin induces osteogenic differentiation of bone mesenchymal stem cells in a MAPK-dependent manner. *Cell Prolif.* **2015**, *48*, 375–384. [[CrossRef](#)]
390. Hayrapetyan, A.; Jansen, J.A.; Beucken, J.J.V.D. Signaling Pathways Involved in Osteogenesis and Their Application for Bone Regenerative Medicine. *Tissue Eng. Part B Rev.* **2015**, *21*, 75–87. [[CrossRef](#)]
391. Xu, H.; Zhou, S.; Qu, R.; Yang, Y.; Gong, X.; Hong, Y.; Jin, A.; Huang, X.; Dai, Q.; Jiang, L. Icariin prevents oestrogen deficiency-induced alveolar bone loss through promoting osteogenesis via STAT3. *Cell Prolif.* **2020**, *53*, e12743. [[CrossRef](#)]
392. Gong, M.; Chi, C.; Ye, J.; Liao, M.; Xie, W.; Wu, C.; Shi, R.; Zhang, L. Icariin-loaded electrospun PCL/gelatin nanofiber membrane as potential artificial periosteum. *Colloids Surfaces B Biointerfaces* **2018**, *170*, 201–209. [[CrossRef](#)] [[PubMed](#)]
393. Li, M.; Gu, Q.; Chen, M.; Zhang, C.; Chen, S.; Zhao, J. Controlled delivery of icariin on small intestine submucosa for bone tissue engineering. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2017**, *71*, 260–267. [[CrossRef](#)] [[PubMed](#)]
394. Xu, H.; Ge, Y.-W.; Lu, J.-W.; Ke, Q.-F.; Liu, Z.-Q.; Zhu, Z.-A.; Guo, Y.-P. Icariin loaded-hollow bioglass/chitosan therapeutic scaffolds promote osteogenic differentiation and bone regeneration. *Chem. Eng. J.* **2018**, *354*, 285–294. [[CrossRef](#)]
395. Hu, Y.; Cao, S.; Chen, J.; Zhao, Y.; He, F.; Li, Q.; Zou, L.; Shi, C. Biomimetic fabrication of icariin loaded nano hydroxyapatite reinforced bioactive porous scaffolds for bone regeneration. *Chem. Eng. J.* **2020**, *394*, 124895. [[CrossRef](#)]
396. Lai, Y.; Cao, H.; Wang, X.; Chen, S.; Zhang, M.; Wang, N.; Yao, Z.; Dai, Y.; Xie, X.; Zhang, P.; et al. Porous composite scaffold incorporating osteogenic phytomolecule icariin for promoting skeletal regeneration in challenging osteonecrotic bone in rabbits. *Biomaterials* **2018**, *153*, 1–13. [[CrossRef](#)] [[PubMed](#)]
397. Jian, J.; Sun, L.; Cheng, X.; Hu, X.; Liang, J.; Chen, Y. Calycosin-7-O- β -d-glucopyranoside stimulates osteoblast differentiation through regulating the BMP/WNT signaling pathways. *Acta Pharm. Sin. B* **2015**, *5*, 454–460. [[CrossRef](#)]
398. Ahangari, N.; Kargozar, S.; Ghayour-Mobarhan, M.; Baino, F.; Pasdar, A.; Sahebkar, A.; Ferns, G.A.A.; Kim, H.-W.; Mozafari, M. Curcumin in tissue engineering: A traditional remedy for modern medicine. *BioFactors* **2019**, *45*, 135–151. [[CrossRef](#)]

399. Kocaadam, B.; Şanlıer, N. Curcumin, an active component of turmeric (*Curcuma longa*), and its effects on health. *Crit. Rev. Food Sci. Nutr.* **2017**, *57*, 2889–2895. [[CrossRef](#)]
400. Hewlings, S.J.; Kalman, D.S. Curcumin: A Review of Its Effects on Human Health. *Foods* **2017**, *6*, 92. [[CrossRef](#)]
401. Li, Y.; Zhang, Z.-Z. Sustained curcumin release from PLGA microspheres improves bone formation under diabetic conditions by inhibiting the reactive oxygen species production. *Drug Des. Dev. Ther.* **2018**, *12*, 1453–1466. [[CrossRef](#)]
402. Jain, S.; Meka, S.R.K.; Chatterjee, K. Curcumin eluting nanofibers augment osteogenesis toward phytochemical based bone tissue engineering. *Biomed. Mater.* **2016**, *11*, 055007. [[CrossRef](#)] [[PubMed](#)]
403. Verma, A.H.; Kumar, T.S.S.; Madhumathi, K.; Rubaiya, Y.; Ramalingan, M.; Doble, M. Curcumin Releasing Eggshell Derived Carbonated Apatite Nanocarriers for Combined Anti-Cancer, Anti-Inflammatory and Bone Regenerative Therapy. *J. Nanosci. Nanotechnol.* **2019**, *19*, 6872–6880. [[CrossRef](#)]
404. Sarkar, N.; Bose, S. Liposome-Encapsulated Curcumin-Loaded 3D Printed Scaffold for Bone Tissue Engineering. *ACS Appl. Mater. Interfaces* **2019**, *11*, 17184–17192. [[CrossRef](#)] [[PubMed](#)]
405. Bose, S.; Sarkar, N.; Banerjee, D. Effects of PCL, PEG and PLGA polymers on curcumin release from calcium phosphate matrix for in vitro and in vivo bone regeneration. *Mater. Today Chem.* **2018**, *8*, 110–120. [[CrossRef](#)] [[PubMed](#)]
406. Ghavimi, M.A.; Shahabadi, A.B.; Jarolmasjed, S.; Memar, M.Y.; Dizaj, S.M.; Sharifi, S. Nanofibrous asymmetric collagen/curcumin membrane containing aspirin-loaded PLGA nanoparticles for guided bone regeneration. *Sci. Rep.* **2020**, *10*, 18200. [[CrossRef](#)]
407. Yadav, M.; Kaushik, M.; Roshni, R.; Reddy, P.; Mehra, N.; Jain, V.; Rana, R. Effect of Green Coffee Bean Extract on Streptococcus mutans Count: A Randomised Control Trial. *J. Clin. Diagn. Res.* **2017**, *11*, ZC68–ZC71. [[CrossRef](#)]
408. Hwang, S.J.; Kim, Y.-W.; Park, Y.; Lee, H.-J.; Kim, K.-W. Anti-inflammatory effects of chlorogenic acid in lipopolysaccharide-stimulated RAW 264.7 cells. *Inflamm. Res.* **2014**, *63*, 81–90. [[CrossRef](#)]
409. Liu, F.; Lu, X.-W.; Zhang, Y.-J.; Kou, L.; Song, N.; Wu, M.-K.; Wang, M.; Wang, H.; Shen, J.-F. Effects of chlorogenic acid on voltage-gated potassium channels of trigeminal ganglion neurons in an inflammatory environment. *Brain Res. Bull.* **2016**, *127*, 119–125. [[CrossRef](#)]
410. Huang, S.; Wang, L.-L.; Xue, N.-N.; Li, C.; Guo, H.-H.; Ren, T.-K.; Zhan, Y.; Li, W.-B.; Zhang, J.; Chen, X.-G.; et al. Chlorogenic acid effectively treats cancers through induction of cancer cell differentiation. *Theranostics* **2019**, *9*, 6745–6763. [[CrossRef](#)]
411. Bin, H.-S.; Jeong, J.-H.; Choi, U.-K. Chlorogenic acid promotes osteoblastogenesis in human adipose tissue-derived mesenchymal stem cells. *Food Sci. Biotechnol.* **2013**, *22*, 107–112. [[CrossRef](#)]
412. Al Anouti, F.; Taha, Z.; Shamim, S.; Khalaf, K.; Al Kaabi, L.; Alsafar, H. An insight into the paradigms of osteoporosis: From genetics to biomechanics. *Bone Rep.* **2019**, *11*, 100216. [[CrossRef](#)] [[PubMed](#)]
413. Calciolari, E.; Mardas, N.; Dereka, X.; Anagnostopoulos, A.K.; Tsangaris, G.T.; Donos, N. The effect of experimental osteoporosis on bone regeneration: Part 2, proteomics results. *Clin. Oral Implant. Res.* **2017**, *28*, e135–e145. [[CrossRef](#)] [[PubMed](#)]
414. Fini, M.; Giavaresi, G.; Torricelli, P.; Borsari, V.; Giardino, R.; Nicolini, A.; Carpi, A. Osteoporosis and biomaterial osteointegration. *BioMedicine* **2004**, *58*, 487–493. [[CrossRef](#)]
415. Zhou, R.P.; Lin, S.J.; Wan, W.B.; Zuo, H.L.; Yao, F.F.; Ruan, H.B.; Xu, J.; Song, W.; Zhou, Y.C.; Wen, S.Y.; et al. Chlorogenic Acid Prevents Osteoporosis by Shp2/PI3K/Akt Pathway in Ovariectomized Rats. *PLoS ONE* **2016**, *11*, e0166751. [[CrossRef](#)]
416. Yamamoto, N.; Tokuda, H.; Kuroyanagi, G.; Kainuma, S.; Ohguchi, R.; Fujita, K.; Matsushima-Nishiwaki, R.; Kozawa, O.; Otsuka, T. Amplification by (–)-epigallocatechin gallate and chlorogenic acid of TNF- α -stimulated interleukin-6 synthesis in osteoblasts. *Int. J. Mol. Med.* **2015**, *36*, 1707–1712. [[CrossRef](#)]
417. Prystaz, K.; Kaiser, K.; Kovtun, A.; Haffner-Luntzer, M.; Fischer, V.; Rapp, A.E.; Liedert, A.; Strauss, G.; Waetzig, G.H.; Rose-John, S.; et al. Distinct Effects of IL-6 Classic and Trans-Signaling in Bone Fracture Healing. *Am. J. Pathol.* **2018**, *188*, 474–490. [[CrossRef](#)]
418. Cheng, X.; Li, K.; Xu, S.; Li, P.; Yan, Y.; Wang, G.; Berman, Z.; Guo, R.; Liang, J.; Traore, S.; et al. Applying chlorogenic acid in an alginate scaffold of chondrocytes can improve the repair of damaged articular cartilage. *PLoS ONE* **2018**, *13*, e0195326. [[CrossRef](#)]
419. Banskota, A.H.; Tezuka, Y.; Kadota, S. Recent progress in pharmacological research of propolis. *Phytother. Res.* **2001**, *15*, 561–571. [[CrossRef](#)]
420. Meimandi-Parizi, A.; Oryan, A.; Sayahi, E.; Bigham-Sadegh, A. Propolis extract a new reinforcement material in improving bone healing: An in vivo study. *Int. J. Surg.* **2018**, *56*, 94–101. [[CrossRef](#)]
421. Zohery, A.A.; Meshri, S.M.; Madi, M.I.; El Rehim, S.S.A.; Nour, Z.M. Egyptian propolis compared to nanohydroxyapatite graft in the treatment of Class II furcation defects in dogs. *J. Periodontol.* **2018**, *89*, 1340–1350. [[CrossRef](#)]
422. Al-Hariri, M. Glycemic control and anti-osteopathic effect of propolis in diabetic rats. *Diabetes Metab. Syndr. Obesity Targets Ther.* **2011**, *4*, 377–384. [[CrossRef](#)]
423. Kresnoadi, U.; Rahayu, R.P.; Ariani, M.D.; Soesanto, S. The Potential of Natural Propolis Extract Combined with Bovine Bone Graft in Increasing Heat Shock Protein 70 and Osteocalcin on Socket Preservation. *Eur. J. Dent.* **2020**, *14*, 031–037. [[CrossRef](#)]
424. Altan, B.A.; Kara, I.M.; Nalcaci, R.; Ozan, F.; Erdogan, S.M.; Ozkut, M.M.; Inan, S. Systemic propolis stimulates new bone formation at the expanded suture: A histomorphometric study. *Angle Orthod.* **2012**, *83*, 286–291. [[CrossRef](#)]
425. Kunugi, H.; Ali, M. Royal Jelly and Its Components Promote Healthy Aging and Longevity: From Animal Models to Humans. *Int. J. Mol. Sci.* **2019**, *20*, 4662. [[CrossRef](#)] [[PubMed](#)]
426. Yanagita, M.; Kojima, Y.; Mori, K.; Yamada, S.; Murakami, S. Osteoinductive and anti-inflammatory effect of royal jelly on periodontal ligament cells. *Biomed. Res.* **2011**, *32*, 285–291. [[CrossRef](#)]

427. Uçan, M.; Koparal, M.; Ağaçayak, S.; Gunay, A.; Ozgoz, M.; Atilgan, S.; Yaman, F. Influence of caffeic acid phenethyl ester on bone healing in a rat model. *J. Int. Med Res.* **2013**, *41*, 1648–1654. [[CrossRef](#)]
428. Günay, A.; Arpağ, O.F.; Atilgan, S.; Yaman, F.; Atalay, Y.; Acikan, I. Effects of caffeic acid phenethyl ester on palatal mucosal defects and tooth extraction sockets. *Drug Des. Dev. Ther.* **2014**, *8*, 2069. [[CrossRef](#)] [[PubMed](#)]
429. Su, C.-Y.; Ming, Q.-L.; Rahman, K.; Han, T.; Qin, L.-P. *Salvia miltiorrhiza*: Traditional medicinal uses, chemistry, and pharmacology. *Chin. J. Nat. Med.* **2015**, *13*, 163–182. [[CrossRef](#)] [[PubMed](#)]
430. Chin, A.; Yang, Y.; Chai, L.; Wong, R.W.K.; Rabie, A.-B.M. Effects of medicinal herb *salvia miltiorrhiza* on osteoblastic cells in vitro. *J. Orthop. Res.* **2011**, *29*, 1059–1063. [[CrossRef](#)] [[PubMed](#)]
431. Cui, L.; Li, T.; Liu, Y.; Zhou, L.; Li, P.; Xu, B.; Huang, L.; Chen, Y.; Liu, Y.; Tian, X.; et al. Salvianolic Acid B Prevents Bone Loss in Prednisone-Treated Rats through Stimulation of Osteogenesis and Bone Marrow Angiogenesis. *PLoS ONE* **2012**, *7*, e34647. [[CrossRef](#)]
432. Xu, D.; Xu, L.; Zhou, C.; Lee, W.Y.; Wu, T.; Cui, L.; Li, G. Salvianolic acid B promotes osteogenesis of human mesenchymal stem cells through activating ERK signaling pathway. *Int. J. Biochem. Cell Biol.* **2014**, *51*, 1–9. [[CrossRef](#)] [[PubMed](#)]
433. Bian, Y.; Xiang, J. Salvianolic acid B promotes the osteogenic differentiation of human perio-dontal ligament cells through Wnt/b-catenin signaling pathway. *Arch Oral. Biol.* **2020**, *113*, 104693. [[CrossRef](#)]
434. Wu, Y.; Zhang, C.; Wu, J.; Han, Y.; Wu, C. Angiogenesis and bone regeneration by mesenchymal stem cell transplantation with danshen in a rabbit model of avascular necrotic femoral head. *Exp. Ther. Med.* **2019**, *18*, 163–171. [[CrossRef](#)] [[PubMed](#)]
435. Lee, D.-H.; Kim, I.-K.; Cho, H.-Y.; Seo, J.-H.; Jang, J.-M.; Kim, J. Effect of herbal extracts on bone regeneration in a rat calvaria defect model and screening system. *J. Korean Assoc. Oral Maxillofac. Surg.* **2018**, *44*, 79–85. [[CrossRef](#)]
436. Yang, Y.J.; Zhu, Z.; Wang, D.T.; Zhang, X.L.; Liu, Y.Y.; Lai, W.X.; Mo, Y.; Li, J.; Liang, Y.L.; Hu, Z.Q.; et al. Tanshinol alleviates impaired bone formation by inhibiting adipogenesis via KLF15/PPAR γ 2 signaling in GIO rats. *Acta Pharmacol. Sin.* **2018**, *39*, 633. [[CrossRef](#)]
437. Yang, Y.; Su, Y.; Wang, D.; Chen, Y.; Liu, Y.; Luo, S.; Wu, T.; Cui, L. Tanshinol Rescues the Impaired Bone Formation Elicited by Glucocorticoid Involved in KLF15 Pathway. *Oxidative Med. Cell. Longev.* **2016**, *2016*, 1092746. [[CrossRef](#)]
438. Chen, G.; Zhang, X.; Lin, H.; Huang, G.; Chen, Y.; Cui, L. Tanshinol Alleviates Osteoporosis and Myopathy in Glucocorticoid-Treated Rats. *Planta Med.* **2017**, *83*, 1264–1273. [[CrossRef](#)]
439. Yang, Y.; Su, Y.; Wang, D.; Chen, Y.; Wu, T.; Li, G.; Sun, X.; Cui, L. Tanshinol Attenuates the Deleterious Effects of Oxidative Stress on Osteoblastic Differentiation via Wnt/FoxO3a Signaling. *Oxidative Med. Cell. Longev.* **2013**, *2013*, 351895. [[CrossRef](#)]
440. Han, J.; Wang, W. Effects of tanshinol on markers of bone turnover in ovariectomized rats and osteoblast cultures. *PLoS ONE* **2017**, *12*, e0181175. [[CrossRef](#)]
441. Koushki, M.; Amiri-Dashatan, N.; Ahmadi, N.; Abbaszadeh, H.-A.; Rezaei-Tavirani, M. Resveratrol: A miraculous natural compound for diseases treatment. *Food Sci. Nutr.* **2018**, *6*, 2473–2490. [[CrossRef](#)]
442. Zhai, J.-L.; Weng, X.-S.; Wu, Z.-H.; Guo, S.-G. Effect of Resveratrol on Preventing Steroid-induced Osteonecrosis in a Rabbit Model. *Chin. Med. J.* **2016**, *129*, 824–830. [[CrossRef](#)] [[PubMed](#)]
443. Rutledge, K.; Cheng, Q.; Jabbarzadeh, E. Modulation of Inflammatory Response and Induction of Bone Formation Based on Combinatorial Effects of Resveratrol. *J. Nanomed. Nanotechnol.* **2016**, *7*, 350. [[CrossRef](#)] [[PubMed](#)]
444. Ornstrup, M.J.; Harsløf, T.; Sørensen, L.; Stenkjær, L.; Langdahl, B.L.; Pedersen, S.B. Resveratrol Increases Osteoblast Differentiation In Vitro Independently of Inflammation. *Calcif. Tissue Int.* **2016**, *99*, 155–163. [[CrossRef](#)]
445. Casarin, R.C.; Casati, M.Z.; Pimentel, S.P.; Cirano, F.R.; Algayer, M.; Pires, P.R.; Ghiraldini, B.; Duarte, P.M.; Ribeiro, F.V. Resveratrol improves bone repair by modulation of bone morphogenetic proteins and osteopontin gene expression in rats. *Int. J. Oral. Maxillofac. Surg.* **2014**, *43*, 900. [[CrossRef](#)]
446. Dosier, C.R.; Erdman, C.P.; Park, J.H.; Schwartz, Z.; Boyan, B.D.; Guldberg, R.E. Resveratrol effect on osteogenic differentiation of rat and human adipose derived stem cells in a 3-D culture environment. *J. Mech. Behav. Biomed. Mater.* **2012**, *11*, 112–122. [[CrossRef](#)] [[PubMed](#)]
447. Ikeda, E.; Ikeda, Y.; Wang, Y.; Fine, N.; Sheikh, Z.; Viniegra, A.; Barzilay, O.; Ganss, B.; Tenenbaum, H.C.; Glogauer, M. Resveratrol derivative-rich melinjo seed extract induces healing in a murine model of established periodontitis. *J. Periodontol.* **2018**, *89*, 586–595. [[CrossRef](#)]
448. Bhattarai, G.; Poudel, S.B.; Kook, S.H.; Lee, J.C. Resveratrol prevents alveolar bone loss in an experimental rat model of periodontitis. *Acta Biomater.* **2016**, *29*, 398. [[CrossRef](#)] [[PubMed](#)]
449. Ozcan-Kucuk, A.; Alan, H.; Gul, M.; Yolcu, U. Evaluating the Effect of Resveratrol on the Healing of Extraction Sockets in Cyclosporine A-Treated Rats. *J. Oral Maxillofac. Surg.* **2018**, *76*, 1404–1413. [[CrossRef](#)]
450. Wang, C.-C.; Chen, H.-C.; Cheng, J.-H.; Chang, S.-J.; Wang, Y.-W.; Chang, A.; Yeh, J.-Z.; Huang, Y.-H.; Liu, C.-C. Combination of resveratrol-containing collagen with adipose stem cells for craniofacial tissue-engineering applications. *Int. Wound J.* **2018**, *15*, 660–672. [[CrossRef](#)]
451. Wang, W.; Sun, L.; Zhang, P.; Song, J.; Liu, W. An anti-inflammatory cell-free collagen/resveratrol scaffold for repairing osteochondral defects in rabbits. *Acta Biomater.* **2014**, *10*, 4983–4995. [[CrossRef](#)]
452. Poornima, B.; Korrapati, P.S. Fabrication of chitosan-polycaprolactone composite nanofibrous scaffold for simultaneous delivery of ferulic acid and resveratrol. *Carbohydr. Polym.* **2017**, *157*, 1741–1749. [[CrossRef](#)] [[PubMed](#)]

453. Li, Y.; Dånmark, S.; Edlund, U.; Finne-Wistrand, A.; He, X.; Norgård, M.; Blomén, E.; Hultenby, K.; Andersson, G.; Lindgren, U. Resveratrol-conjugated poly- ϵ -caprolactone facilitates in vitro mineralization and in vivo bone regeneration. *Acta Biomater.* **2011**, *7*, 751–758. [[CrossRef](#)]
454. Winkins, S.; Kamath, M.; Dhanasekaran, M.; Ahmed, S.S. Polycaprolactone scaffold engineered for sustained release of resveratrol: Therapeutic enhancement in bone tissue engineering. *Int. J. Nanomed.* **2014**, *9*, 183–195. [[CrossRef](#)] [[PubMed](#)]
455. Sheu, S.-Y.; Chen, W.-S.; Sun, J.-S.; Lin, F.-H.; Wu, T. Biological characterization of oxidized hyaluronic acid/resveratrol hydrogel for cartilage tissue engineering. *J. Biomed. Mater. Res. Part A* **2013**, *101*, 3457–3466. [[CrossRef](#)] [[PubMed](#)]
456. Guo, D.W.; Han, Y.X.; Cong, L.; Liang, D.; Tu, G.J. Resveratrol prevents osteoporosis in ovariectomized rats by regulating microRNA-338-3p. *Mol. Med. Rep.* **2015**, *12*, 2098. [[CrossRef](#)]
457. Lee, A.M.; Shandala, T.; Nguyen, L.; Muhlhausler, B.S.; Chen, K.M.; Howe, P.R.; Xian, C.J. Effects of resveratrol supplementation on bone growth in young rats and microarchitecture and re-modeling in ageing rats. *Nutrients* **2014**, *6*, 5871. [[CrossRef](#)]
458. Hussain, S.; Tamizhselvi, R.; George, L.; Manickam, V. Assessment of the Role of Noni (*Morinda citrifolia*) Juice for Inducing Osteoblast Differentiation in Isolated Rat Bone Marrow Derived Mesenchymal Stem Cells. *Int. J. Stem Cells* **2016**, *9*, 221–229. [[CrossRef](#)]
459. Osman, W.N.W.; Tantowi, N.A.C.A.; Lau, S.F.; Mohamed, S. Epicatechin and scopoletin rich *Morinda citrifolia* (Noni) leaf extract supplementation, mitigated Osteoarthritis via anti-inflammatory, anti-oxidative, and anti-protease pathways. *J. Food Biochem.* **2019**, *43*, e12755. [[CrossRef](#)]
460. Ganeshpurkar, A.; Saluja, A.K. The Pharmacological Potential of Rutin. *Saudi Pharm. J.* **2017**, *25*, 149–164. [[CrossRef](#)]
461. Gu, H.; Boonantananasarn, K.; Kang, M.; Kim, I.; Woo, K.M.; Ryoo, H.-M.; Baek, J.-H. *Morinda citrifolia* Leaf Extract Enhances Osteogenic Differentiation Through Activation of Wnt/ β -Catenin Signaling. *J. Med. Food* **2018**, *21*, 57–69. [[CrossRef](#)]
462. Min, S.K.; Oh, J.; Park, J.-B. The Effects of *Morinda citrifolia* (Noni) on the Cellular Viability and Osteogenesis of Stem Cell Spheroids. *Medicina* **2020**, *56*, 389. [[CrossRef](#)] [[PubMed](#)]
463. Zhao, B.; Zhang, W.; Xiong, Y.; Zhang, Y.; Zhang, D.; Xu, X. Effects of rutin on the oxidative stress, proliferation and osteogenic differentiation of periodontal ligament stem cells in LPS-induced inflammatory environment and the underlying mechanism. *Histochem. J.* **2020**, *51*, 161–171. [[CrossRef](#)] [[PubMed](#)]
464. Shalan, N.A.A.M.; Mustapha, N.M.; Mohamed, S. Noni leaf and black tea enhance bone regeneration in estrogen-deficient rats. *Nutrition* **2017**, *33*, 42–51. [[CrossRef](#)] [[PubMed](#)]
465. Zhao, B.; Zhang, W.; Xiong, Y.; Zhang, Y.; Jia, L.; Xu, X. Rutin protects human periodontal ligament stem cells from TNF- α induced damage to osteogenic differentiation through suppressing mTOR signaling pathway in inflammatory environment. *Arch. Oral Biol.* **2020**, *109*, 104584. [[CrossRef](#)] [[PubMed](#)]
466. Zhao, B.; Xiong, Y.; Zhang, Y.; Jia, L.; Zhang, W.; Xu, X. Rutin promotes osteogenic differentiation of periodontal ligament stem cells through the GPR30-mediated PI3K/AKT/mTOR signaling pathway. *Exp. Biol. Med.* **2020**, *245*, 552–561. [[CrossRef](#)]
467. Zhao, B.; Zhang, Y.; Xiong, Y.; Xu, X. Rutin promotes the formation and osteogenic differentiation of human periodontal ligament stem cell sheets in vitro. *Int. J. Mol. Med.* **2019**, *44*, 2289–2297. [[CrossRef](#)]
468. Zhang, Z.-R.; Leung, W.N.; Li, G.; Kong, S.K.; Lu, X.; Wong, Y.M.; Chan, C.W. Osthole Enhances Osteogenesis in Osteoblasts by Elevating Transcription Factor Osterix via cAMP/CREB Signaling In Vitro and In Vivo. *Nutrients* **2017**, *9*, 588. [[CrossRef](#)]
469. Zhao, D.; Wang, Q.; Zhao, Y.B.; Zhang, H.; Sha, N.B.; Tang, D.; Liu, S.; Lu, S.B.; Shi, Q.; Zhang, Y.; et al. The naturally derived small compound Osthole inhibits osteoclastogenesis to prevent ovariectomy-induced bone loss in mice. *Menopause* **2018**, *25*, 1459–1469. [[CrossRef](#)]
470. Wang, P.; Ying, J.; Luo, C.; Jin, X.; Zhang, S.; Xu, T.; Zhang, L.; Mi, M.; Chen, D.; Tong, P.; et al. Osthole Promotes Bone Fracture Healing through Activation of BMP Signaling in Chondrocytes. *Int. J. Biol. Sci.* **2017**, *13*, 996–1007. [[CrossRef](#)]
471. Zhang, Z.; Leung, W.N.; Li, G.; Lai, Y.M.; Chan, C.W. Osthole Promotes Endochondral Ossification and Accelerates Fracture Healing in Mice. *Calcif. Tissue Int.* **2016**, *99*, 649–660. [[CrossRef](#)]
472. Sun, J.; Dong, Z.; Zhang, Y.; He, X.; Fei, D.; Jin, F.; Yuan, L.; Li, B.; Jin, Y. Osthole improves function of periodontitis periodontal ligament stem cells via epigenetic modification in cell sheets engineering. *Sci. Rep.* **2017**, *7*, 5254. [[CrossRef](#)]
473. Gao, L.-N.; An, Y.; Lei, M.; Li, B.; Yang, H.; Lu, H.; Chen, F.-M.; Jin, Y. The effect of the coumarin-like derivative osthole on the osteogenic properties of human periodontal ligament and jaw bone marrow mesenchymal stem cell sheets. *Biomaterials* **2013**, *34*, 9937–9951. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.